APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 9
SEPTEMBER 2015



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

35th EDITION

Department of Health and Human Services
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs

2015

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

35th EDITION

Cumulative Supplement 9

September 2015

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

35th EDITION

CUMULATIVE SUPPLEMENT 9
September 2015

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 35th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov. Send changes by FAX: 301-595-1446.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
AGILA SPECIALTIES PRIVATE LTD (AGILA SPECLTS)	MYLAN LABORORATORIES LTD (MYLAN LABS LTD)
EXCELLIUM PHARMACEUTICAL INC (EXCELLIUM)	LEADING PHARMA LLC (LEADING PHARMA LLC)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
ONCO THERAPIES LTD (ONCO THERAPIES LTD)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
REDKITT BENCKISER PHARMACEUTICALS INC (RECKITT BENCKISER)	INDIVIOR INC (INDIVIOR INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies

to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752)tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent

number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2014	MAR 2015	JUN 2015	SEPT 2015	DEC 2015
DRUG PRODUCTS LISTED	16150	16352	16543	16824	
SINGLE SOURCE	2572 (15.9%)	2608 (15.9%)	2586 (15.6%)	2613 (15.5%)	
MULTISOURCE	13578 (84.1%)	13744 (84.1%)	13957 (84.4%)	14211 (84.5%)	
THERAPEUTICALLY EQUIVALENT	13443 (83.2%)	13610 (83.2%)	13832 (83.6%)	14089 (83.7%)	
NOT THERAPEUTICALLY EQUIVALENT	135 (0.8%)	134 (0.8%)	125 (0.8%)	122 (0.7%)	
EXCEPTIONS[1]	77 (0.5%)	75 (0.5%)	75 (0.5%)	75 (0.4%)	
NEW MOLECULAR ENTITIES APPROVED	13	22	12	37	
NUMBER OF APPLICANTS	927	935	957	975	

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.

CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

		ACETAMINOPHEN; BUTALBITAL; CAFFEINE							
		TABLET;ORAL							
		FIORICET							
		@ ACTAVIS LABS UT INC	325MG;50MG;40MG	A088616	001	Nov 09, 1984	Feb CAHN		
		ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE							
		CAPSULE;ORAL							
		FIORICET W/ CODEINE							
	AB	+ ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N020232	001	Jul 30, 1992	Jan CAHN		
		ACETAMINOPHEN; CODEINE PHOSPHATE							
		TABLET;ORAL							
		ACETAMINOPHEN AND CODEINE PHOSPHATE							
	AA	SUN PHARM INDS LTD	300MG;30MG	A085868	001		Apr CAHN		
	AA		300MG;60MG	A087083	001		Apr CAHN		
		ACETAMINOPHEN; HYDROCODONE BITARTRATE							
		TABLET;ORAL							
		HYDROCODONE BITARTRATE AND ACETAMINOPHEN							
	AA	+ MIKART	325MG;2.5MG	A040846	001	Jun 09, 2010	Feb CTEC		
		@ SUN PHARM INDS LTD	325MG;10MG	A040826	001	Aug 16, 2007	Apr CAHN		
		NORCO							
	AA	ACTAVIS LABS FL INC	325MG;2.5MG	A040148	004	Jul 07, 2014	Feb NEWA		
	AA		325MG;5MG	A040148	005	Jul 07, 2014	Feb NEWA		
		ACETAZOLAMIDE							
		CAPSULE, EXTENDED RELEASE;ORAL							
		DIAMOX							
	AB	+ TEVA BRANDED PHARM	500MG	N012945	001		Jun CAHN		
		ACETOHEXAMIDE							
		TABLET;ORAL							
		ACETOHEXAMIDE							
		@ ANI PHARMS INC	250MG	A070869	001	Feb 09, 1987	Jul CAHN		
		@	500MG	A070870	001	Feb 09, 1987	Jul CAHN		
		ACETYLCYSTEINE							
		INJECTABLE;INTRAVENOUS							
		ACETYLCYSTEINE							
	AP	AKORN INC	6GM/30ML (200MG/ML)	A203173	001	Mar 24, 2015	Mar NEWA		
	AP	MYLAN INSTITUTIONAL	6GM/30ML (200MG/ML)	A203624	001	Jun 19, 2015	Jun NEWA		
		SOLUTION;INHALATION, ORAL							
		ACETYLCYSTEINE							
>A>	AN	ALVOGEN INC	10%	A204674	001	Feb 11, 2014	Sep CAHN		
>A>	AN		20%	A203853	001	Jun 21, 2012	Sep CAHN		
>D>	AN	INNOPHARMA LICENSING	10%	A204674	001	Feb 11, 2014	Sep CAHN		
>D>	AN		20%	A203853	001	Jun 21, 2012	Sep CAHN		
		ACITRETIN							
		CAPSULE;ORAL							
		ACITRETIN							
	AB	MYLAN PHARMS INC	10MG	A202148	001	Sep 10, 2015	Aug NEWA		
	AB		17.5MG	A203707	001	Sep 10, 2015	Aug NEWA		
	AB		22.5MG	A203707	002	Sep 10, 2015	Aug NEWA		
	AB		25MG	A202148	002	Sep 10, 2015	Aug NEWA		
	AB	SIGMAPHARM LABS LLC	10MG	A204633	001	May 22, 2015	May NEWA		
	AB		17.5MG	A204633	002	May 22, 2015	May NEWA		
	AB		22.5MG	A204633	003	May 22, 2015	May NEWA		
	AB		25MG	A204633	004	May 22, 2015	May NEWA		
		ACLIDINIUM BROMIDE							
		POWDER, METERED;INHALATION							
		TUDORZA PRESSAIR							
		+ ASTRAZENECA PHARMS	0.375MG/INH	N202450	001	Jul 23, 2012	Apr CAHN		
		+	0.4MG/INH	N202450	001	Jul 23, 2012	Aug CPOT		

ACYCLOVIR

TABLET;ORAL

ACYCLOVIR

AB		SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998	Apr	CAHN
AB			800MG	A074980	002	Sep 30, 1998	Apr	CAHN

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

>A> AB		ACTAVIS MID ATLANTIC	0.1%;2.5%	A203790	001	Sep 30, 2015	Sep	NEWA

EPIDUO

>D>	+	GALDERMA LABS LP	0.1%;2.5%	N022320	001	Dec 08, 2008	Sep	CFTG
>A> AB	+		0.1%;2.5%	N022320	001	Dec 08, 2008	Sep	CFTG

EPIDUO FORTE

	+	GALDERMA LABS	0.3%;2.5%	N207917	001	Jul 15, 2015	Aug	CAHN
	+	GALDERMA R AND D	0.3%;2.5%	N207917	001	Jul 15, 2015	Jul	NEWA

ADENOSINE

INJECTABLE;INJECTION

ADENOSINE

AP		EUROHLTH INTL SARL	3MG/ML	A076500	001	Jun 16, 2004	Jun	CAHN
>A>	@		3MG/ML	A076501	001	Jun 16, 2004	Sep	CAHN
>D>	@	HIKMA MAPLE	3MG/ML	A076501	001	Jun 16, 2004	Sep	CAHN
	@	WOCKHARDT	3MG/ML	A090220	001	Jul 20, 2009	May	DISC

ALBENDAZOLE

TABLET, CHEWABLE;ORAL

ALBENZA

	+	AMEDRA PHARMS LLC	200MG	N207844	001	Jun 11, 2015	Jun	NEWA

ALBUTEROL SULFATE

POWDER, METERED;INHALATION

PROAIR RESPICLICK

	+	TEVA BRANDED PHARM	EQ 0.090MG BASE/INH	N205636	001	Mar 31, 2015	Mar	NEWA

SYRUP;ORAL

ALBUTEROL SULFATE

AA		G AND W LABS INC	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	Apr	CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED;INHALATION

COMBIVENT

	@	BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH;0.018MG/INH	N020291	001	Oct 24, 1996	May	DISC

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALFUZOSIN HYDROCHLORIDE

	@	WOCKHARDT LTD	10MG	A090221	001	Aug 10, 2012	Feb	DISC

UROXATRAL

AB	+	CONCORDIA PHARMS INC	10MG	N021287	001	Jun 12, 2003	Jun	CAHN

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

TABLET;ORAL

TEKAMLO

	@	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE	N022545	001	Aug 26, 2010	May	DISC
	@		EQ 150MG BASE;EQ 10MG BASE	N022545	002	Aug 26, 2010	May	DISC
	@		EQ 300MG BASE;EQ 5MG BASE	N022545	003	Aug 26, 2010	May	DISC
	@		EQ 300MG BASE;EQ 10MG BASE	N022545	004	Aug 26, 2010	May	DISC

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

AMTURNIDE

	@	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE;12.5MG	N200045	001	Dec 21, 2010	May	DISC
	@		EQ 300MG BASE;EQ 5MG BASE;12.5MG	N200045	002	Dec 21, 2010	May	DISC
	@		EQ 300MG BASE;EQ 5MG BASE;25MG	N200045	003	Dec 21, 2010	May	DISC
	@		EQ 300MG BASE;EQ 10MG BASE;12.5MG	N200045	004	Dec 21, 2010	May	DISC
	@		EQ 300MG BASE;EQ 10MG BASE;25MG	N200045	005	Dec 21, 2010	May	DISC

ALMOTRIPTAN MALATE

TABLET;ORAL

ALMOTRIPTAN MALATE

AB	TEVA PHARMS USA	EQ 6.25MG BASE	A078027	001	Jul 07, 2015	Jun	NEWA
AB		EQ 12.5MG BASE	A078027	002	Jul 07, 2015	Jun	NEWA

AXERT

AB	JANSSEN PHARMS	EQ 6.25MG BASE	N021001	001	May 07, 2001	Jun	CFTG
AB +		EQ 12.5MG BASE	N021001	002	May 07, 2001	Jun	CFTG

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

ALOSETRON HYDROCHLORIDE

AB	ROXANE	EQ 0.5MG BASE	A200652	001	May 04, 2015	Apr	NEWA
AB		EQ 1MG BASE	A200652	002	May 04, 2015	Apr	NEWA

LOTRONEX

AB	PROMETHEUS LABS	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Apr	CFTG
AB +		EQ 1MG BASE	N021107	001	Feb 09, 2000	Apr	CFTG

ALPRAZOLAM

TABLET;ORAL

ALPRAZOLAM

@	ANI PHARMS INC	0.25MG	A074085	001	Feb 16, 1994	Jul	CAHN
@		0.5MG	A074085	002	Feb 16, 1994	Jul	CAHN
@		1MG	A074085	003	Feb 16, 1994	Jul	CAHN
@		2MG	A074085	004	Feb 26, 1996	Jul	CAHN
AB	AUROBINDO PHARMA LTD	0.25MG	A203346	001	Jul 31, 2015	Jul	NEWA
AB		0.5MG	A203346	002	Jul 31, 2015	Jul	NEWA
AB		1MG	A203346	003	Jul 31, 2015	Jul	NEWA
AB		2MG	A203346	004	Jul 31, 2015	Jul	NEWA
AB	NATCO PHARMA LTD	0.25MG	A200739	001	Apr 15, 2015	Mar	NEWA
AB		0.5MG	A200739	002	Apr 15, 2015	Mar	NEWA
AB		1MG	A200739	003	Apr 15, 2015	Mar	NEWA
AB		2MG	A200739	004	Apr 15, 2015	Mar	NEWA

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

>A> AB	HERITAGE PHARMS INC	0.5MG	A078489	001	Oct 17, 2008	Sep	CAHN
>A> AB		1MG	A078489	002	Oct 17, 2008	Sep	CAHN
>A> AB		2MG	A078489	003	Oct 17, 2008	Sep	CAHN
>A> AB		3MG	A078489	004	Oct 17, 2008	Sep	CAHN
>D> AB	ZYDUS PHARMS USA INC	0.5MG	A078489	001	Oct 17, 2008	Sep	CAHN
>D> AB		1MG	A078489	002	Oct 17, 2008	Sep	CAHN
>D> AB		2MG	A078489	003	Oct 17, 2008	Sep	CAHN
>D> AB		3MG	A078489	004	Oct 17, 2008	Sep	CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB	BANNER LIFE SCIENCES	100MG	A078720	001	May 29, 2008	Jan	CAHN

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

@	G AND W LABS INC	50MG/5ML	A072655	001	Oct 30, 1990	May	CAHN

AMIKACIN SULFATE

INJECTABLE;INJECTION

AMIKACIN SULFATE

@	IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995	Mar	CAHN
@		EQ 250MG BASE/ML	A063169	001	Dec 14, 1995	Mar	CAHN

AMILORIDE HYDROCHLORIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	5MG	A204180	001	Aug 07, 2015	Jul	NEWA

AMINO ACIDS

INJECTABLE;INJECTION

BRANCHAMIN 4% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	4% (4GM/100ML)	N018684	001	Sep 28, 1984	Feb	DISC

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

	@	BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N020177	001	Oct 23, 1995	Feb	DISC

AMINOCAPROIC ACID

SYRUP;ORAL

AMINOCAPROIC ACID

AA		VERSAPHARM INC	1.25GM/5ML	A074759	001	Sep 02, 1998	May	CAHN

TABLET;ORAL

AMINOCAPROIC

AB		VERSAPHARM INC	500MG	A075602	001	May 24, 2001	May	CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

	@	ANI PHARMS INC	10MG	A084910	003		Aug	CAHN
	@		25MG	A085031	001		Aug	CAHN
	@		50MG	A085032	001		Aug	CAHN
	@		75MG	A085030	001		Aug	CAHN

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

LIMBITROL

	@	HERITAGE PHARMS INC	EQ 12.5MG BASE;5MG	N016949	001		Jul	CAHN

LIMBITROL DS

	@	HERITAGE PHARMS INC	EQ 25MG BASE;10MG	N016949	002		Jul	CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

	AB	CHINA RESOURCES	EQ 5MG BASE	A090752	001	Apr 15, 2011	Mar	CAHN
	AB		EQ 10MG BASE	A090752	002	Apr 15, 2011	Mar	CAHN
>D>	AB	MATRIX LABS LTD	EQ 2.5MG BASE	A078224	001	Feb 27, 2008	Sep	CAHN
>D>	AB		EQ 5MG BASE	A078224	002	Feb 27, 2008	Sep	CAHN
>D>	AB		EQ 10MG BASE	A078224	003	Feb 27, 2008	Sep	CAHN
>A>	AB	MYLAN PHARMS INC	EQ 2.5MG BASE	A078224	001	Feb 27, 2008	Sep	CAHN
>A>	AB		EQ 5MG BASE	A078224	002	Feb 27, 2008	Sep	CAHN
>A>	AB		EQ 10MG BASE	A078224	003	Feb 27, 2008	Sep	CAHN
	AB	SOVEREIGN PHARMS	EQ 2.5MG BASE	A204900	001	Jul 23, 2015	Jul	NEWA
	AB		EQ 5MG BASE	A204900	002	Jul 23, 2015	Jul	NEWA
	AB		EQ 10MG BASE	A204900	003	Jul 23, 2015	Jul	NEWA
	AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007	Apr	CAHN
	AB		EQ 5MG BASE	A077974	002	Jul 09, 2007	Apr	CAHN
	AB		EQ 10MG BASE	A077974	003	Jul 09, 2007	Apr	CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

	AB	LUPIN LTD	5MG;12.5MG;160MG	A200797	001	Jun 03, 2015	May	NEWA
	AB		5MG;25MG;160MG	A200797	002	Jun 03, 2015	May	NEWA
	AB		10MG;12.5MG;160MG	A200797	003	Jun 03, 2015	May	NEWA
	AB		10MG;25MG;160MG	A200797	004	Jun 03, 2015	May	NEWA
	AB		10MG;25MG;320MG	A200797	005	Jun 03, 2015	May	NEWA
	AB	PAR PHARM	5MG;12.5MG;160MG	A201087	001	Jun 01, 2015	May	NEWA
	AB		5MG;25MG;160MG	A201087	002	Jun 01, 2015	May	NEWA
	AB		10MG;12.5MG;160MG	A201087	003	Jun 01, 2015	May	NEWA
	AB		10MG;25MG;160MG	A201087	004	Jun 01, 2015	May	NEWA
	AB		10MG;25MG;320MG	A201087	005	Jun 01, 2015	May	NEWA
	AB	TEVA PHARMS	5MG;12.5MG;160MG	A200435	001	Sep 25, 2012	May	CAIN
	AB		5MG;25MG;160MG	A200435	002	Sep 25, 2012	May	CAIN
	AB		10MG;12.5MG;160MG	A200435	005	Sep 25, 2012	May	CAIN
	AB		10MG;25MG;160MG	A200435	003	Sep 25, 2012	May	CAIN
	AB		10MG;25MG;320MG	A200435	004	Sep 25, 2012	May	CAIN
>D>	AB	TORRENT PHARMS LTD	5MG;12.5MG;160MG	A201593	001	Jun 04, 2015	Sep	CMS1
>A>	AB		5MG;12.5MG;160MG	A201593	001	Jun 03, 2015	Sep	CMS1
	AB		5MG;12.5MG;160MG	A201593	001	Jun 04, 2015	May	NEWA
>D>	AB		5MG;25MG;160MG	A201593	002	Jun 04, 2015	Sep	CMS1
>A>	AB		5MG;25MG;160MG	A201593	002	Jun 03, 2015	Sep	CMS1
	AB		5MG;25MG;160MG	A201593	002	Jun 04, 2015	May	NEWA
>D>	AB		10MG;12.5MG;160MG	A201593	003	Jun 04, 2015	Sep	CMS1

TABLET;ORAL
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

>A>	AB	10MG;12.5MG;160MG	A201593	003	Jun 03, 2015	Sep	CMS1
	AB	10MG;12.5MG;160MG	A201593	003	Jun 04, 2015	May	NEWA
>D>	AB	10MG;25MG;160MG	A201593	004	Jun 04, 2015	Sep	CMS1
>A>	AB	10MG;25MG;160MG	A201593	004	Jun 03, 2015	Sep	CMS1
	AB	10MG;25MG;160MG	A201593	004	Jun 04, 2015	May	NEWA
>D>	AB	10MG;25MG;320MG	A201593	005	Jun 04, 2015	Sep	CMS1
>A>	AB	10MG;25MG;320MG	A201593	005	Jun 03, 2015	Sep	CMS1
	AB	10MG;25MG;320MG	A201593	005	Jun 04, 2015	May	NEWA

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL
PRESTALIA

	SYMPLMED PHARMS LLC	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Jan	NEWA
		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Jan	NEWA
+		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Jan	NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL
AMLODIPINE BESYLATE AND VALSARTAN

AB	ALEMBIC PHARMS LTD	EQ 5MG BASE;160MG	A202713	001	Apr 03, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A202713	003	Apr 03, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A202713	002	Apr 03, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A202713	004	Apr 03, 2015	Mar	NEWA
AB	LUPIN	EQ 5MG BASE;160MG	A090245	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A090245	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A090245	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A090245	004	Mar 30, 2015	Mar	NEWA
AB	MATRIX LABS LTD	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Mar	NEWA
AB	MYLAN PHARMS INC	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Apr	CAHN
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Apr	CAHN
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Apr	CAHN
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Apr	CAHN
AB	NOVEL LABS INC	EQ 5MG BASE;160MG	A202829	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A202829	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A202829	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A202829	004	Mar 30, 2015	Mar	NEWA
AB	TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Mar	NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE;160MG	A202377	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A202377	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A202377	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A202377	004	Mar 30, 2015	Mar	NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS
AMMONIA N 13

AP	BIOMEDCL RES FDN	48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)	A204352	001	May 01, 2015	Apr	NEWA
	CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539	001	Jun 23, 2015	Jun	NEWA
AP	IBA MOLECULAR N AM	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	Apr	NEWA
	NCM USA BRONX LLC	3.75-260mCi/mL	A204515	001	Feb 04, 2015	Jan	NEWA
	PRECISION NUCLEAR	3.75-260mCi/ML	A204547	001	Aug 14, 2015	Aug	NEWA
AP	SPECTRON MRC LLC	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Apr	NEWA

AMOXICILLIN

CAPSULE;ORAL
AMOXICILLIN

AB	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Apr	CAHN
AB		500MG	A065016	002	Apr 08, 1999	Apr	CAHN

FOR SUSPENSION;ORAL
AMOXICILLIN

@	SUN PHARM INDS LTD	200MG/5ML	A065113	001	Nov 29, 2002	Apr	CAHN
@		400MG/5ML	A065113	002	Nov 29, 2002	Apr	CAHN

TABLET;ORAL
AMOXICILLIN

AB	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000	Apr	CAHN
AB		875MG	A065059	002	Nov 24, 2000	Apr	CAHN

TABLET, CHEWABLE;ORAL
AMOXICILLIN

AB	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999	Apr	CAHN
@		200MG	A065060	001	Nov 29, 2000	Apr	CAHN
AB		250MG	A065021	002	Dec 23, 1999	Apr	CAHN
@		400MG	A065060	002	Nov 29, 2000	Apr	CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Apr	CAHN
AB		400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Apr	CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Apr	CAHN

TABLET;ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

@	SUN PHARM INDS LTD	500MG;EQ 125MG BASE	A065109	001	Nov 04, 2002	Apr	CAHN
AB		875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002	Apr	CAHN

TABLET, CHEWABLE;ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Apr	CAHN
AB		400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Apr	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	COREPHARMA	1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014	May	NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014	May	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014	May	NEWA

AMPHETAMINE SULFATE

TABLET;ORAL
EVEKEO

	ARBOR PHARMS LLC	5MG	A200166	001	Aug 09, 2012	Mar	CTNA
+		10MG	A200166	002	Aug 09, 2012	Mar	CTNA

AMPICILLIN SODIUM

INJECTABLE;INJECTION
AMPICILLIN SODIUM

AP	HOSPIRA INC	EQ 250MG BASE/VIAL	A202864	001	Sep 04, 2015	Aug	NEWA
AP		EQ 500MG BASE/VIAL	A202864	002	Sep 04, 2015	Aug	NEWA
AP		EQ 1GM BASE/VIAL	A202864	003	Sep 04, 2015	Aug	NEWA
AP		EQ 2GM BASE/VIAL	A202864	004	Sep 04, 2015	Aug	NEWA
AP		EQ 10GM BASE/VIAL	A202865	001	Sep 04, 2015	Aug	NEWA

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION;ORAL
PROBAMPACIN

@	G AND W LABS INC	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001		Apr	CAHN

ANASTROZOLE

TABLET;ORAL
ANASTROZOLE

@	KREMERS URBAN PHARMS	1MG	A091331	001	Jan 05, 2011	Mar	CAHN

ARGATROBAN

INJECTABLE;INJECTION
ARGATROBAN

AP	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Apr	CDFR
AP +	PFIZER	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	Aug	CTNA

INJECTABLE;IV (INFUSION)
ARGATROBAN

AP	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Mar	NEWA

ARIPIPRAZOLE

SOLUTION;ORAL

ARIPIPRAZOLE

	AA		AMNEAL PHARMS	1MG/ML	A203906	001	Aug 14, 2015	Aug NEWA
>A>	AA		APOTEX INC	1MG/ML	A204094	001	Sep 30, 2015	Sep NEWA
	AA		SILARX PHARMS INC	1MG/ML	A204171	001	Aug 14, 2015	Aug NEWA

TABLET;ORAL

ABILIFY

	AB		OTSUKA	2MG	N021436	006	Nov 15, 2002	Apr CFTG
	AB	+		5MG	N021436	005	Nov 15, 2002	Apr CFTG
	AB	+		10MG	N021436	001	Nov 15, 2002	Apr CFTG
	AB			15MG	N021436	002	Nov 15, 2002	Apr CFTG
	AB			20MG	N021436	003	Nov 15, 2002	Apr CFTG
	AB			30MG	N021436	004	Nov 15, 2002	Apr CFTG

ARIPIPRAZOLE

	AB		ALEMBIC PHARMS LTD	2MG	A202101	001	Apr 28, 2015	Apr NEWA
	AB			5MG	A202101	002	Apr 28, 2015	Apr NEWA
	AB			10MG	A202101	003	Apr 28, 2015	Apr NEWA
	AB			15MG	A202101	004	Apr 28, 2015	Apr NEWA
	AB			20MG	A202101	005	Apr 28, 2015	Apr NEWA
	AB			30MG	A202101	006	Apr 28, 2015	Apr NEWA
	AB		APOTEX INC	2MG	A078583	001	Jul 24, 2015	Jul NEWA
	AB			5MG	A078583	002	Jul 24, 2015	Jul NEWA
	AB			10MG	A078583	003	Jul 24, 2015	Jul NEWA
	AB			15MG	A078583	004	Jul 24, 2015	Jul NEWA
	AB			20MG	A078583	005	Jul 24, 2015	Jul NEWA
	AB			30MG	A078583	006	Jul 24, 2015	Jul NEWA
>A>	AB		AUROBINDO PHARMA LTD	2MG	A203908	001	Oct 08, 2015	Sep NEWA
>A>	AB			5MG	A203908	002	Oct 08, 2015	Sep NEWA
>A>	AB			10MG	A203908	003	Oct 08, 2015	Sep NEWA
>A>	AB			15MG	A203908	004	Oct 08, 2015	Sep NEWA
>A>	AB			20MG	A203908	005	Oct 08, 2015	Sep NEWA
>A>	AB			30MG	A203908	006	Oct 08, 2015	Sep NEWA
	AB		HETERO LABS LTD V	2MG	A205064	001	Apr 28, 2015	Apr NEWA
	AB			5MG	A205064	002	Apr 28, 2015	Apr NEWA
	AB			10MG	A205064	003	Apr 28, 2015	Apr NEWA
	AB			15MG	A205064	004	Apr 28, 2015	Apr NEWA
	AB			20MG	A205064	005	Apr 28, 2015	Apr NEWA
	AB			30MG	A205064	006	Apr 28, 2015	Apr NEWA
	AB		TEVA PHARMS USA	2MG	A078607	001	Apr 28, 2015	Apr NEWA
	AB			5MG	A078607	002	Apr 28, 2015	Apr NEWA
	AB			10MG	A078608	001	Apr 28, 2015	Apr NEWA
	AB			15MG	A078708	001	Apr 28, 2015	Apr NEWA
	AB			20MG	A078708	002	Apr 28, 2015	Apr NEWA
	AB			30MG	A078708	003	Apr 28, 2015	Apr NEWA
	AB		TORRENT PHARMS LTD	2MG	A201519	001	Apr 28, 2015	Apr NEWA
	AB			10MG	A201519	003	Apr 28, 2015	Apr NEWA
	AB			5MG	A201519	002	Apr 28, 2015	Apr NEWA
	AB			15MG	A201519	004	Apr 28, 2015	Apr NEWA
	AB			20MG	A201519	005	Apr 28, 2015	Apr NEWA
	AB			30MG	A201519	006	Apr 28, 2015	Apr NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

ABILIFY

	AB	+	OTSUKA	10MG	N021729	002	Jun 07, 2006	Apr CFTG
	AB			15MG	N021729	003	Jun 07, 2006	Apr CFTG

ARIPIPRAZOLE

	AB		ALEMBIC PHARMS LTD	10MG	A202102	001	Apr 28, 2015	Apr NEWA
	AB			15MG	A202102	002	Apr 28, 2015	Apr NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 LYOPHILIZED

		@	IGI LABS INC	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N018933	002	Aug 08, 1985	Jun CAHN

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID

	@	NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM; 7.5GM	A	090145	001	Jan 25, 2012	Aug CTNA

ASENAPINE MALEATE

TABLET;SUBLINGUAL

SAPHRIS

		FOREST LABS LLC	EQ 5MG BASE	N	022117	001	Aug 13, 2009	Jun CAHN
	+		EQ 10MG BASE	N	022117	002	Aug 13, 2009	Jun CAHN

ASPIRIN

CAPSULE, EXTENDED RELEASE;ORAL

DURLAZA

>A>	+	NEW HAVEN PHARMS	162.5MG	N	200671	001	Sep 04, 2015	Sep NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

FIORINAL

AA	+	ACTAVIS LABS UT INC	325MG;50MG;40MG	N	017534	005	Apr 16, 1986	Jan CAHN

TABLET;ORAL

FIORINAL

	@	ACTAVIS LABS UT INC	325MG;50MG;40MG	N	017534	003	Apr 16, 1986	Jan CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

FIORINAL W/CODEINE

AB	+	ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N	019429	003	Oct 26, 1990	Jan CAHN

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

SYNALGOS-DC

	+	SUN PHARM INDS	356.4MG;30MG;16MG	N	011483	004	Sep 06, 1983	Aug CAHN

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

NORGESIC

	@	MEDICIS	385MG;30MG;25MG	N	013416	003	Oct 27, 1982	Mar DISC

NORGESIC FORTE

	@	MEDICIS	770MG;60MG;50MG	N	013416	004	Oct 27, 1982	Mar DISC

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

		SANDOZ	385MG;30MG;25MG	A	074654	001	Dec 31, 1996	Mar CTEC
	+		770MG;60MG;50MG	A	074654	002	Dec 31, 1996	Mar CTEC

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

AA		ACTAVIS LABS FL INC	325MG;4.8355MG	A	090084	001	Mar 22, 2011	Mar CAHN

ATAZANAVIR SULFATE; COBICISTAT

TABLET;ORAL

EVOTAZ

	+	BRISTOL MYERS SQUIBB	EQ 300MG BASE;150MG	N	206353	001	Jan 29, 2015	Jan NEWA

ATENOLOL

TABLET;ORAL

ATENOLOL

AB		ALVOGEN IPCO SARL	25MG	A	073646	001	Jul 31, 1992	Jul CAHN
AB			50MG	A	072303	001	Jul 15, 1988	Jul CAHN
AB			100MG	A	072304	001	Jul 15, 1988	Jul CAHN
	@	DAVA PHARMS INC	25MG	A	074099	001	Apr 28, 1992	Jun DISC

TENORMIN

AB		ALVOGEN IPCO SARL	25MG	N	018240	004	Apr 09, 1990	Feb CAHN
AB			50MG	N	018240	001		Feb CAHN
AB	+		100MG	N	018240	002		Feb CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB	ALVOGEN IPCO SARL	50MG;25MG	A072301	001	May 31, 1990	Jul	CAHN
AB		100MG;25MG	A072302	001	May 31, 1990	Jul	CAHN

TENORETIC 100

AB +	ALVOGEN IPCO SARL	100MG;25MG	N018760	001	Jun 08, 1984	Feb	CAHN

TENORETIC 50

AB	ALVOGEN IPCO SARL	50MG;25MG	N018760	002	Jun 08, 1984	Feb	CAHN

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	KREMERS URBAN PHARMS	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar	CAHN
AB		EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar	CAHN
AB		EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar	CAHN
AB		EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar	CAHN
AB	SUN PHARM INDS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Apr	CAHN
AB		EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr	CAHN
AB		EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr	CAHN
AB		EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr	CAHN

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

LIPTRUZET

@	MERCK SHARP DOHME	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	May	DISC
@		EQ 20MG BASE;10MG	N200153	002	May 03, 2013	May	DISC
@		EQ 40MG BASE;10MG	N200153	003	May 03, 2013	May	DISC
@		EQ 80MG BASE;10MG	N200153	004	May 03, 2013	May	DISC

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET;ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB	GLENMARK GENERICS	62.5MG;25MG	A091211	002	Apr 06, 2015	Mar	NEWA

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

AP	AUROBINDO PHARMA LTD	10MG/ML	A206011	001	Apr 08, 2015	Mar	NEWA

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP	AUROBINDO PHARMA LTD	10MG/ML	A206010	001	Apr 08, 2015	Mar	NEWA

ATROPINE SULFATE

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

+	AKORN	1%	N206289	001	Jul 18, 2014	May	CRLD

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET;ORAL

MOTOFEN

+	SEBELA IRELAND LTD	0.025MG;1MG	N017744	002		Feb	CAHN

MOTOFEN HALF-STRENGTH

@	SEBELA IRELAND LTD	0.025MG;0.5MG	N017744	001		Feb	CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@	ANI PHARMS INC	0.025MG;2.5MG	A086727	001		Jul	CAHN

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;IV (INFUSION)

AVYCAZ

+	CEREXA INC	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	Feb	NEWA

AZELAIC ACID

AEROSOL, FOAM;TOPICAL

FINACEA

+	BAYER HLTHCARE	15%	N207071	001	Jul 29, 2015	Jul	NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

AB	BRECKENRIDGE PHARMS	EQ 0.125MG BASE/SPRAY	A090176	001	Jul 28, 2015	Jul NEWA

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB	LUPIN LTD	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	May NEWA
AB		EQ 200MG BASE/5ML	A065488	002	May 15, 2015	May NEWA

INJECTABLE;INJECTION

AZITHROMYCIN

AP	AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A203294	001	Jun 19, 2015	Jun NEWA

TABLET;ORAL

AZITHROMYCIN

AB	LUPIN LTD	EQ 250MG BASE	A065398	001	May 15, 2015	May NEWA
AB		EQ 500MG BASE	A065399	001	May 15, 2015	May NEWA
AB		EQ 600MG BASE	A065400	001	May 15, 2015	May NEWA

BALSALAZIDE DISODIUM

CAPSULE;ORAL

COLAZAL

AB	+ VALEANT PHARMS INTL	750MG	N020610	001	Jul 18, 2000	Jul CAHN

TABLET;ORAL

BALSALAZIDE DISODIUM

AB	PAR PHARM INC	1.1GM	A206336	001	Sep 08, 2015	Aug NEWA

GIAZO

AB	+ VALEANT PHARMS INTL	1.1GM	N022205	001	Feb 03, 2012	Aug CFTG
	+	1.1GM	N022205	001	Feb 03, 2012	Jul CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB	AMNEAL PHARMS LLC	5MG	A076820	001	Feb 03, 2006	Jan CAHN
AB		10MG	A076820	002	Feb 03, 2006	Jan CAHN
AB		20MG	A076820	003	Feb 03, 2006	Jan CAHN
AB		40MG	A076820	004	Feb 03, 2006	Jan CAHN
AB	SUN PHARM INDS LTD	5MG	A076344	001	Feb 11, 2004	Apr CAHN
AB		10MG	A076344	002	Feb 11, 2004	Apr CAHN
AB		20MG	A076344	003	Feb 11, 2004	Apr CAHN
AB		40MG	A076344	004	Feb 11, 2004	Apr CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS LTD	5MG;6.25MG	A077483	001	Sep 08, 2005	Apr CAHN
AB		10MG;12.5MG	A077483	002	Sep 08, 2005	Apr CAHN
AB		20MG;12.5MG	A077483	003	Sep 08, 2005	Apr CAHN
AB		20MG;25MG	A077483	004	Sep 08, 2005	Apr CAHN

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA	APOTEX INC	100MG	A091310	001	Jan 16, 2015	Jan NEWA
AA		200MG	A091310	002	Jan 16, 2015	Jan NEWA
AA	BANNER LIFE SCIENCES	100MG	A081297	001	Jan 29, 1993	Jan CAHN
AA		200MG	A081297	002	Oct 30, 2007	Jan CAHN
AA	CSPC NBP PHARM CO	200MG	A202765	001	Jul 31, 2015	Jul NEWA
AA	STRIDES ARCOLAB LTD	100MG	A091133	001	Jul 30, 2015	Jul NEWA
AA		200MG	A091133	002	Jul 30, 2015	Jul NEWA
AA	STRIDES PHARMA	100MG	A091133	001	Jul 30, 2015	Aug CAHN
AA		200MG	A091133	002	Jul 30, 2015	Aug CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

ACANYA

AB	+ DOW PHARM	2.5%;EQ 1.2% BASE	N050819	001	Oct 23, 2008	Jun CFTG

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	ACTAVIS LABS UT INC	2.5%;EQ 1.2% BASE	A205128	001	Jun 19, 2015	Jun NEWA
>A> AB	PERRIGO ISRAEL	5%;EQ 1% BASE	A202440	001	Sep 21, 2015	Sep NEWA

		GEL;TOPICAL							
		ONEXTON							
	+	DOW PHARM	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	Jan CRLD
		BENZOYL PEROXIDE; ERYTHROMYCIN							
		GEL;TOPICAL							
		ERYTHROMYCIN AND BENZOYL PEROXIDE							
>A>	AB	LYNE	5%;3%	A065385	001	Sep 18, 2015	Sep NEWA
		BENZPHETAMINE HYDROCHLORIDE							
		TABLET;ORAL							
		BENZPHETAMINE HYDROCHLORIDE							
	AA	+ KVK TECH	50MG	A090968	001	Jul 20, 2010	Jun CRLD
		DIDREX							
		@ PHARMACIA AND UPJOHN	50MG	N012427	002		Jun DISC
		BENZTROPINE MESYLATE							
		TABLET;ORAL							
		BENZTROPINE MESYLATE							
	AA	NUVO PHARM INC	0.5MG	A204713	001	Apr 14, 2015	Mar NEWA
	AA		1MG	A204713	002	Apr 14, 2015	Mar NEWA
	AA		2MG	A204713	003	Apr 14, 2015	Mar NEWA
		BETAMETHASONE DIPROPIONATE							
		LOTION;TOPICAL							
		BETAMETHASONE DIPROPIONATE							
	AB	G AND W LABS INC	EQ 0.05% BASE	A071467	001	Aug 10, 1987	Apr CAHN
		@	EQ 0.05% BASE	A071882	001	Jun 06, 1988	Apr CAHN
		BETAMETHASONE VALERATE							
		CREAM;TOPICAL							
		BETA-VAL							
	AB	G AND W LABS INC	EQ 0.1% BASE	N018642	001	Mar 24, 1983	Aug CAHN
		LOTION;TOPICAL							
		BETA-VAL							
	AB	G AND W LABS INC	EQ 0.1% BASE	A070072	001	Jun 27, 1985	Apr CAHN
		BETHANECHOL CHLORIDE							
		TABLET;ORAL							
		BETHANECHOL CHLORIDE							
	AA	HERITAGE PHARMA	5MG	A091256	001	May 04, 2010	Mar CAHN
	AA		10MG	A091256	002	May 04, 2010	Mar CAHN
	AA		25MG	A091256	003	May 04, 2010	Mar CAHN
	AA		50MG	A091256	004	May 04, 2010	Mar CAHN
	AA	LANNETT HOLDINGS INC	5MG	A040703	001	Mar 27, 2008	Feb CMFD
	AA		50MG	A040677	001	Mar 27, 2008	Feb CMFD
		DUVOID							
	AA	WELLSPRING PHARM	10MG	A086262	001		Jan CMFD
	AA		25MG	A086263	001		May CMFD
	AA		50MG	A085882	003		May CMFD
		BEXAROTENE							
		CAPSULE;ORAL							
		BEXAROTENE							
	AB	BANNER LIFE SCIENCES	75MG	A203174	001	Aug 12, 2014	Jun CMFD
		@	75MG	A203174	001	Aug 12, 2014	Jan CAHN
		TARGRETIN							
	AB	+ VALEANT LUXEMBOURG	75MG	N021055	001	Dec 29, 1999	Jun CTEC
		BICALUTAMIDE							
		TABLET;ORAL							
		BICALUTAMIDE							
	AB	APOTEX INC	50MG	A200274	001	May 21, 2015	May NEWA
	AB	STASON PHARMS	50MG	A091011	001	Jun 10, 2015	May NEWA
		BIMATOPROST							
		SOLUTION/DROPS;OPHTHALMIC							
		BIMATOPROST							
	AT	ALCON RES LTD	0.03%	A202565	001	May 05, 2015	Apr NEWA
	AT	APOTEX INC	0.03%	A090449	001	Jul 20, 2015	Jul NEWA
	AT	+ LUPIN LTD	0.03%	A203991	001	Feb 20, 2015	Apr CTEC
		+	0.03%	A203991	001	Feb 20, 2015	Mar CTEC

		SOLUTION/DROPS;OPHTHALMIC						
		BIMATOPROST						
	AT	+	0.03%	A203991	001	Feb 20, 2015	Feb	NEWA
		BIPERIDEN HYDROCHLORIDE						
		TABLET;ORAL						
		AKINETON						
		@ ABBVIE	2MG	N012003	001		Aug	DISC
		BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE						
		CAPSULE;ORAL						
		PYLERA						
		+ FOREST LABS LLC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Jul	CAHN
		BIVALIRUDIN						
		INJECTABLE;INTRAVENOUS						
		BIVALIRUDIN						
	AP	HOSPIRA INC	250MG/VIAL	A090811	001	Jul 14, 2015	Jun	NEWA
	AP		250MG/VIAL	A090816	001	Jul 14, 2015	Jun	NEWA
		BOSUTINIB MONOHYDRATE						
		TABLET;ORAL						
		BOSULIF						
		+ WYETH PHARMS INC	EQ 100MG BASE	N203341	001	Sep 04, 2012	Jun	CRLD
			EQ 500MG BASE	N203341	002	Sep 04, 2012	Jun	CRLD
		BREXPIPRAZOLE						
		TABLET;ORAL						
		REXULTI						
		OTSUKA PHARM CO LTD	0.25MG	N205422	001	Jul 10, 2015	Jul	NEWA
			0.5MG	N205422	002	Jul 10, 2015	Jul	NEWA
			1MG	N205422	003	Jul 10, 2015	Jul	NEWA
			2MG	N205422	004	Jul 10, 2015	Jul	NEWA
			3MG	N205422	005	Jul 10, 2015	Jul	NEWA
		+	4MG	N205422	006	Jul 10, 2015	Jul	NEWA
		BROMFENAC SODIUM						
		SOLUTION/DROPS;OPHTHALMIC						
>D>		BROMDAY						
>D>	AT2	+ BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Sep	DISC
>A>		@	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Sep	DISC
	AT2	+	EQ 0.09% ACID	N021664	002	Oct 16, 2010	May	CTEC
		BROMFENAC SODIUM						
	AT2	APOTEX INC	EQ 0.09% ACID	A202620	001	Jun 23, 2014	May	CTEC
	AT1	+ COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	May	CRLD
	AT2	HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	May	CTEC
	AT1	PADDOCK LLC	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Jan	NEWA
		BUDESONIDE						
		AEROSOL, FOAM;RECTAL						
		UCERIS						
		+ VALEANT PHARMS INTL	2MG/ACTUATION	N205613	001	Oct 07, 2014	Apr	CAHN
		SPRAY, METERED;NASAL						
		BUDESONIDE						
		APOTEX INC	0.032MG/INH	A078949	001	May 12, 2014	Mar	CTEC
		TABLET, EXTENDED RELEASE;ORAL						
		UCERIS						
		+ VALEANT PHARMS INTL	9MG	N203634	001	Jan 14, 2013	Aug	CAHN
		BUMETANIDE						
		INJECTABLE;INJECTION						
		BUMETANIDE						
	AP	EUROHLTH INTL SARL	0.25MG/ML	A079196	001	Apr 30, 2008	Jun	CAHN
		BUPRENORPHINE HYDROCHLORIDE						
		INJECTABLE;INJECTION						
		BUPRENORPHINE HYDROCHLORIDE						
	AP	PAR STERILE PRODUCTS	EQ 0.3MG BASE/ML	A206586	001	Jul 28, 2015	Jul	NEWA
		TABLET;SUBLINGUAL						
		BUPRENORPHINE HYDROCHLORIDE						
	AB	ACTAVIS ELIZABETH	EQ 2MG BASE	A090819	001	Feb 19, 2015	Feb	NEWA

TABLET;SUBLINGUAL
BUPRENORPHINE HYDROCHLORIDE

AB		EQ 8MG BASE	A090819	002	Feb 19, 2015	Feb	NEWA
AB	MYLAN PHARMS INC	EQ 2MG BASE	A201066	001	Mar 06, 2015	Feb	NEWA
AB		EQ 8MG BASE	A201066	002	Mar 06, 2015	Feb	NEWA
AB	SANDOZ INC	EQ 2MG BASE	A090279	001	Jun 10, 2015	May	NEWA
AB		EQ 8MG BASE	A090279	002	Jun 10, 2015	May	NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL
SUBOXONE

>A>	INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE	N022410	001	Aug 30, 2010	Sep	CDFR
>A>		EQ 4MG BASE;EQ 1MG BASE	N022410	003	Aug 10, 2012	Sep	CDFR
>A>		EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010	Sep	CDFR
>A> +		EQ 12MG BASE;EQ 3MG BASE	N022410	004	Aug 10, 2012	Sep	CDFR

FILM;SUBLINGUAL
SUBOXONE

>D>	INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE	N022410	001	Aug 30, 2010	Sep	CDFR
>D>		EQ 4MG BASE;EQ 1MG BASE	N022410	003	Aug 10, 2012	Sep	CDFR
>D>		EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010	Sep	CDFR
>D> +		EQ 12MG BASE;EQ 3MG BASE	N022410	004	Aug 10, 2012	Sep	CDFR

TABLET;SUBLINGUAL
ZUBSOLV

	OREXO AB	EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Jun	NEWA

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL
APLENZIN

	VALEANT PHARMS NORTH	174MG	N022108	001	Apr 23, 2008	Feb	CAHN
		348MG	N022108	002	Apr 23, 2008	Feb	CAHN
+		522MG	N022108	003	Apr 23, 2008	Feb	CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

AB1	PRINSTON INC	100MG	A202304	001	May 26, 2015	May	NEWA
AB1		150MG	A202304	002	May 26, 2015	May	NEWA
AB1		200MG	A202304	003	May 26, 2015	May	NEWA
AB2	SANDOZ INC	150MG	A077475	001	Mar 12, 2008	Mar	CAHN
@	WOCKHARDT LTD	100MG	A201331	001	Aug 30, 2012	May	DISC
@		150MG	A201331	002	Aug 30, 2012	May	DISC
@		200MG	A201331	003	Aug 30, 2012	May	DISC

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL
BUSPIRONE HYDROCHLORIDE

>A> AB	EMCURE PHARMS USA	5MG	A204582	001	Sep 18, 2015	Sep	NEWA
>A> AB		10MG	A204582	002	Sep 18, 2015	Sep	NEWA
>A> AB		15MG	A204582	003	Sep 18, 2015	Sep	NEWA
>A> AB		30MG	A204582	004	Sep 18, 2015	Sep	NEWA

BUTABARBITAL SODIUM

ELIXIR;ORAL
BUTISOL SODIUM

@	MEDA PHARMS	30MG/5ML	A085380	001			Jul DISC

TABLET;ORAL
BUTISOL SODIUM

@	MEDA PHARMS	50MG	N000793	003			May DISC

BUTOCONAZOLE NITRATE

CREAM;VAGINAL
BUTOCONAZOLE NITRATE

@	ELAN PHARMA INTL LTD	2%	N019881	001	Feb 07, 1997	May	CTNA

GYNAZOLE-1

+	PERRIGO ISRAEL	2%	A200923	001	May 18, 2012	Jun	CTNA

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS

CAFFEINE CITRATE

>A>	AP	AUROBINDO PHARMA LTD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A205013	001	Sep 22, 2015	Sep	NEWA

CALCIPOTRIENE

CREAM;TOPICAL

CALCIPOTRIENE

	AB	GLENMARK PHARMS LTD	0.005%	A205772	001	Jun 09, 2015	May	NEWA

CALCITONIN SALMON

INJECTABLE;INJECTION

CALCITONIN-SALMON

		@ IGI LABS INC	200 IU/ML	A073690	001	Apr 14, 1995	Mar	CAHN

MIACALCIN

		@ MYLAN IRELAND LTD	100 IU/ML	N017808	001	Jul 03, 1986	Aug	CAHN
	+		200 IU/ML	N017808	002	Mar 29, 1991	Aug	CAHN

SPRAY, METERED;NASAL

MIACALCIN

	AB +	MYLAN IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995	Aug	CAHN

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

	AB	BANNER LIFE SCIENCES	0.25MCG	A091174	001	May 24, 2013	Jan	CAHN
	AB		0.5MCG	A091174	002	May 24, 2013	Jan	CAHN
	AB	STRIDES PHARMA	0.25MCG	A091356	001	Dec 12, 2014	Jan	CAHN
	AB		0.5MCG	A091356	002	Dec 12, 2014	Jan	CAHN

INJECTABLE;INJECTION

CALCIJEX

		@ ABBVIE	0.001MG/ML	N018874	001	Sep 25, 1986	Jun	DISC
		@	0.002MG/ML	N018874	002	Sep 25, 1986	Jun	DISC

CALCITRIOL

		@ AKORN	0.002MG/ML	A078066	002	Jan 29, 2008	Jun	DISC
		@ FRESENIUS KABI USA	0.001MG/ML	A075836	001	Dec 31, 2002	Jun	DISC
		@	0.002MG/ML	A075836	002	Dec 31, 2002	Jun	DISC
		@ FRESENIUS MEDCL	0.001MG/ML	A075766	001	Feb 20, 2003	Jun	DISC
		@	0.002MG/ML	A075766	002	Feb 20, 2003	Jun	DISC
		@ LUITPOLD	0.001MG/ML	A075746	001	Sep 26, 2003	Jun	DISC
		@	0.002MG/ML	A075746	002	Sep 26, 2003	Jun	DISC
		@ SAGENT PHARMS	0.001MG/ML	A077102	001	Feb 08, 2006	Jun	DISC

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

>A>	AB	HERITAGE PHARMS INC	EQ 169MG CALCIUM	A202315	001	Jun 29, 2015	Sep	CAHN
	AB	LUPIN LTD	EQ 169MG CALCIUM	A202127	001	Jul 09, 2015	Jun	NEWA
>D>	AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202315	001	Jun 29, 2015	Sep	CAHN
	AB		EQ 169MG CALCIUM	A202315	001	Jun 29, 2015	Jun	NEWA

TABLET;ORAL

CALCIUM ACETATE

>A>	AB	HERITAGE PHARMS INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Sep	CAHN
>D>	AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Sep	CAHN
	AB		EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Jan	NEWA

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

	+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Jan	CPOT

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

		@ GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Jan	CPOT

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

	+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07	N021703	011	Oct 10, 2008	Jan	CPOT

INJECTABLE;INJECTION

	PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER						
		GM/1000ML (5000ML)					
	PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER						
+	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/10 00ML;3.05GM/1000ML;0.314GM/1000ML; 2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Jan	CPOT
	PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER						
+	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/10 00ML;3.05GM/1000ML;N/A/1000ML;3.09 GM/1000ML;6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Jan	CPOT
	PRISMASOL BGK 2/0 IN PLASTIC CONTAINER						
+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000M L;2.03GM/1000ML;0.157GM/1000ML;3.0 9GM/1000ML;6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Jan	CPOT
	PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER						
+	GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/10 00ML;2.03GM/1000ML;0.157GM/1000ML; 3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Jan	CPOT
	PRISMASOL BGK 4/0 IN PLASTIC CONTAINER						
@	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000M L;3.05GM/1000ML;0.314GM/1000ML;3.0 9GM/1000ML;6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Jan	CPOT
	PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER						
+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000M L;2.44GM/1000ML;0.314GM/1000ML;3.0 9GM/1000ML;6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Jan	CPOT
	PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER						
+	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/10 00ML;3.05GM/1000ML;0.314GM/1000ML; 3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Jan	CPOT
	PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER						
@	GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/10 00ML;2.03GM/1000ML;0.314GM/1000ML; 3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Jan	CPOT
	PRISMASOL BK 0/0 IN PLASTIC CONTAINER						
@	GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML ;3.05GM/1000ML;N/A/1000ML;3.09GM/1 000ML;6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Jan	CPOT
	PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER						
+	GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML ;2.44GM/1000ML;N/A/1000ML;3.09GM/1 000ML;6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Jan	CPOT
	PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER						
+	GAMBRO RENAL PRODS	5.15GM/1000ML;N/A/1000ML;5.4GM/100 0ML;2.03GM/1000ML;N/A/1000ML;3.09G M/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Jan	CPOT
	PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER						
@	GAMBRO RENAL PRODS	3.68GM/1000ML;N/A/1000ML;5.4GM/100 0ML;3.05GM/1000ML;0.314GM/1000ML;3 .09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Jan	CPOT

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER						
+	GAMBRO LUNDIA	N/A/1000ML;N/A/1000ML;N/A/1000ML;3 .05GM/1000ML;0.314GM/1000ML;2.21GM /1000ML;6.95GM/1000ML;0.187GM/1000 ML (5000ML)	N207026	002	Jan 13, 2015	Jan	NEWA
	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER						
+	GAMBRO LUNDIA	3.68GM/1000ML;N/A/1000ML;N/A/1000M L;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187 GM/1000ML (5000ML)	N207026	001	Jan 13, 2015	Jan	NEWA

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

NAVSTEL

	@	ALCON PHARMS LTD	0.154MG/ML;0.92MG/ML;0.2MG/ML;0.184MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N	022193	001	Jul 24, 2008	Jun DISC

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

	@	BAXTER HLTHCARE	37MG/100ML;5GM/100ML;30MG/100ML;119MG/100ML;161MG/100ML;94MG/100ML;138MG/100ML	N	017390	001		Mar DISC

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

	@	BAXTER HLTHCARE	36.8MG/100ML;30.5MG/100ML;74.6MG/100ML;640MG/100ML;496MG/100ML;89.6MG/100ML	N	017438	001		Mar DISC

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

	+	GAMBRO LUNDIA	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N	207026	002	Jan 13, 2015	Feb CAIN

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

	+	GAMBRO LUNDIA	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.34GM/1000ML;0.187	N	207026	001	Jan 13, 2015	Feb CAIN

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

>D> AT	+	BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N	019933	001	Aug 29, 1989	Sep DISC
>A>	@		20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N	019933	001	Aug 29, 1989	Sep DISC

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB		MACLEODS PHARMS LTD	16MG;12.5MG	A	204100	001	Feb 27, 2015	Feb NEWA
AB			32MG;12.5MG	A	204100	002	Feb 27, 2015	Feb NEWA
AB			32MG;25MG	A	204100	003	Feb 27, 2015	Feb NEWA

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB		ACCORD HLTHCARE	150MG	A	202593	001	Apr 23, 2015	Apr NEWA
AB			500MG	A	202593	002	Apr 23, 2015	Apr NEWA

CAPTOPRIL

TABLET;ORAL

CAPOTEN

	@	PAR PHARM	12.5MG	N	018343	005	Jan 17, 1985	May DISC
	@		25MG	N	018343	002		May DISC
	@		50MG	N	018343	001		May DISC
	@		100MG	N	018343	003		May DISC

CAPTOPRIL

	@	G AND W LABS INC	12.5MG	A	074433	001	Feb 13, 1996	Jul CAHN
	@		12.5MG	A	074462	001	Feb 13, 1996	Apr CAHN
	@		12.5MG	A	074483	001	Feb 13, 1996	Jul CAHN
	@		12.5MG	A	074590	004	Aug 30, 1996	Apr CAHN
	@		25MG	A	074433	002	Feb 13, 1996	Jul CAHN
	@		25MG	A	074462	002	Feb 13, 1996	Apr CAHN
	@		25MG	A	074483	002	Feb 13, 1996	Jul CAHN
	@		25MG	A	074590	002	Aug 30, 1996	Apr CAHN
	@		50MG	A	074433	003	Feb 13, 1996	Jul CAHN

TABLET;ORAL
CAPTOPRIL

	@		50MG	A074462	003	Feb 13, 1996	Apr CAHN
	@		50MG	A074483	003	Feb 13, 1996	Jul CAHN
	@		50MG	A074590	001	Aug 30, 1996	Apr CAHN
	@		100MG	A074433	004	Feb 13, 1996	Jul CAHN
	@		100MG	A074462	004	Feb 13, 1996	Apr CAHN
	@		100MG	A074483	004	Feb 13, 1996	Jul CAHN
	@		100MG	A074590	003	Aug 30, 1996	Apr CAHN
AB	+	MYLAN	100MG	A074434	004	Feb 13, 1996	May CRLD

CAPTOPRIL; HYDROCHLOROTHIAZIDE
TABLET;ORAL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB		G AND W LABS INC	25MG;15MG	A074827	001	Dec 29, 1997	Apr CAHN
AB			25MG;25MG	A074827	002	Dec 29, 1997	Apr CAHN
AB			50MG;15MG	A074827	004	Dec 29, 1997	Apr CAHN
AB			50MG;25MG	A074827	003	Dec 29, 1997	Apr CAHN

CARBAMAZEPINE
CAPSULE, EXTENDED RELEASE;ORAL
CARBAMAZEPINE

AB		MYLAN PHARMS INC	100MG	A076697	001	May 20, 2011	May CAHN
AB			200MG	A076697	002	May 20, 2011	May CAHN
AB			300MG	A076697	003	May 20, 2011	May CAHN

CARBIDOPA; LEVODOPA
CAPSULE, EXTENDED RELEASE;ORAL
RYTARY

		IMPAX LABS INC	23.75MG;95MG	N203312	001	Jan 07, 2015	Jan NEWA
			36.25MG;145MG	N203312	002	Jan 07, 2015	Jan NEWA
			48.75MG;195MG	N203312	003	Jan 07, 2015	Jan NEWA
	+		61.25MG;245MG	N203312	004	Jan 07, 2015	Jan NEWA

SUSPENSION;ENTERAL
DUOPA

	+	ABBVIE INC	4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015	Jan NEWA

>A> CARIPRAZINE HYDROCHLORIDE
>A> CAPSULE;ORAL
>A> VRAYLAR

>A>		FOREST RES INST INC	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Sep NEWA
>A>			EQ 3MG BASE	N204370	002	Sep 17, 2015	Sep NEWA
>A>			EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Sep NEWA
>A>	+		EQ 6MG BASE	N204370	004	Sep 17, 2015	Sep NEWA

CARISOPRODOL
TABLET;ORAL
CARISOPRODOL

AB		INDICUS PHARMA	250MG	A205126	001	Jul 08, 2015	Jun NEWA
AA			350MG	A205126	002	Jul 08, 2015	Jun NEWA

SOMA

AB	+	MEDA PHARMS	250MG	N011792	004	Sep 13, 2007	Jun CTEC

CARVEDILOL
TABLET;ORAL
CARVEDILOL

	@	HIKMA	3.125MG	A077887	001	Sep 07, 2007	Jun DISC
	@		6.25MG	A077887	002	Sep 07, 2007	Jun DISC
	@		12.5MG	A077887	003	Sep 07, 2007	Jun DISC
	@		25MG	A077887	004	Sep 07, 2007	Jun DISC
AB		SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Apr CAHN
AB			6.25MG	A076989	002	Sep 05, 2007	Apr CAHN
AB			12.5MG	A076989	003	Sep 05, 2007	Apr CAHN
AB			25MG	A076989	004	Sep 05, 2007	Apr CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE
FOR SUSPENSION;ORAL
CEFADROXIL

		SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Apr CAHN
AB			EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Apr CAHN
AB			EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Apr CAHN

CEFAZOLIN SODIUM

INJECTABLE;INJECTION

CEFAZOLIN SODIUM

AP		FACTA FARMA	EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A063207	001	Dec 27, 1991	Jan	CAHN
AP			EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991	Jan	CAHN
AP	+		EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jan	CAHN

SOLUTION;INTRAVENOUS

CEFAZOLIN IN PLASTIC CONTAINER

>A>		BAXTER HLTHCARE	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Sep	CAHN
>D>		CELERITY PHARMS	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Sep	CAHN
			EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Aug	NEWA

CEFIXIME

FOR SUSPENSION;ORAL

CEFIXIME

AB		AUROBINDO PHARMA LTD	100MG/5ML	A204835	001	Apr 14, 2015	Apr	NEWA
AB			200MG/5ML	A204835	002	Apr 14, 2015	Apr	NEWA

SUPRAX

AB		LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Apr	CFTG
AB			200MG/5ML	A065355	001	Apr 10, 2007	Apr	CFTG

CEFOTETAN DISODIUM

INJECTABLE;INJECTION

CEFOTAN

	@	IGI LABS INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	May	CAHN
	@		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Mar	CAHN
	@		EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	May	CAHN
	@		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Mar	CAHN
	@		EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Mar	CAHN

CEFOTAN IN PLASTIC CONTAINER

	@	IGI LABS INC	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Mar	CAHN
	@		EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Mar	CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL

CEFPODOXIME PROXETIL

AB		SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Apr	CAHN
AB			EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Apr	CAHN

TABLET;ORAL

CEFPODOXIME PROXETIL

AB		SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Apr	CAHN
AB			EQ 200MG BASE	A065083	002	Aug 20, 2003	Apr	CAHN

CEFTAZIDIME

INJECTABLE;INJECTION

FORTAZ

AP	+	CONCORDIA PHARMS INC	500MG/VIAL	N050578	001	Jul 19, 1985	Jun	CAHN
AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Jun	CAHN
AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Jun	CAHN
AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Jun	CAHN

CEFTAZIDIME SODIUM

INJECTABLE;INJECTION

FORTAZ IN PLASTIC CONTAINER

	@	CONCORDIA PHARMS INC	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Jun	CAHN
	+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Jun	CAHN
	+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Jun	CAHN

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER;IV (INFUSION)

ZERBAXA

	+	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014	Aug	CAHN

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

AP		FACTA FARMA	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007	Jan CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

	@	FACTA FARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007	Jan CAHN
	@		EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007	Jan CAHN
	@	FRESENIUS KABI USA	EQ 250MG BASE/VIAL	A065245	001	Feb 15, 2006	Jul DISC

CEFUROXIME AXETIL

FOR SUSPENSION;ORAL

CEFUROXIME AXETIL

AB		SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Apr CAHN
AB			EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Apr CAHN

TABLET;ORAL

CEFUROXIME AXETIL

AB		ANI PHARMS INC	EQ 250MG BASE	A065190	001	Oct 18, 2004	Jul CAHN
AB			EQ 500MG BASE	A065190	002	Oct 18, 2004	Jul CAHN
AB		SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Apr CAHN
AB			EQ 250MG BASE	A065118	002	Apr 25, 2003	Apr CAHN
AB			EQ 500MG BASE	A065118	003	Apr 25, 2003	Apr CAHN

CEFUROXIME SODIUM

INJECTABLE;INJECTION

CEFUROXIME SODIUM

AP		FACTA FARMA	EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Jan CAHN
AP			EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Jan CAHN

ZINACEF

AP	+	CONCORDIA PHARMS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jun CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jun CAHN

ZINACEF IN PLASTIC CONTAINER

	@	CONCORDIA PHARMS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jun CAHN
	+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jun CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

AB		FACTA FARMA	EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Jan CAHN

ZINACEF

AB	+	CONCORDIA PHARMS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jun CAHN

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AB		ALEMBIC PHARMS LTD	50MG	A204519	001	Aug 21, 2015	Aug NEWA
AB			100MG	A204519	002	Aug 21, 2015	Aug NEWA
AB			200MG	A204519	003	Aug 21, 2015	Aug NEWA
AB			400MG	A204519	004	Aug 21, 2015	Aug NEWA
AB		APOTEX INC	50MG	A204197	001	Jun 02, 2015	May NEWA
AB			100MG	A204197	002	Jun 02, 2015	May NEWA
AB			200MG	A204197	003	Jun 02, 2015	May NEWA
>A> AB		CIPLA LTD	50MG	A207446	001	Sep 23, 2015	Sep NEWA
>A> AB			100MG	A207446	002	Sep 23, 2015	Sep NEWA
>A> AB			200MG	A207446	003	Sep 23, 2015	Sep NEWA
>A> AB			400MG	A207446	004	Sep 23, 2015	Sep NEWA
AB		LUPIN LTD	100MG	A202240	002	Jun 09, 2015	May NEWA
AB			200MG	A202240	003	Jun 09, 2015	May NEWA
AB			400MG	A202240	004	Jun 09, 2015	May NEWA
AB		MYLAN PHARMS INC	100MG	A078857	002	Feb 11, 2015	Jan NEWA
AB			200MG	A078857	003	Feb 11, 2015	Jan NEWA
AB			400MG	A078857	004	Feb 11, 2015	Jan NEWA
AB		WATSON LABS INC	50MG	A200562	001	Feb 11, 2015	Jan NEWA
AB			100MG	A200562	002	Feb 11, 2015	Jan NEWA
AB			200MG	A200562	003	Feb 11, 2015	Jan NEWA
AB			400MG	A200562	004	Feb 11, 2015	Jan NEWA

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

AB		SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Apr CAHN
AB			EQ 500MG BASE	A065007	002	Sep 16, 1999	Apr CAHN

FOR SUSPENSION;ORAL
CEPHALEXIN

	@	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001	Apr CAHN
	@		EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001	Apr CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL
ZYRTEC

AA	+	J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Aug CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION
CHLOROTHIAZIDE SODIUM

AP		SAGENT PHARMS	EQ 500MG BASE/VIAL	A202462	001	May 29, 2015	May NEWA

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE;ORAL
CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE

		SPRIASO LLC	8MG;54.3MG	N206323	001	Jun 22, 2015	Jun NEWA

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

AA		TRIS PHARMA INC	4MG/5ML;5MG/5ML	A206438	001	Jan 27, 2015	Jan NEWA
		VITUZ					
AA	+	CYPRESS PHARM	4MG/5ML;5MG/5ML	N204307	001	Feb 20, 2013	Jan CFTG

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL
HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA		COASTAL PHARMS	4MG/5ML;5MG/5ML;60MG/5ML	A205657	001	Aug 03, 2015	Jul NEWA

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL
TUZISTRA XR

	+	TRIS PHARMA INC	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Apr NEWA
	+	VERNALIS R AND D LTD	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Jun CAHN

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL
CHLORPROMAZINE HYDROCHLORIDE INTENSOL

	@	CYCLE PHARMS LTD	30MG/ML	A088157	001	Apr 27, 1983	Jun CAHN
	@		100MG/ML	A088158	001	Apr 27, 1983	Jun CAHN

INJECTABLE;INJECTION
CHLORPROMAZINE HYDROCHLORIDE

	+	EUROHLTH INTL SARL	25MG/ML	A083329	001		Feb CAHN

TABLET;ORAL
CHLORPROMAZINE HYDROCHLORIDE

	@	CYCLE PHARMS LTD	10MG	A085331	001		Jun CAHN
	@		25MG	A085331	002		Jun CAHN
	@		50MG	A085331	003		Jun CAHN
	@		100MG	A085331	004		Jun CAHN
	@		200MG	A085331	005		Jun CAHN
	@	SANDOZ	10MG	A080439	001		May DISC
	@		25MG	A080439	002		May DISC
	@		50MG	A080439	003		May DISC
	@		100MG	A080439	004		May DISC
	@		200MG	A080439	005		May DISC

CHLORTHALIDONE

TABLET;ORAL
CHLORTHALIDONE

	@	G AND W LABS INC	50MG	A088651	001	May 30, 1985	Apr CAHN
AB		MUTUAL PHARM	50MG	A089286	001	Jul 21, 1986	Mar CMFD
AB	+	MYLAN	50MG	A086831	001		Jun CTEC
		THALITONE					
	@	CITRON PHARMA LLC	15MG	N019574	001	Dec 20, 1988	Jun DISC

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

		@	ANI PHARMS INC	EQ 4GM RESIN/PACKET	A074554	001	Oct 02, 1996	Aug CAHN
		@		EQ 4GM RESIN/SCOOPFUL	A074554	002	Oct 02, 1996	Aug CAHN

CHOLIC ACID

CAPSULE;ORAL

CHOLBAM

			ASKLEPION PHARMS LLC	50MG	N205750	001	Mar 17, 2015	Mar NEWA
		+		250MG	N205750	002	Mar 17, 2015	Mar NEWA
			RTRX	50MG	N205750	001	Mar 17, 2015	Apr CAHN
		+		250MG	N205750	002	Mar 17, 2015	Apr CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

FENOFIBRIC ACID

>A>	AB		ACTAVIS ELIZABETH	EQ 45MG FENOFIBRIC ACID	A200920	001	Oct 07, 2015	Sep NEWA
>A>	AB			EQ 135MG FENOFIBRIC ACID	A200920	002	Oct 07, 2015	Sep NEWA

CICLOPIROX

SOLUTION;TOPICAL

CICLOPIROX

>D>		@	APOTEX INC	8%	A078172	001	Sep 18, 2007	Sep CMFD
>A>	AT			8%	A078172	001	Sep 18, 2007	Sep CMFD

CIDOFOVIR

INJECTABLE;INJECTION

CIDOFOVIR

	AP	+	MYLAN INSTITUTIONAL	EQ 75MG BASE/ML	A201276	001	Jun 27, 2012	May CRLD

VISTIDE

		@	GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	May DISC

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

		@	G AND W LABS INC	EQ 300MG BASE/5ML	A074176	001	Jun 01, 1994	Apr CAHN

CIPROFLOXACIN

INJECTABLE;INJECTION

CIPROFLOXACIN

	AP		CLARIS PHARMASERVICE	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Apr CAHN
	AP			400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Apr CAHN

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

	AP		CLARIS PHARMASERVICE	200MG/100ML	A078024	001	Mar 18, 2008	Apr CAHN
	AP			400MG/200ML	A078024	002	Mar 18, 2008	Apr CAHN

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

	AB		SUN PHARM INDS LTD	EQ 250MG BASE	A075747	001	Jun 09, 2004	Apr CAHN
	AB			EQ 500MG BASE	A075747	002	Jun 09, 2004	Apr CAHN
	AB			EQ 750MG BASE	A075747	003	Jun 09, 2004	Apr CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

	AP		FRESENIUS KABI USA	EQ 2MG BASE/ML	A203183	001	Feb 26, 2015	Feb NEWA

CISATRACURIUM BESYLATE PRESERVATIVE FREE

	AP		FRESENIUS KABI USA	EQ 2MG BASE/ML	A203182	001	Feb 26, 2015	Feb NEWA
	AP			EQ 10MG BASE/ML	A203182	002	Feb 26, 2015	Feb NEWA

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN

	AP		ACCORD HLTHCARE	1MG/ML	A206774	001	Aug 18, 2015	Aug NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

AB		G AND W LABS INC	EQ 10MG BASE	A077048	001	Nov 16, 2004	Apr	CAHN
AB			EQ 20MG BASE	A077048	002	Nov 16, 2004	Apr	CAHN
AB			EQ 40MG BASE	A077048	003	Nov 16, 2004	Apr	CAHN

CLARITHROMYCIN

FOR SUSPENSION;ORAL

CLARITHROMYCIN

AB		SUN PHARM INDS LTD	125MG/5ML	A065382	001	Aug 30, 2007	Apr	CAHN
AB			250MG/5ML	A065382	002	Aug 30, 2007	Apr	CAHN

TABLET;ORAL

CLARITHROMYCIN

>A> AB		HEC PHARM USA INC	250MG	A203584	001	Sep 28, 2015	Sep	NEWA
>A> AB			500MG	A203584	002	Sep 28, 2015	Sep	NEWA
AB		SUN PHARM INDS LTD	250MG	A065174	001	Sep 24, 2004	Apr	CAHN
AB			500MG	A065174	002	Sep 24, 2004	Apr	CAHN

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

AB		LUPIN LTD	500MG	A202532	001	Sep 15, 2015	Aug	NEWA
AB	+	TEVA	500MG	A065154	001	May 18, 2005	Jan	CRLD

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE;INJECTION

TIMENTIN

	@	GLAXOSMITHKLINE	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	A062691	001	Dec 19, 1986	May	DISC
	@		EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	001	Apr 01, 1985	May	DISC
	@		EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	002	Apr 01, 1985	May	DISC
	@		EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987	May	DISC

TIMENTIN IN PLASTIC CONTAINER

	@	GLAXOSMITHKLINE	EQ 100MG BASE/100ML;EQ 3GM BASE/100ML	N050658	001	Dec 15, 1989	May	DISC

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

	@	ANI PHARMS INC	1.34MG	A073282	001	Jan 31, 1992	Jul	CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

AB		G AND W LABS INC	EQ 150MG BASE	A063029	001	Sep 20, 1989	Apr	CAHN
AB			EQ 300MG BASE	A063029	002	Aug 05, 2005	Apr	CAHN
AB		SUN PHARM INDS LTD	EQ 150MG BASE	A065061	001	Feb 02, 2001	Apr	CAHN
AB			EQ 300MG BASE	A065061	002	Feb 02, 2001	Apr	CAHN

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE

>A> AP		ALVOGEN INC	EQ 150MG BASE/ML	A062800	001	Jul 24, 1987	Sep	CAHN
>A> AP			EQ 150MG BASE/ML	A062801	001	Jul 24, 1987	Sep	CAHN
>A> AP			EQ 150MG BASE/ML	A062943	001	Sep 29, 1988	Sep	CAHN
>D> AP		HOSPIRA	EQ 150MG BASE/ML	A062800	001	Jul 24, 1987	Sep	CAHN
>D> AP			EQ 150MG BASE/ML	A062801	001	Jul 24, 1987	Sep	CAHN
>D> AP			EQ 150MG BASE/ML	A062943	001	Sep 29, 1988	Sep	CAHN
	@	IGI LABS INC	EQ 150MG BASE/ML	A062928	001	Feb 13, 1989	Mar	CAHN

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

	@	BOCA PHARMA LLC	EQ 1% BASE	A062944	001	Jan 11, 1989	Jan	CAHN
AT		VINTAGE PHARMS	EQ 1% BASE	A203343	001	May 29, 2015	May	NEWA

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB		ACTAVIS MID ATLANTIC	1.2%;0.025%	A202564	001	Jun 12, 2015	Jun	NEWA

ZIANA

AB	+	MEDICIS	1.2%;0.025%	N050802	001	Nov 07, 2006	Jun	CTEC

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	+	FOUGERA PHARMS	0.05%	A075430	001	May 26, 1999	May	CRLD

CORMAX

AB1	+	HI TECH PHARMA	0.05%	A074220	001	May 16, 1997	Jun	CRLD

TEMOVATE

	@	FOUGERA PHARMS	0.05%	N019322	001	Dec 27, 1985	Jun	DISC

TEMOVATE E

	@	FOUGERA PHARMS	0.05%	N020340	001	Jun 17, 1994	May	DISC

GEL;TOPICAL

CLOBETASOL PROPIONATE

AB	+	FOUGERA PHARMS	0.05%	A075368	001	Feb 15, 2000	May	CRLD

TEMOVATE

	@	FOUGERA PHARMS	0.05%	N020337	001	Apr 29, 1994	May	DISC

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

AB		G AND W LABS INC	0.05%	A074089	001	Feb 16, 1994	Feb	CAHN

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

AT		G AND W LABS INC	0.05%	A074331	001	Dec 15, 1995	Mar	CMFD

CLOMIPHENE CITRATE

TABLET;ORAL

SEROPHENE

	@	EMD SERONO	50MG	N018361	001	Mar 22, 1982	Jun	DISC

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

CLONIDINE

AB		ACTAVIS LABS UT INC	0.1MG/24HR	A090873	001	May 06, 2014	Mar	CAHN
AB			0.2MG/24HR	A090873	002	May 06, 2014	Mar	CAHN
AB			0.3MG/24HR	A090873	003	May 06, 2014	Mar	CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

	@	DAVA PHARMS INC	0.1MG	A071783	001	Apr 05, 1988	May	DISC
	@		0.2MG	A071784	001	Apr 05, 1988	May	DISC
	@		0.3MG	A071785	001	Apr 05, 1988	May	DISC

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB2		ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015	May	NEWA
AB1			0.1MG	A203320	001	May 15, 2015	May	NEWA
	@		0.2MG	A202792	002	May 15, 2015	Aug	DISC
AB2			0.2MG	A202792	002	May 15, 2015	May	NEWA
	@		0.2MG	A203320	002	May 15, 2015	Aug	DISC
AB1			0.2MG	A203320	002	May 15, 2015	May	NEWA
	@	ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014	Aug	DISC
AB2			0.1MG	A202983	001	Apr 02, 2014	May	CTEC
	@		0.2MG	A202983	002	Apr 02, 2014	Aug	DISC
AB2			0.2MG	A202983	002	Apr 02, 2014	May	CTEC

CLONIDINE HYDROCHLORIDE

AB1		ANCHEN PHARMS	0.1MG	A202984	001	Sep 30, 2013	May	CTEC
	@		0.2MG	A202984	002	Sep 30, 2013	Aug	DISC
AB1			0.2MG	A202984	002	Sep 30, 2013	May	CTEC

KAPVAY

AB1	+	CONCORDIA PHARMS INC	0.1MG	N022331	003	Sep 28, 2010	Aug	CRLD
AB1			0.1MG	N022331	003	Sep 28, 2010	Jun	CRLD
AB1	+		0.1MG	N022331	003	Sep 28, 2010	May	CTEC
	@		0.2MG	N022331	004	Sep 28, 2010	Aug	DISC
AB1	+		0.2MG	N022331	004	Sep 28, 2010	Jun	CRLD
AB1			0.2MG	N022331	004	Sep 28, 2010	May	CTEC

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

AB		SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004	Apr	CAHN
AB			7.5MG	A076911	002	Sep 29, 2004	Apr	CAHN
AB			15MG	A076911	003	Sep 29, 2004	Apr	CAHN

CLOZAPINE

TABLET;ORAL

CLOZAPINE

>A> AB		ACTAVIS LABS FL INC	25MG	A203807	001	Sep 17, 2015	Sep	NEWA
>A> AB			100MG	A203807	002	Sep 17, 2015	Sep	NEWA

CLOZARIL

AB		HERITAGE LIFE	25MG	N019758	001	Sep 26, 1989	Aug	CAHN
AB	+		100MG	N019758	002	Sep 26, 1989	Aug	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

CLOZAPINE

AB		MYLAN PHARMS INC	25MG	A201824	002	Sep 15, 2015	Aug	NEWA
AB			100MG	A201824	003	Sep 15, 2015	Aug	NEWA

FAZACLO ODT

AB		JAZZ PHARMS III	25MG	N021590	001	Feb 10, 2004	Aug	CFTG
AB	+		100MG	N021590	002	Feb 10, 2004	Aug	CFTG

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL

PREZCOBIX

+		JANSSEN PRODS	150MG;EQ 800MG BASE	N205395	001	Jan 29, 2015	Jan	NEWA

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA		AMNEAL PHARMS	10MG/5ML;5MG/5ML;6.25MG/5ML	A200963	001	Aug 26, 2015	Aug	NEWA

CODEINE SULFATE

SOLUTION;ORAL

CODEINE SULFATE

	@	ROXANE	30MG/5ML	N202245	001	Jun 30, 2011	Jan	DISC

COLCHICINE

CAPSULE;ORAL

MITIGARE

		HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014	Jan	CAHN

COLCHICINE; PROBENECID

TABLET;ORAL

PROBENECID AND COLCHICINE

	@	ANI PHARMS INC	0.5MG;500MG	A083734	001		Aug	CAHN

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

AP		XELLIA PHARMS APS	EQ 150MG BASE/VIAL	A205356	001	May 29, 2015	May	NEWA

CORTICOTROPIN

INJECTABLE;INJECTION

H.P. ACTHAR GEL

	@	MALLINCKRODT ARD	40 UNITS/ML	N008372	006		Aug	CAHN
	+		80 UNITS/ML	N008372	008		Aug	CAHN

CYANOCOBALAMIN

INJECTABLE;INJECTION

CYANOCOBALAMIN

	@	EUROHLTH INTL SARL	1MG/ML	A080515	002		Feb	CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB		ORIT LABS LLC	5MG	A078218	002	Jun 19, 2015	Jun	NEWA
AB		SUN PHARM INDS LTD	5MG	A078722	001	May 12, 2008	Apr	CAHN
AB			7.5MG	A078722	002	May 12, 2008	Apr	CAHN
AB			10MG	A078722	003	May 12, 2008	Apr	CAHN

CYPROHEPTADINE HYDROCHLORIDE

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

>A>	AA	MIRROR PHARMS LLC	4MG	A205087	001	Sep 23, 2015	Sep	NEWA

DABRAFENIB MESYLATE

CAPSULE;ORAL

TAFINLAR

		NOVARTIS PHARMS CORP	EQ 50MG BASE	N202806	001	May 29, 2013	Mar	CAHN
	+		EQ 75MG BASE	N202806	002	May 29, 2013	Mar	CAHN

DACLATASVIR DIHYDROCHLORIDE

TABLET;ORAL

DAKLINZA

		BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843	001	Jul 24, 2015	Jul	NEWA
	+		EQ 60MG BASE	N206843	002	Jul 24, 2015	Jul	NEWA

DALTEPARIN SODIUM

INJECTABLE;INJECTION

FRAGMIN

	@	PFIZER INC	7,500 IU/0.75ML	N020287	008	Apr 04, 2002	Jun	CAHN
	@	PHARMACIA AND UPJOHN	7,500 IU/0.75ML	N020287	008	Apr 04, 2002	Apr	CAHN

INJECTABLE;SUBCUTANEOUS

FRAGMIN

		PFIZER INC	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994	Jun	CAHN
			5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996	Jun	CAHN
			7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002	Jun	CAHN
	@		10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Jun	CAHN
			10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998	Jun	CAHN
			12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007	Jun	CAHN
			15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007	Jun	CAHN
			18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007	Jun	CAHN
	+		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002	Jun	CAHN
	@		95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Jun	CAHN
		PHARMACIA AND UPJOHN	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994	Apr	CAHN
			5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996	Apr	CAHN
			7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002	Apr	CAHN
	@		10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Apr	CAHN
			10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998	Apr	CAHN
			12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007	Apr	CAHN
			15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007	Apr	CAHN
			18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007	Apr	CAHN
	+		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002	Apr	CAHN
	@		95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Apr	CAHN

DANTROLENE SODIUM

CAPSULE;ORAL

DANTROLENE SODIUM

AB		ELITE LABS INC	25MG	A076686	001	Oct 24, 2005	May	CAHN
AB			50MG	A076686	002	Oct 24, 2005	May	CAHN
AB			100MG	A076686	003	Oct 24, 2005	May	CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

DARIFENACIN HYDROBROMIDE

AB		ANCHEN PHARMS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	Mar	NEWA
AB			EQ 15MG BASE	A091190	002	Mar 13, 2015	Mar	NEWA

ENABLEX

AB		WARNER CHILCOTT LLC	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Mar	CFTG
AB	+		EQ 15MG BASE	N021513	002	Dec 22, 2004	Mar	CFTG

DASATINIB

TABLET;ORAL

SPRYCEL

>D>		BRISTOL MYERS SQUIBB	100MG	N021986	004	May 30, 2008	Sep	CRLD
>A>	+		100MG	N021986	004	May 30, 2008	Sep	CRLD
>D>	+		140MG	N021986	006	Oct 28, 2010	Sep	CRLD
>A>			140MG	N021986	006	Oct 28, 2010	Sep	CRLD

DECITABINE
INJECTABLE;INTRAVENOUS
DACOGEN

AP	+	OTSUKA PHARM CO LTD	50MG/VIAL	N021790	001	May 02, 2006	Jan	CAHN

DEFERASIROX
TABLET;ORAL
JADENU

		NOVARTIS PHARMS CORP	90MG	N206910	001	Mar 30, 2015	Mar	NEWA
			180MG	N206910	002	Mar 30, 2015	Mar	NEWA
	+		360MG	N206910	003	Mar 30, 2015	Mar	NEWA

DEFERIPRONE
SOLUTION;ORAL
FERRIPROX

>A>	+	APOPHARMA INC	100MG/ML	N208030	001	Sep 09, 2015	Sep	NEWA

DEMECLOCYCLINE HYDROCHLORIDE
TABLET;ORAL
DEMECLOCYCLINE HYDROCHLORIDE

AB		EPIC PHARMA LLC	150MG	A065447	001	Aug 18, 2015	Aug	NEWA
AB			300MG	A065447	002	Aug 18, 2015	Aug	NEWA

DEOXYCHOLIC ACID
SOLUTION;SUBCUTANEOUS
KYBELLA

	+	KYTHERA BIOPHARMS	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Apr	NEWA

DESIPRAMINE HYDROCHLORIDE
TABLET;ORAL
DESIPRAMINE HYDROCHLORIDE

>A>		ANI PHARMS INC	25MG	A071803	002	Dec 08, 1987	Sep	CMS1
>A>			50MG	A071803	003	Dec 08, 1987	Sep	CMS1
>A>			75MG	A071803	004	Dec 08, 1987	Sep	CMS1
>A>			150MG	A071803	005	May 29, 1997	Sep	CMS1

DESIRUDIN RECOMBINANT
INJECTABLE;SUBCUTANEOUS
IPRIVASK

	+	VALEANT PHARMS NORTH	15MG/VIAL	N021271	001	Apr 04, 2003	May	CAHN

DESLORATADINE
SOLUTION;ORAL
CLARINEX

AA	+	MERCK SHARP DOHME	0.5MG/ML	N021300	001	Sep 01, 2004	Jun	CFTG

DESLORATADINE

AA		TARO PHARM INDS	0.5MG/ML	A202592	001	Jun 30, 2015	Jun	NEWA

DESMOPRESSIN ACETATE
TABLET;ORAL
DDAVP

AB		FERRING PHARMS INC	0.1MG	N019955	001	Sep 06, 1995	Jan	CAHN
AB	+		0.2MG	N019955	002	Sep 06, 1995	Jan	CAHN

DESMOPRESSIN ACETATE

AB		GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015	May	NEWA
AB			0.2MG	A201831	002	May 28, 2015	May	NEWA

DESOGESTREL; ETHINYL ESTRADIOL
TABLET;ORAL-28
BEKYREE

AB		LUPIN LTD	0.15MG,N/A;0.02MG,0.01MG	A202226	001	Aug 12, 2015	Jul	NEWA

CYCLESSA

AB	+	ASPEN GLOBAL INC	0.1MG,0.125MG,0.15MG;0.025MG,0.025 MG,0.025MG	N021090	001	Dec 20, 2000	Aug	CAHN

ISIBLOOM

AB		SANDOZ INC	0.15MG;0.03MG	A202789	001	Aug 12, 2015	Jul	NEWA

KARIVA

AB	+	BARR	0.15MG,N/A;0.02MG,0.01MG	A075863	001	Apr 05, 2002	Apr	CTEC

KIMIDESS

AB		VINTAGE PHARMS	0.15MG,N/A;0.02MG,0.01MG	A076681	001	Apr 30, 2015	Apr	NEWA

DESONIDE

CREAM;TOPICAL

DESONIDE

AB		TEVA PHARMS	0.05%	A074027	001	Sep 28, 1992	May CMFD

DESOXIMETASONE

CREAM;TOPICAL

DESOXIMETASONE

AB		ACTAVIS MID ATLANTIC	0.25%	A205082	001	Sep 04, 2015	Aug NEWA
AB		VERSAPHARM INC	0.25%	A203234	001	Jun 12, 2015	Jun NEWA

OINTMENT;TOPICAL

DESOXIMETASONE

AB		PERRIGO NEW YORK	0.25%	A077770	001	Apr 20, 2015	Apr NEWA

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

AB		ALEMBIC PHARMS LTD	EQ 50MG BASE	A204003	001	Jun 29, 2015	Jun NEWA
AB			EQ 100MG BASE	A204003	002	Jun 29, 2015	Jun NEWA
AB		LUPIN LTD	EQ 50MG BASE	A204172	001	Jun 29, 2015	Jun NEWA
AB			EQ 100MG BASE	A204172	002	Jun 29, 2015	Jun NEWA
AB		MYLAN PHARMS INC	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jun NEWA
AB			EQ 100MG BASE	A204095	002	Jun 29, 2015	Jun NEWA
AB		SANDOZ INC	EQ 50MG BASE	A204028	001	Jun 29, 2015	Jun NEWA
AB			EQ 100MG BASE	A204028	002	Jun 29, 2015	Jun NEWA

PRISTIQ

AB	+	WYETH PHARMS INC	EQ 50MG BASE	N021992	001	Feb 29, 2008	Jun CFTG
AB	+		EQ 100MG BASE	N021992	002	Feb 29, 2008	Jun CFTG

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

>A> AP		BD RX	EQ 4MG PHOSPHATE/ML	A203129	001	Sep 30, 2015	Sep NEWA
	@	EUROHLTH INTL SARL	EQ 4MG PHOSPHATE/ML	A084282	001		Mar CAHN
AP	+		EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Feb CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MAXITROL

AT	+	ALCON LABS INC	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050065	002		Mar CAHN

SUSPENSION/DROPS;OPHTHALMIC

MAXITROL

AT	+	ALCON LABS INC	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002		Mar CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

>A> AP		FRESENIUS KABI USA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A201072	001	Sep 18, 2015	Sep NEWA
AP		SUN PHARM INDS INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A202126	001	Aug 20, 2015	Aug NEWA

PRECEDEX

		HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Jan NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		MYLAN PHARMS INC	5MG	A204266	001	Aug 25, 2015	Aug NEWA
AB			10MG	A204266	002	Aug 25, 2015	Aug NEWA
AB			15MG	A204266	003	Aug 25, 2015	Aug NEWA
AB			40MG	A204266	007	Aug 25, 2015	Aug NEWA
AB		WATSON LABS INC	5MG	A079108	001	Aug 05, 2015	Jul NEWA
AB			10MG	A079108	002	Aug 05, 2015	Jul NEWA

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

>A> AB		SUN PHARM INDS LTD	2.5MG	A201231	001	Sep 24, 2015	Sep NEWA
>A> AB			5MG	A201231	002	Sep 24, 2015	Sep NEWA
>A> AB			10MG	A201231	003	Sep 24, 2015	Sep NEWA

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	5GM/100ML;30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017451	001			Mar	DISC

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE;INJECTION

MD-76R

AP	+	LIEBEL-FLARSHEIM	66%;10%	N019292	001	Sep 29, 1989	Feb	CAHN

SOLUTION;ORAL, RECTAL

MD-GASTROVIEW

AA		LIEBEL-FLARSHEIM	66%;10%	A087388	001		Jan	CAHN

DICHLORPHENAMIDE

TABLET;ORAL

KEVEYIS

		TARO	50MG	N011366	002	Aug 07, 2015	Aug	NEWA

DICLOFENAC SODIUM

GEL;TOPICAL

VOLTAREN

	+	GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Aug	CAHN

SOLUTION;TOPICAL

DICLOFENAC SODIUM

AT		IGI LABS INC	1.5%	A202769	001	Jul 08, 2015	Jun	NEWA
AT		LUPIN LTD	1.5%	A204132	001	Aug 20, 2015	Aug	NEWA

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

TENUATE

AA	+	ACTAVIS LABS UT INC	25MG	N011722	002		Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL

TENUATE DOSPAN

AB	+	ACTAVIS LABS UT INC	75MG	N012546	001		Mar	CAHN

DIFLORASONE DIACETATE

OINTMENT;TOPICAL

DIFLORASONE DIACETATE

AB		VERSAPHARM INC	0.05%	A206572	001	Jul 24, 2015	Jul	NEWA

DIFLUNISAL

TABLET;ORAL

DIFLUNISAL

AB		HERITAGE PHARMA	500MG	A202845	001	Mar 08, 2012	Mar	CAHN

DIGOXIN

INJECTABLE;INJECTION

DIGOXIN

AP		EUROHLTH INTL SARL	0.25MG/ML	A083391	001		Feb	CAHN

TABLET;ORAL

DIGOXIN

AB		MYLAN PHARMS INC	0.125MG	A040282	001	Dec 23, 1999	Jan	CTEC
AB			0.25MG	A040282	002	Dec 23, 1999	Jan	CTEC
AB		SUN PHARM INDS INC	0.125MG	A076363	001	Jan 31, 2003	Feb	CMFD
AB			0.25MG	A076363	002	Jan 31, 2003	Feb	CMFD

LANOXIN

		CONCORDIA PHARMS INC	0.0625MG	N020405	001	Sep 30, 1997	Apr	CAHN
AB			0.125MG	N020405	002	Sep 30, 1997	Apr	CAHN
			0.1875MG	N020405	003	Sep 30, 1997	Apr	CAHN
AB	+		0.25MG	N020405	004	Sep 30, 1997	Apr	CAHN
	@		0.375MG	N020405	005	Sep 30, 1997	Apr	CAHN
	@		0.5MG	N020405	006	Sep 30, 1997	Apr	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB2	+	MYLAN	240MG	A075124	001	Mar 18, 1998	Feb	CRLD

TIAZAC

AB4		VALEANT PHARMS NORTH	120MG	N020401	001	Sep 11, 1995	Feb	CAHN
AB4			180MG	N020401	002	Sep 11, 1995	Feb	CAHN
AB4			240MG	N020401	003	Sep 11, 1995	Feb	CAHN
AB4			300MG	N020401	004	Sep 11, 1995	Feb	CAHN
AB4			360MG	N020401	005	Sep 11, 1995	Feb	CAHN
AB4	+		420MG	N020401	006	Oct 16, 1998	Feb	CAHN

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

AP		EUROHLTH INTL SARL	5MG/ML	A078538	001	Dec 17, 2008	Jun	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

AP	+	EUROHLTH INTL SARL	50MG/ML	A080817	002		Jun	CAHN

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

AP		EUROHLTH INTL SARL	5MG/ML	A074521	001	Oct 18, 1996	Jun	CAHN

DISULFIRAM

TABLET;ORAL

DISULFIRAM

AB		MYLAN PHARMS INC	250MG	A203916	001	Mar 04, 2015	Feb	NEWA
AB			500MG	A203916	002	Mar 04, 2015	Feb	NEWA

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

AB		AMNEAL PHARMS	EQ 250MG VALPROIC ACID	A203730	001	May 29, 2015	May	NEWA
AB			EQ 500MG VALPROIC ACID	A203730	002	May 29, 2015	May	NEWA
	@	G AND W LABS INC	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009	Jul	CAHN

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

	@	IGI LABS INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995	Mar	CAHN

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

AP		TEVA PHARMS USA	20MG/ML (20MG/ML)	A203877	001	Sep 16, 2015	Aug	NEWA
AP			80MG/4ML (20MG/ML)	A203877	002	Sep 16, 2015	Aug	NEWA

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

AB		HETERO LABS LTD V	5MG	A203034	001	Jan 30, 2015	Jan	NEWA
AB			10MG	A203034	002	Jan 30, 2015	Jan	NEWA
AB		SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010	Apr	CAHN
AB			10MG	A076786	002	Nov 26, 2010	Apr	CAHN
AB			23MG	A204293	001	Jun 05, 2015	May	NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

NAMZARIC

		FOREST LABS LLC	10MG;14MG	N206439	001	Dec 23, 2014	Mar	CAHN
	+		10MG;28MG	N206439	002	Dec 23, 2014	Mar	CAHN

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE

	@	IGI LABS INC	40MG/ML	A070087	001	Oct 23, 1985	Mar	CAHN
	@		40MG/ML	N018656	001	Jun 28, 1983	Mar	CAHN
	@		80MG/ML	A070089	001	Oct 23, 1985	Mar	CAHN
	@		80MG/ML	A070090	001	Oct 23, 1985	Mar	CAHN

	INJECTABLE;INJECTION						
	DOPAMINE HYDROCHLORIDE						
	@	80MG/ML	A070091	001	Oct 23, 1985	Mar	CAHN
	@	160MG/ML	A070092	001	Oct 23, 1985	Mar	CAHN
	@	160MG/ML	A070093	001	Oct 23, 1985	Mar	CAHN
	@	160MG/ML	A070094	001	Oct 23, 1985	Mar	CAHN
	DOXAPRAM HYDROCHLORIDE						
	INJECTABLE;INJECTION						
	DOPRAM						
AP	+ EUROHLTH INTL SARL	20MG/ML	N014879	001		Jun	CAHN
	DOXEPIN HYDROCHLORIDE						
	CAPSULE;ORAL						
	DOXEPIN HYDROCHLORIDE						
AB	+ MYLAN PHARMS INC	EQ 100MG BASE	A070791	005	May 13, 1986	Jan	CRLD
	+ PAR PHARM	EQ 150MG BASE	A071669	001	Nov 09, 1987	Jan	CRLD
	CREAM;TOPICAL						
	ZONALON						
	+ DELCOR ASSET CORP	5%	N020126	001	Apr 01, 1994	Mar	CAHN
	DOXERCALCIFEROL						
	INJECTABLE;INJECTION						
	DOXERCALCIFEROL						
AP	AKORN INC	4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015	Apr	NEWA
	DOXYCYCLINE						
	CAPSULE;ORAL						
	DOXYCYCLINE						
AB	NOVEL LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	May	NEWA
AB		EQ 75MG BASE	A204446	002	May 28, 2015	May	NEWA
AB		EQ 100MG BASE	A204446	003	May 28, 2015	May	NEWA
AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065053	001	Nov 22, 2000	Apr	CAHN
AB		EQ 75MG BASE	A065053	003	Sep 10, 2003	Apr	CAHN
AB		EQ 100MG BASE	A065053	002	Nov 22, 2000	Apr	CAHN
	TABLET;ORAL						
	DOXYCYCLINE						
AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065356	001	May 31, 2006	Apr	CAHN
AB		EQ 75MG BASE	A065356	002	May 31, 2006	Apr	CAHN
AB		EQ 100MG BASE	A065356	003	May 31, 2006	Apr	CAHN
	DOXYCYCLINE HYCLATE						
	INJECTABLE;INJECTION						
	DOXYCYCLINE						
	@ EUROHLTH INTL SARL	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983	Jun	CAHN
	@	EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983	Jun	CAHN
	DROPERIDOL						
	INJECTABLE;INJECTION						
	DROPERIDOL						
	@ IGI LABS INC	2.5MG/ML	A072019	001	Oct 19, 1988	Mar	CAHN
	@	2.5MG/ML	A072020	001	Oct 19, 1988	Mar	CAHN
	@	2.5MG/ML	A072021	001	Oct 19, 1988	Mar	CAHN
	DROSPIRENONE; ETHINYL ESTRADIOL						
	TABLET;ORAL						
	DROSPIRENONE AND ETHINYL ESTRADIOL						
AB	GLENMARK PHARMS LTD	3MG;0.02MG	A204296	001	Aug 17, 2015	Aug	NEWA
	DULOXETINE HYDROCHLORIDE						
	CAPSULE, DELAYED REL PELLETS;ORAL						
	DULOXETINE HYDROCHLORIDE						
AB	ALKEM LABS LTD	EQ 20MG BASE	A203197	001	Aug 26, 2015	Aug	NEWA
AB		EQ 30MG BASE	A203197	002	Aug 26, 2015	Aug	NEWA
AB		EQ 60MG BASE	A203197	003	Aug 26, 2015	Aug	NEWA

ECONAZOLE NITRATE

CREAM;TOPICAL

ECONAZOLE NITRATE

AB		FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Mar CRLD
AB	+	PERRIGO NEW YORK	1%	A076479	001	Jun 23, 2004	Mar CRLD

EDOXABAN TOSYLATE

TABLET;ORAL

SAVAYSA

		DAIICHI SANKYO	EQ 15MG BASE	N206316	001	Jan 08, 2015	Jan NEWA
			EQ 30MG BASE	N206316	002	Jan 08, 2015	Jan NEWA
	+		EQ 60MG BASE	N206316	003	Jan 08, 2015	Jan NEWA

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

ENLON

	+	MYLAN INSTITUTIONAL	10MG/ML	A088873	001	Aug 06, 1985	Mar CRLD

TENSILON

	@	IGI LABS INC	10MG/ML	N007959	001		Apr CAHN
	@	VALEANT PHARMS	10MG/ML	N007959	001		Mar DISC

TENSILON PRESERVATIVE FREE

	@	IGI LABS INC	10MG/ML	N007959	002		Apr CAHN
	@	VALEANT PHARMS	10MG/ML	N007959	002		Mar DISC

ELTROMBOPAG OLAMINE

FOR SUSPENSION;ORAL

PROMACTA

	+	NOVARTIS PHARMS CORP	EQ 25MG ACID/PACKET	N207027	001	Aug 24, 2015	Aug NEWA

TABLET;ORAL

PROMACTA

		NOVARTIS PHARMS CORP	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Mar CAHN
			EQ 25MG ACID	N022291	001	Nov 20, 2008	Mar CAHN
			EQ 50MG ACID	N022291	002	Nov 20, 2008	May CRLD
	+		EQ 50MG ACID	N022291	002	Nov 20, 2008	Mar CAHN
	+		EQ 75MG ACID	N022291	003	Sep 08, 2009	May CRLD
			EQ 75MG ACID	N022291	003	Sep 08, 2009	Mar CAHN
	+		EQ 100MG ACID	N022291	005	Nov 16, 2012	May CRLD
			EQ 100MG ACID	N022291	005	Nov 16, 2012	Mar CAHN

ELUXADOLINE

TABLET;ORAL

VIBERZI

		FOREST TOSARA LTD	75MG	N206940	001	May 27, 2015	Jul CAHN
	+		100MG	N206940	002	May 27, 2015	Jul CAHN
		FURIEX PHARMS	75MG	N206940	001	May 27, 2015	May NEWA
	+		100MG	N206940	002	May 27, 2015	May NEWA

EMPAGLIFLOZIN; LINAGLIPTIN

TABLET;ORAL

GLYXAMBI

		BOEHRINGER INGELHEIM	10MG;5MG	N206073	001	Jan 30, 2015	Jan NEWA
	+		25MG;5MG	N206073	002	Jan 30, 2015	Jan NEWA

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

SYNJARDY

		BOEHRINGER INGELHEIM	5MG;500MG	N206111	001	Aug 26, 2015	Aug NEWA
			5MG;1GM	N206111	002	Aug 26, 2015	Aug NEWA
			12.5MG;500MG	N206111	003	Aug 26, 2015	Aug NEWA
	+		12.5MG;1GM	N206111	004	Aug 26, 2015	Aug NEWA

ENALAPRIL MALEATE

TABLET;ORAL

ENALAPRIL MALEATE

AB		SANDOZ INC	2.5MG	A075496	001	Aug 22, 2000	Mar CMFD
AB			5MG	A075496	002	Aug 22, 2000	Mar CMFD
AB			10MG	A075459	001	Aug 22, 2000	Mar CMFD
AB			20MG	A075459	002	Aug 22, 2000	Mar CMFD
	@	SUN PHARM INDS LTD	2.5MG	A075556	001	Aug 22, 2000	Apr CAHN
	@		5MG	A075556	002	Aug 22, 2000	Apr CAHN
	@		10MG	A075556	003	Aug 22, 2000	Apr CAHN

TABLET;ORAL
ENALAPRIL MALEATE

	@	20MG	A075556	004	Aug 22, 2000		Apr CAHN

VASOTEC

AB	VALEANT PHARMS NORTH	2.5MG	N018998	005	Jul 26, 1988		Apr CAHN
AB		5MG	N018998	001	Dec 24, 1985		Apr CAHN
AB		10MG	N018998	002	Dec 24, 1985		Apr CAHN
AB	+	20MG	N018998	003	Dec 24, 1985		Apr CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB	G AND W LABS INC	5MG;12.5MG	A075727	001	Sep 18, 2001		Apr CAHN
AB		10MG;25MG	A075727	002	Sep 18, 2001		Apr CAHN

ENTACAPONE

TABLET;ORAL
ENTACAPONE

AB	AUROBINDO PHARMA LTD	200MG	A203437	001	Jun 19, 2015		Jun NEWA

ENTECAVIR

TABLET;ORAL
ENTECAVIR

AB	AUROBINDO PHARMA LTD	0.5MG	A206217	001	Aug 26, 2015		Aug NEWA
AB		1MG	A206217	002	Aug 26, 2015		Aug NEWA
AB	HETERO LABS LTD V	0.5MG	A205740	001	Aug 21, 2015		Aug NEWA
AB		1MG	A205740	002	Aug 21, 2015		Aug NEWA

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS
ADRENALIN

+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012		Jul CAIN

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
ADRENALIN

+	PAR STERILE PRODUCTS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013		Jul CAIN

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

>A>	@ EUROHLTH INTL SARL	0.01MG/ML;1%	A080406	001			Sep CAHN
>A>	@	0.01MG/ML;2%	A080406	002			Sep CAHN
>D>	@ HIKMA MAPLE	0.01MG/ML;1%	A080406	001			Sep CAHN
>D>	@	0.01MG/ML;2%	A080406	002			Sep CAHN

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
TEVETEN HCT

	@ ABBVIE	600MG;12.5MG	N021268	001	Nov 01, 2001		Jun DISC
	@	600MG;25MG	N021268	002	Nov 01, 2001		Jun DISC

EPTIFIBATIDE

INJECTABLE;INJECTION
EPTIFIBATIDE

AP	TEVA PHARMS USA	2MG/ML	A090854	001	Jun 12, 2015		Jun NEWA
AP		75MG/100ML	A091555	001	Jun 05, 2015		May NEWA

INTEGRILIN

AP	+ SCHERING	2MG/ML	N020718	001	May 18, 1998		Jun CTEC
AP	+	75MG/100ML	N020718	002	May 18, 1998		May CFTG

ERGOCALCIFEROL

CAPSULE;ORAL
VITAMIN D

AA	BANNER LIFE SCIENCES	50,000 IU	A080704	001			Jan CAHN

ERGOTAMINE TARTRATE

TABLET;SUBLINGUAL
ERGOSTAT

	@ WATSON LABS INC	2MG	A088337	001	Jun 08, 1984		Aug CAHN

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

>D>	AB	MYLAN PHARMS INC	EQ 25MG BASE	A091002	001	Jun 11, 2014	Sep	DISC
>A>		@	EQ 25MG BASE	A091002	001	Jun 11, 2014	Sep	DISC
>D>	AB		EQ 100MG BASE	A091002	002	Jun 11, 2014	Sep	DISC
>A>		@	EQ 100MG BASE	A091002	002	Jun 11, 2014	Sep	DISC
>D>	AB		EQ 150MG BASE	A091002	003	Jun 11, 2014	Sep	DISC
>A>		@	EQ 150MG BASE	A091002	003	Jun 11, 2014	Sep	DISC
	AB	TEVA PHARMS USA	EQ 100MG BASE	A091059	002	Aug 28, 2015	Aug	NEWA
	AB		EQ 150MG BASE	A091059	003	Aug 28, 2015	Aug	NEWA

TARCEVA

>D>	AB	OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	Sep	CTEC
>A>			EQ 25MG BASE	N021743	001	Nov 18, 2004	Sep	CTEC

ERYTHROMYCIN ESTOLATE

SUSPENSION;ORAL

ERYTHROMYCIN ESTOLATE

		@ G AND W LABS INC	EQ 125MG BASE/5ML	A062169	001	Oct 17, 1990	Apr	CAHN
		@	EQ 250MG BASE/5ML	A062169	002	Oct 17, 1990	Apr	CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE

		@ ANI PHARMS INC	EQ 200MG BASE/5ML	A062055	001		Jul	CAHN

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

	AA	ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	May	NEWA

TABLET;ORAL

ESCITALOPRAM OXALATE

	AB	MYLAN PHARMS INC	EQ 5MG BASE	A077550	001	May 14, 2015	Apr	NEWA
	AB		EQ 10MG BASE	A077550	002	May 14, 2015	Apr	NEWA
	AB		EQ 20MG BASE	A077550	003	May 14, 2015	Apr	NEWA
	AB	PRINSTON INC	EQ 5MG BASE	A078032	001	Aug 28, 2015	Aug	NEWA
	AB		EQ 10MG BASE	A078032	002	Aug 28, 2015	Aug	NEWA
	AB		EQ 20MG BASE	A078032	003	Aug 28, 2015	Aug	NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

ESMOLOL HYDROCHLORIDE

	AP	AUROBINDO PHARMA LTD	10MG/ML	A205520	001	Jul 23, 2015	Jul	NEWA
	AP	LUITPOLD	10MG/ML	A201126	001	Feb 20, 2015	Feb	NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

>A>	AB	DR REDDYS LABS LTD	EQ 20MG BASE	A078279	001	Sep 25, 2015	Sep	NEWA
>A>	AB		EQ 40MG BASE	A078279	002	Sep 25, 2015	Sep	NEWA
>A>	AB	HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015	Sep	NEWA
>A>	AB		EQ 40MG BASE	A202784	002	Sep 21, 2015	Sep	NEWA
	AB	IVAX SUB TEVA PHARMS	EQ 20MG BASE	A078003	001	Jan 26, 2015	Jan	NEWA
	AB		EQ 40MG BASE	A078003	002	Jan 26, 2015	Jan	NEWA
>D>	AB	MYLAN LABS LTD	EQ 20MG BASE	A078936	001	Aug 02, 2015	Sep	CAHN
	AB		EQ 20MG BASE	A078936	001	Aug 02, 2015	Jul	NEWA
>D>	AB		EQ 40MG BASE	A078936	002	Aug 03, 2015	Sep	CAHN
	AB		EQ 40MG BASE	A078936	002	Aug 03, 2015	Jul	NEWA
>A>	AB	MYLAN PHARMS INC	EQ 20MG BASE	A078936	001	Aug 02, 2015	Sep	CAHN
>A>	AB		EQ 40MG BASE	A078936	002	Aug 03, 2015	Sep	CAHN

NEXIUM

	AB	ASTRAZENECA PHARMS	EQ 20MG BASE	N021153	001	Feb 20, 2001	Jan	CFTG
	AB +		EQ 40MG BASE	N021153	002	Feb 20, 2001	Jan	CFTG

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

>A>	AP	ACCORD HLTHCARE	EQ 40MG BASE/VIAL	A205379	001	Sep 25, 2015	Sep	NEWA

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE STRONTIUM

		HANMI PHARM CO LTD	24.65MG	N202342	001	Aug 06, 2013	Aug CPOT
	+		49.3MG	N202342	002	Aug 06, 2013	Aug CPOT

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

ALORA

BX		ACTAVIS LABS UT INC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar CAHN
BX			0.05MG/24HR	N020655	001	Dec 20, 1996	Mar CAHN
BX			0.075MG/24HR	N020655	002	Dec 20, 1996	Mar CAHN
BX			0.1MG/24HR	N020655	003	Dec 20, 1996	Mar CAHN

MINIVELLE

		NOVEN	0.025MG/24HR	N203752	005	Sep 23, 2014	Jan NEWA

TABLET;VAGINAL

ESTRADIOL

	@	AMNEAL PHARMS	10MCG	A205256	001	May 29, 2015	May DISC

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

AB		MACLEODS PHARMS LTD	1MG	A202929	001	Jan 30, 2015	Jan NEWA
AB			2MG	A202929	002	Jan 30, 2015	Jan NEWA
AB			3MG	A202929	003	Jan 30, 2015	Jan NEWA

ETHACRYNATE SODIUM

INJECTABLE;INJECTION

EDECRIN

AP	+	ATON	EQ 50MG BASE/VIAL	N016093	001		Jul CFTG

ETHACRYNATE SODIUM

AP		PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A205473	001	Jul 29, 2015	Jul NEWA

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL

ETHAMBUTOL HYDROCHLORIDE

AB		VERSAPHARM INC	100MG	A075095	001	Nov 30, 1999	Jan CMFD
AB			400MG	A075095	002	Nov 30, 1999	Jan CMFD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

ASHLYNA

AB		GLENMARK GENERICS	0.03MG,0.01MG;0.15MG,N/A	A203163	001	Feb 23, 2015	Feb NEWA

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB		GLENMARK GENERICS	0.02MG;0.09MG	A202791	001	Apr 09, 2015	Mar NEWA
AB		GLENMARK PHARMS LTD	0.03MG;0.15MG	A203164	001	Jun 12, 2015	Jun NEWA
AB	+	WATSON LABS	0.02MG;0.09MG	A079218	001	Jun 06, 2011	Mar CTEC

TABLET;ORAL-28

LEVORA 0.15/30-28

AB	+	WATSON LABS	0.03MG;0.15MG	A073594	001	Dec 13, 1993	Aug CRLD

NORDETTE-28

	@	TEVA BRANDED PHARM	0.03MG;0.15MG	N018782	001	Jul 21, 1982	Aug DISC

VIENVA

AB1		SANDOZ INC	0.02MG;0.1MG	A201088	001	May 21, 2015	May NEWA

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

XULANE

AB	+	MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Feb CRLD

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

BREVICON 21-DAY

	@	ACTAVIS LABS UT INC	0.035MG;0.5MG	N017566	001		Mar CAHN

NORINYL 1+35 21-DAY

AB		ACTAVIS LABS UT INC	0.035MG;1MG	N017565	001		Feb CAHN

TRI-NORINYL 21-DAY

	@	ACTAVIS LABS UT INC	0.035MG,0.035MG,0.035MG;0.5MG,1MG, 0.5MG	N018977	001	Apr 13, 1984	Feb CAHN

TABLET;ORAL-28
BREVICON 28-DAY

AB		ACTAVIS LABS UT INC	0.035MG;0.5MG	N017743	001			Mar CAHN

NORETHINDRONE AND ETHINYL ESTRADIOL

AB		FAMY CARE LTD	0.035MG;0.4MG	A200897	001	May 11, 2015	Apr	NEWA
AB	+	JAI PHARMA LTD	0.035MG;0.4MG	A200897	001	May 11, 2015	Jul	CRLD
	+		0.05MG;1MG	A203006	001	Aug 05, 2013	Jul	CTEC

NORINYL 1+35 28-DAY

AB		ACTAVIS LABS UT INC	0.035MG;1MG	N017565	002		Feb	CAHN

OVCON-35

		@ WARNER CHILCOTT LLC	0.035MG;0.4MG	N017716	001		Jul	DISC

TRI-NORINYL 28-DAY

AB	+	ACTAVIS LABS UT INC	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG	N018977	002	Apr 13, 1984	Feb	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL
FEMHRT

AB		WARNER CHILCOTT LLC	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Mar	CTEC

LARIN 24 FE

AB		NOVAST LABS LTD	0.02MG;1MG	A202994	001	Feb 18, 2015	Feb	NEWA

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	+	BARR LABS INC	0.005MG;1MG	A076221	001	Nov 06, 2009	Mar	CTEC
AB		GLENMARK GENERICS	0.0025MG;0.5MG	A203038	001	Apr 02, 2015	Mar	NEWA
AB			0.005MG;1MG	A203038	002	Apr 02, 2015	Mar	NEWA

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	+	AMNEAL PHARMS	0.02MG;1MG	A078267	001	Sep 01, 2009	Jan	CRLD

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28
NORGESTIMATE AND ETHINYL ESTRADIOL

AB		JAI PHARMA LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A202132	001	Sep 09, 2015	Aug	NEWA
AB		OC PHARMA	0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG	A200383	001	Apr 07, 2015	Mar	NEWA
AB			0.035MG;0.25MG	A200384	001	Apr 07, 2015	Mar	NEWA

TRI-LO-ESTARYLLA

AB		SANDOZ INC	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A091232	001	Jun 29, 2015	Jun	NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-28
LOW-OGESTREL-28

AB		WATSON LABS	0.03MG;0.3MG	A075288	002	Jul 28, 1999	Feb	CMFD

ETHOSUXIMIDE

CAPSULE;ORAL
ETHOSUXIMIDE

AB		BANNER LIFE SCIENCES	250MG	A040430	001	Oct 28, 2002	Jan	CAHN
>A> AB		HERITAGE PHARMS INC	250MG	A200892	001	Sep 25, 2012	Sep	CAHN
>D> AB		ZYDUS PHARMS USA INC	250MG	A200892	001	Sep 25, 2012	Sep	CAHN

ETODOLAC

TABLET;ORAL
ETODOLAC

>D>		@ AAIPHARMA LLC	400MG	A074927	001	Oct 30, 1997	Sep	CAHN
>A>		@ LEHIGH VALLEY	400MG	A074927	001	Oct 30, 1997	Sep	CAHN

ETONOGESTREL

IMPLANT;IMPLANTATION
IMPLANON

		@ ORGANON USA INC	68MG/IMPLANT	N021529	001	Jul 17, 2006	Jun	DISC

EZETIMIBE

TABLET;ORAL
EZETIMIBE

		@ GLENMARK PHARMS LTD	10MG	A078560	001	Jun 26, 2015	Jun	DISC
AB			10MG	A078560	001	Jun 26, 2015	Jun	NEWA

ZETIA

	+	MSD INTL GMBH	10MG	N021445	001	Oct 25, 2002	Jun	CTEC
AB	+		10MG	N021445	001	Oct 25, 2002	Jun	CFTG

FAMOTIDINE

INJECTABLE;INJECTION

FAMOTIDINE

AP	+	EUROHLTH INTL SARL	10MG/ML	A075488	001	Apr 16, 2001	Jun CAHN
>A>		@	10MG/ML	A075799	001	Apr 30, 2002	Sep CAHN
>D>		@ HIKMA MAPLE	10MG/ML	A075799	001	Apr 30, 2002	Sep CAHN

FAMOTIDINE PRESERVATIVE FREE

AP	+	EUROHLTH INTL SARL	10MG/ML	A075486	001	Apr 16, 2001	Jun CAHN

TABLET;ORAL

PEPCID

AB		VALEANT PHARMS NORTH	20MG	N019462	001	Oct 15, 1986	Feb CAHN
AB	+		40MG	N019462	002	Oct 15, 1986	Feb CAHN

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

AB		ORCHID HLTHCARE	2.5MG	A203032	001	May 21, 2015	May NEWA
AB			5MG	A203032	002	May 21, 2015	May NEWA
AB			10MG	A203032	003	May 21, 2015	May NEWA
AB		SUN PHARM INDS LTD	2.5MG	A091200	001	Dec 13, 2013	Apr CAHN
AB			5MG	A091200	002	Dec 13, 2013	Apr CAHN
AB			10MG	A091200	003	Dec 13, 2013	Apr CAHN

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE

AB		SUN PHARM INDS LTD	43MG	A201748	001	Oct 31, 2014	Apr CAHN
AB			130MG	A201748	002	Oct 31, 2014	Apr CAHN

TABLET;ORAL

FENOFIBRATE

AB		LUPIN LTD	54MG	A204019	001	Aug 17, 2015	Aug NEWA
AB			160MG	A204019	002	Aug 17, 2015	Aug NEWA
AB		SUN PHARM INDS LTD	54MG	A076635	001	Oct 31, 2005	Apr CAHN
			107MG	A076635	002	Oct 31, 2005	Apr CAHN
AB			160MG	A076635	003	Oct 31, 2005	Apr CAHN
AB		VALEANT PHARMS NORTH	48MG	A090715	001	Apr 05, 2012	Aug CAHN
AB			145MG	A090715	002	Apr 05, 2012	Aug CAHN

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

		TRIBUTE PHARMS INTL	35MG	N022418	001	Aug 14, 2009	Jun CAHN
	+		105MG	N022418	002	Aug 14, 2009	Jun CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

AB		ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar CAHN

FENTANYL-12

AB		MALLINCKRODT INC	12.5MCG/HR	A077154	005	Jun 11, 2015	Jun NEWA

FENTANYL-25

AB		ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar CAHN

FENTANYL-50

AB		ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar CAHN

FENTANYL-75

AB		ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar CAHN

FENTANYL CITRATE

FILM;BUCCAL

ONSOLIS

		@ BIODELIVERY SCI INTL	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	Mar CAHN
		@	EQ 0.4MG BASE	N022266	002	Jul 16, 2009	Mar CAHN
		@	EQ 0.6MG BASE	N022266	003	Jul 16, 2009	Mar CAHN
		@	EQ 0.8MG BASE	N022266	004	Jul 16, 2009	Mar CAHN
		@	EQ 1.2MG BASE	N022266	005	Jul 16, 2009	Mar CAHN

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP	+	EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb CAHN

FENTANYL HYDROCHLORIDE

SYSTEM;IONTOPHORESIS, TRANSDERMAL

IONSYS

	@	THE MEDICINES CO	10.8MCG	N021338	001	May 22, 2006	Apr CAHN
	+		EQ 40MCG BASE/ACTIVATION	N021338	001	May 22, 2006	Jun CMFD

FERRIC CITRATE

TABLET;ORAL

AURYXIA

	+	KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014	Jan CTNA

FERRIC PYROPHOSPHATE CITRATE

SOLUTION;IV (INFUSION)

TRIFERIC

	+	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015	Jan NEWA

FIDAXOMICIN

TABLET;ORAL

DIFICID

	+	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011	Aug CAHN

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

AB		ANI PHARMS INC	50MG	A075882	001	Oct 28, 2002	Apr CAHN
AB			100MG	A075882	002	Oct 28, 2002	Apr CAHN
AB			150MG	A075882	003	Oct 28, 2002	Apr CAHN
AB		AUROBINDO PHARMA LTD	50MG	A202821	001	Jul 08, 2015	Jun NEWA
AB			100MG	A202821	002	Jul 08, 2015	Jun NEWA
AB			150MG	A202821	003	Jul 08, 2015	Jun NEWA
AB		SUN PHARM INDS LTD	50MG	A076421	001	Mar 28, 2003	Apr CAHN
AB			100MG	A076421	002	Mar 28, 2003	Apr CAHN
AB			150MG	A076421	003	Mar 28, 2003	Apr CAHN

FLIBANSERIN

TABLET;ORAL

ADDYI

	+	SPROUT PHARMS	100MG	N022526	001	Aug 18, 2015	Aug NEWA

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

AB		SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Apr CAHN
AB			200MG/5ML	A076332	002	Jul 29, 2004	Apr CAHN

INJECTABLE;INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	Apr CAHN
AP			400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	Apr CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP		CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077947	001	May 26, 2010	Apr CAHN
AP			400MG/200ML (2MG/ML)	A077947	002	May 26, 2010	Apr CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		CLARIS PHARMASERVICE	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr NEWA
			100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr CAHN
AP			200MG/100ML (2MG/ML)	A077909	001	May 26, 2010	Apr CAHN
AP			400MG/200ML (2MG/ML)	A077909	002	May 26, 2010	Apr CAHN

TABLET;ORAL

FLUCONAZOLE

AB		HARRIS PHARM	50MG	A078423	001	Mar 07, 2011	May CMFD
AB			100MG	A078423	002	Mar 07, 2011	May CMFD
AB			150MG	A078423	003	Mar 07, 2011	May CMFD
AB			200MG	A078423	004	Mar 07, 2011	May CMFD

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP		IBA MOLECULAR N AM	20-300mCi/ML	A203591	001	Aug 31, 2015	Aug NEWA
AP		METHODIST HOSP RES	20-300mCi/ML	A203904	001	Apr 23, 2015	Apr NEWA
AP		MIPS CRF	20-300mCi/ML	A204472	001	Sep 11, 2015	Aug NEWA
		PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015	Mar NEWA
		QUEEN HAMAMATSU PET	10-100mCi/ML	A203771	001	Aug 31, 2015	Aug NEWA

		INJECTABLE;INTRAVENOUS						
		FLUDEOXYGLUCOSE F18						
		SPECTRON MRC LLC	4-500mCi/ML	A203911	001	Apr 22, 2015	Apr NEWA
	AP	UNIV MICHIGAN	20-300mCi/ML	A204531	001	Jul 17, 2015	Jul NEWA
		FLUMAZENIL						
		INJECTABLE;INJECTION						
		FLUMAZENIL						
		@ CLARIS PHARMASERVICE	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Apr CAHN
		@	1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Apr CAHN
	AP	EUROHLTH INTL SARL	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jun CAHN
	AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jun CAHN
		FLUOCINOLONE ACETONIDE						
		OIL;TOPICAL						
		FLUOCINOLONE ACETONIDE						
	AT	VERSAPHARM INC	0.01%	A091514	001	Jun 25, 2015	Jun NEWA
		SOLUTION;TOPICAL						
		FLUOCINOLONE ACETONIDE						
	AT	GAVIS PHARMS LLC	0.01%	A206422	001	Sep 02, 2015	Aug NEWA
		FLUOCINONIDE						
		GEL;TOPICAL						
		FLUOCINONIDE						
	AB	G AND W LABS INC	0.05%	A072537	001	Feb 07, 1989	Apr CAHN
		FLUOROURACIL						
		CREAM;TOPICAL						
		CARAC						
	AB +	VALEANT PHARMS NORTH	0.5%	N020985	001	Oct 27, 2000	Apr CFTG
	+		0.5%	N020985	001	Oct 27, 2000	Feb CAHN
		FLUOROURACIL						
	AB	SPEAR PHARMS INC	0.5%	A203122	001	Apr 20, 2015	Apr NEWA
>A>		TOLAK						
>A>	+	HILL DERMACEUTICALS	4%	N022259	001	Sep 18, 2015	Sep NEWA
		FLUOXETINE HYDROCHLORIDE						
		CAPSULE;ORAL						
		FLUOXETINE HYDROCHLORIDE						
		@ ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Mar DISC
		@	EQ 20MG BASE	A076287	002	May 20, 2008	Mar DISC
	+	MYLAN	EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar CRLD
			EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar CTEC
		@ SANDOZ	EQ 10MG BASE	A077469	001	Nov 17, 2008	Mar DISC
		@	EQ 20MG BASE	A077469	002	Nov 17, 2008	Mar DISC
	AB1	SCIEGEN PHARMS INC	EQ 10MG BASE	A204597	001	Mar 16, 2015	Mar NEWA
	AB1		EQ 20MG BASE	A204597	002	Mar 16, 2015	Mar NEWA
	AB		EQ 40MG BASE	A204597	003	Mar 16, 2015	Mar NEWA
	AB	SUN PHARM INDS LTD	EQ 40MG BASE	A076990	001	Dec 13, 2004	Apr CAHN
		FLURANDRENOLIDE						
		OINTMENT;TOPICAL						
		CORDRAN						
	+	AQUA PHARMS	0.05%	N012806	001		Jun CRLD
			0.05%	N012806	001		May CMFD
		TAPE;TOPICAL						
		CORDRAN						
	+	ACTAVIS LABS UT INC	0.004MG/SQ CM	N016455	001		Mar CAHN
		FLUTICASONE FUROATE; VILANTEROL TRIFENATATE						
		POWDER;INHALATION						
		BREO ELLIPTA						
		GLAXO GRP LTD	0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015	Apr NEWA
		FLUVASTATIN SODIUM						
		TABLET, EXTENDED RELEASE;ORAL						
		FLUVASTATIN SODIUM						
	AB	MYLAN PHARMS INC	80MG	A202458	001	Sep 11, 2015	Aug NEWA
		LESCOL XL						
	AB +	NOVARTIS	80MG	N021192	001	Oct 06, 2000	Aug CFTG

FLUVOXAMINE MALEATE

TABLET;ORAL

FLUVOXAMINE MALEATE

AB		ANI PHARMS INC	25MG	A075897	001	Jan 25, 2001	Jul CAHN
	@		25MG	A075898	001	Mar 12, 2001	Jul CAHN
AB			50MG	A075897	002	Jan 25, 2001	Jul CAHN
	@		50MG	A075898	002	Mar 12, 2001	Jul CAHN
AB			100MG	A075897	003	Jan 25, 2001	Jul CAHN
	@		100MG	A075898	003	Mar 12, 2001	Jul CAHN

FOLIC ACID

TABLET;ORAL

FOLIC ACID

AA		AIPING PHARM INC	1MG	A091145	001	Jul 12, 2013	Aug CAHN
AA		NUVO PHARM INC	1MG	A204418	001	Jul 28, 2015	Jul NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB		SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004	Apr CAHN
AB			20MG;12.5MG	A076739	002	Dec 17, 2004	Apr CAHN

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

	@	IGI LABS INC	10MG/ML	A070095	001	Sep 09, 1985	Mar CAHN
	@		10MG/ML	A070096	001	Sep 09, 1985	Mar CAHN

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

AB		SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005	Apr CAHN
AB			300MG	A076606	002	Oct 07, 2005	Apr CAHN
AB			400MG	A076606	003	Oct 07, 2005	Apr CAHN

TABLET;ORAL

GABAPENTIN

	@	HIKMA PHARMS	600MG	A078782	001	Jul 21, 2011	Jun DISC
	@		800MG	A078782	002	Jul 21, 2011	Jun DISC

GADOVERSETAMIDE

INJECTABLE;INJECTION

OPTIMARK

+		LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999	Feb CAHN
+			3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999	Feb CAHN
+			4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999	Feb CAHN
+			6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999	Feb CAHN
+			16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999	Feb CAHN

OPTIMARK IN PLASTIC CONTAINER

+		LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999	Feb CAHN
+			4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999	Feb CAHN
+			6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999	Feb CAHN
+			9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999	Feb CAHN

GEFITINIB

TABLET;ORAL

IRESSA

+		ASTRAZENECA PHARMS	250MG	N206995	001	Jul 13, 2015	Jul NEWA

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

AB		AUROBINDO PHARMA LTD	600MG	A202726	001	Sep 16, 2015	Aug NEWA

GEMIFLOXACIN MESYLATE

TABLET;ORAL

FACTIVE

AB	+	LG LIFE SCIENCES	EQ 320MG BASE	N021158	001	Apr 04, 2003	Jun CFTG

GEMIFLOXACIN MESYLATE

AB		ORCHID HLTHCARE	EQ 320MG BASE	A090466	001	Jun 15, 2015	Jun NEWA

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS

COPAXONE

AP	+	TEVA PHARMS USA	20MG/ML	N020622	002	Feb 12, 2002	Mar	CFTG

GLATOPA

AP		SANDOZ INC	20MG/ML	A090218	001	Apr 16, 2015	Mar	NEWA

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

	@	HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013	Apr	DISC
	@		2MG	A078952	002	Aug 01, 2013	Apr	DISC
	@		4MG	A078952	003	Aug 01, 2013	Apr	DISC

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDARYL

	@	SB PHARMCO	1MG;4MG	N021700	001	Nov 23, 2005	Jun	DISC
	@		2MG;4MG	N021700	002	Nov 23, 2005	Jun	DISC
	@		2MG;8MG	N021700	004	Mar 30, 2007	Jun	DISC
	@		4MG;4MG	N021700	003	Nov 23, 2005	Jun	DISC
	@		4MG;8MG	N021700	005	Mar 30, 2007	Jun	DISC

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

	@	ANI PHARMS INC	5MG	A074387	001	Mar 04, 1996	Aug	CAHN
	@		10MG	A074387	002	Mar 04, 1996	Aug	CAHN

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

AB		MYLAN PHARMS INC	2.5MG	A202298	001	May 19, 2015	May	NEWA
AB			5MG	A202298	002	May 19, 2015	May	NEWA
AB			10MG	A202298	003	May 19, 2015	May	NEWA

GLUCAGON HYDROCHLORIDE

POWDER;INTRAMUSCULAR, INTRAVENOUS

GLUCAGON

	+	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	001	May 08, 2015	May	NEWA

GLYBURIDE

TABLET;ORAL

DIABETA

>D> BX		SANOFI AVENTIS US	1.25MG	N017532	001	May 01, 1984	Sep	CFTG
>A> AB2			1.25MG	N017532	001	May 01, 1984	Sep	CFTG
>D> BX			2.5MG	N017532	002	May 01, 1984	Sep	CFTG
>A> AB2			2.5MG	N017532	002	May 01, 1984	Sep	CFTG
>D> BX	+		5MG	N017532	003	May 01, 1984	Sep	CFTG
>A> AB2	+		5MG	N017532	003	May 01, 1984	Sep	CFTG

GLYBURIDE

>D> AB		AUROBINDO PHARMA	1.25MG	A077537	001	Oct 18, 2007	Sep	CTEC
>A> AB1			1.25MG	A077537	001	Oct 18, 2007	Sep	CTEC
>D> AB			2.5MG	A077537	002	Oct 18, 2007	Sep	CTEC
>A> AB1			2.5MG	A077537	002	Oct 18, 2007	Sep	CTEC
>D> AB			5MG	A077537	003	Oct 18, 2007	Sep	CTEC
>A> AB1			5MG	A077537	003	Oct 18, 2007	Sep	CTEC
>D> AB		COREPHARMA	1.25MG	A076257	001	Jun 27, 2002	Sep	CTEC
>A> AB1			1.25MG	A076257	001	Jun 27, 2002	Sep	CTEC
>A> AB2			1.25MG	A206079	001	Sep 30, 2015	Sep	NEWA
>D> AB			2.5MG	A076257	002	Jun 27, 2002	Sep	CTEC
>A> AB1			2.5MG	A076257	002	Jun 27, 2002	Sep	CTEC
>A> AB2			2.5MG	A206079	002	Sep 30, 2015	Sep	NEWA
>D> AB			5MG	A076257	003	Jun 27, 2002	Sep	CTEC
>A> AB1			5MG	A076257	003	Jun 27, 2002	Sep	CTEC
>A> AB2			5MG	A206079	003	Sep 30, 2015	Sep	NEWA
>D> AB		HERITAGE PHARMS INC	1.25MG	A090937	001	Feb 28, 2011	Sep	CTEC
>A> AB1			1.25MG	A090937	001	Feb 28, 2011	Sep	CTEC
>D> AB			2.5MG	A090937	002	Feb 28, 2011	Sep	CTEC
>A> AB1			2.5MG	A090937	002	Feb 28, 2011	Sep	CTEC
>D> AB			5MG	A090937	003	Feb 28, 2011	Sep	CTEC
>A> AB1			5MG	A090937	003	Feb 28, 2011	Sep	CTEC
>D> AB		TEVA	1.25MG	A074388	001	Aug 29, 1995	Sep	CTEC

TABLET;ORAL
GLYBURIDE

>A>	AB1		1.25MG		A074388	001	Aug 29, 1995	Sep CTEC
>D>	AB		2.5MG		A074388	002	Aug 29, 1995	Sep CTEC
>A>	AB1		2.5MG		A074388	002	Aug 29, 1995	Sep CTEC
>D>	AB	+	5MG		A074388	003	Aug 29, 1995	Sep CTEC
>A>	AB1	+	5MG		A074388	003	Aug 29, 1995	Sep CTEC

GLYCEROL PHENYLBUTYRATE
LIQUID;ORAL
RAVICTI

		+	HORIZON THERAPS INC	1.1GM/ML	N203284	001	Feb 01, 2013	May CAHN

GLYCOPYRROLATE
INJECTABLE;INJECTION
ROBINUL

	AP	+	EUROHLTH INTL SARL	0.2MG/ML	N017558	001		Jun CAHN

TABLET;ORAL
GLYCOPYRROLATE

	AA		SUN PHARM INDS LTD	1MG	A040844	001	Aug 18, 2009	Apr CAHN
	AA			2MG	A040844	002	Aug 18, 2009	Apr CAHN

GRANISETRON HYDROCHLORIDE
INJECTABLE;INJECTION
GRANISETRON HYDROCHLORIDE

	AP		BANNER LIFE SCIENCES	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan CAHN
	AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan CAHN
		@	CLARIS PHARMASERVICE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Apr CAHN
		@		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Apr CAHN
	AP		EUROHLTH INTL SARL	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jun CAHN

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

	AP		BANNER LIFE SCIENCES	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE
SOLUTION;ORAL
FLOWTUSS

>D>			MIKART INC	200MG/5ML;2.5MG/5ML	N022424	001	May 14, 2015	Sep CAHN
				200MG/5ML;2.5MG/5ML	N022424	001	May 14, 2015	May NEWA
>A>			MISSION PHARMACAL CO	200MG/5ML;2.5MG/5ML	N022424	001	May 14, 2015	Sep CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE
SOLUTION;ORAL
HYCOFENIX

		+	MIKART INC	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001	May 14, 2015	May NEWA

GUANFACINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
GUANFACINE HYDROCHLORIDE

	AB		MYLAN PHARMS INC	EQ 1MG BASE	A202578	001	Jun 02, 2015	May NEWA
	AB			EQ 2MG BASE	A202578	002	Jun 02, 2015	May NEWA
	AB			EQ 3MG BASE	A202578	003	Jun 02, 2015	May NEWA
	AB			EQ 4MG BASE	A202578	004	Jun 02, 2015	May NEWA
	AB		SANDOZ INC	EQ 1MG BASE	A202568	001	Jun 03, 2015	May NEWA
	AB			EQ 2MG BASE	A202568	002	Jun 03, 2015	May NEWA
	AB			EQ 3MG BASE	A202568	003	Jun 03, 2015	May NEWA
	AB			EQ 4MG BASE	A202568	004	Jun 03, 2015	May NEWA
	AB		TEVA PHARMS USA	EQ 1MG BASE	A201382	001	Jun 02, 2015	May NEWA
	AB			EQ 2MG BASE	A201382	002	Jun 02, 2015	May NEWA
	AB			EQ 3MG BASE	A201382	003	Jun 02, 2015	May NEWA
	AB			EQ 4MG BASE	A201382	004	Jun 02, 2015	May NEWA
	AB		TWI PHARMS INC	EQ 1MG BASE	A201408	001	Jun 02, 2015	May NEWA
	AB			EQ 2MG BASE	A201408	002	Jun 02, 2015	May NEWA
	AB			EQ 3MG BASE	A201408	003	Jun 02, 2015	May NEWA
	AB			EQ 4MG BASE	A201408	004	Jun 02, 2015	May NEWA

HALOPERIDOL
TABLET;ORAL
HALOPERIDOL

		@	CYCLE PHARMS LTD	0.5MG	A071128	001	Feb 17, 1987	May CAHN
		@		1MG	A071129	001	Feb 17, 1987	Jun CAHN
		@		5MG	A071131	001	Feb 17, 1987	Jun CAHN

		TABLET;ORAL						
		HALOPERIDOL						
		@	10MG	A071132	001	May 12, 1987	Jun	CAHN
		@	20MG	A071133	001	May 12, 1987	May	CAHN
		@ ROXANE	2MG	A071130	001	Feb 17, 1987	Jun	CAHN
	HALOPERIDOL LACTATE							
		CONCENTRATE;ORAL						
		HALOPERIDOL INTENSOL						
		@ CYCLE PHARMS LTD	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988	May	CAHN
		INJECTABLE;INJECTION						
		HALOPERIDOL						
		@ CLARIS PHARMASERVICE	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Apr	CAHN
		@	EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	May	CAHN
	HEPARIN SODIUM							
		INJECTABLE;INJECTION						
		HEPARIN SODIUM						
		@ EUROHLTH INTL SARL	1,000 UNITS/ML	N017007	001		Aug	CAHN
AP	+		1,000 UNITS/ML	N017037	001		Jun	CAHN
		@	2,500 UNITS/ML	N017007	007		Aug	CAHN
		@	5,000 UNITS/ML	N017007	002		Aug	CAHN
		@	5,000 UNITS/0.5ML	N017007	010		Aug	CAHN
AP	+		5,000 UNITS/ML	N017037	002		Jun	CAHN
		@	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Jun	CAHN
		@	7,500 UNITS/ML	N017007	003		Aug	CAHN
		@	10,000 UNITS/ML	N017007	004		Aug	CAHN
AP	+		10,000 UNITS/ML	N017037	003		Jun	CAHN
		@	15,000 UNITS/ML	N017007	005		Aug	CAHN
		@	20,000 UNITS/ML	N017007	006		Aug	CAHN
	HYDRALAZINE HYDROCHLORIDE							
		INJECTABLE;INJECTION						
		HYDRALAZINE HYDROCHLORIDE						
AP	+	AKORN	20MG/ML	A040730	001	Apr 21, 2009	Feb	CRLD
AP		LUITPOLD	20MG/ML	A040136	001	Jun 30, 1997	Feb	CRLD
AP		X-GEN PHARMS INC	20MG/ML	A203110	001	Jun 29, 2015	Jun	NEWA
		TABLET;ORAL						
		HYDRALAZINE HYDROCHLORIDE						
>A>		@ HERITAGE PHARMS INC	10MG	A040858	001	Feb 26, 2010	Sep	CAHN
>A>		@	25MG	A040858	002	Feb 26, 2010	Sep	CAHN
>A>		@	50MG	A040858	003	Feb 26, 2010	Sep	CAHN
>A>		@	100MG	A040858	004	Feb 26, 2010	Sep	CAHN
>D>		@ ZYDUS PHARMS USA	10MG	A040858	001	Feb 26, 2010	Sep	CAHN
>D>		@	25MG	A040858	002	Feb 26, 2010	Sep	CAHN
>D>		@	50MG	A040858	003	Feb 26, 2010	Sep	CAHN
>D>		@	100MG	A040858	004	Feb 26, 2010	Sep	CAHN
	HYDROCHLOROTHIAZIDE							
		CAPSULE;ORAL						
		HYDROCHLOROTHIAZIDE						
		@ SUN PHARM INDS INC	12.5MG	A090651	001	Apr 07, 2014	Aug	DISC
		MICROZIDE						
AB	+	ACTAVIS LABS UT INC	12.5MG	N020504	001	Dec 27, 1996	Feb	CAHN
	HYDROCHLOROTHIAZIDE; LISINOPRIL							
		TABLET;ORAL						
		LISINOPRIL AND HYDROCHLOROTHIAZIDE						
AB		SUN PHARM INDS LTD	12.5MG;10MG	A076007	001	Jul 01, 2002	Apr	CAHN
AB			12.5MG;20MG	A076007	002	Jul 01, 2002	Apr	CAHN
AB			25MG;20MG	A076007	003	Jul 01, 2002	Apr	CAHN
		ZESTORETIC						
AB		ALVOGEN IPCO SARL	12.5MG;10MG	N019888	003	Nov 18, 1993	Feb	CAHN
AB	+		12.5MG;20MG	N019888	001	Sep 20, 1990	Feb	CAHN
AB	+		25MG;20MG	N019888	002	Jul 20, 1989	Feb	CAHN
	HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE							
		TABLET, EXTENDED RELEASE;ORAL						
		DUTOPROL						
		CONCORDIA PHARMS INC	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006	Jun	CAHN
			12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006	Jun	CAHN
	+		12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Jun	CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@ ANI PHARMS INC	25MG;40MG	A070704	001	Oct 01, 1986	Jul	CAHN
AB		25MG;40MG	A072042	001	Mar 14, 1988	Aug	CAHN
	@	25MG;80MG	A070705	001	Oct 01, 1986	Jul	CAHN
AB		25MG;80MG	A072043	001	Mar 14, 1988	Aug	CAHN

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS LTD	12.5MG;EQ 10MG BASE	A078211	001	Mar 04, 2009	Apr	CAHN
AB		12.5MG;EQ 20MG BASE	A078211	002	Mar 04, 2009	Apr	CAHN
AB		25MG;EQ 20MG BASE	A078211	003	Mar 04, 2009	Apr	CAHN

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

	@ ANI PHARMS INC	25MG;37.5MG	A074970	001	Jan 06, 1998	Aug	CAHN

TABLET;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	ANI PHARMS INC	50MG;75MG	A073467	001	Jan 31, 1996	Aug	CAHN

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

ZOHYDRO ER

+	FERRIMILL LTD	10MG	N202880	001	Oct 25, 2013	Apr	CAHN
		15MG	N202880	002	Oct 25, 2013	Apr	CAHN
		20MG	N202880	003	Oct 25, 2013	Apr	CAHN
		30MG	N202880	004	Oct 25, 2013	Apr	CAHN
		40MG	N202880	005	Oct 25, 2013	Apr	CAHN
		50MG	N202880	006	Oct 25, 2013	Apr	CAHN
+	PERNIX IRELAND PAIN	10MG	N202880	001	Oct 25, 2013	Jun	CAHN
		15MG	N202880	002	Oct 25, 2013	Jun	CAHN
		20MG	N202880	003	Oct 25, 2013	Jun	CAHN
		30MG	N202880	004	Oct 25, 2013	Jun	CAHN
		40MG	N202880	005	Oct 25, 2013	Jun	CAHN
		50MG	N202880	006	Oct 25, 2013	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL

HYSINGLA

+	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Mar	CRLD

HYDROCORTISONE

CREAM;TOPICAL

HYDROCORTISONE

AT	RISING PHARMS INC	2.5%	A040879	001	Aug 20, 2010	Mar	CAHN

POWDER;FOR RX COMPOUNDING

HYDRO-RX

	@ X GEN PHARMS	100%	A085982	001		Apr	DISC

TABLET;ORAL

HYDROCORTISONE

AB	HIKMA INTL PHARMS	5MG	A083365	002	Feb 23, 2015	Feb	NEWA
AB		10MG	A083365	003	Feb 23, 2015	Feb	NEWA
AB		20MG	A083365	001		Feb	CMFD

HYDROCORTISONE ACETATE

POWDER;FOR RX COMPOUNDING

HYDROCORTISONE ACETATE

	@ X GEN PHARMS	100%	A085981	001		Apr	DISC

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE

	@ G AND W LABS INC	0.2%	A074489	001	Aug 12, 1998	Apr	CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OTIC

CORTISPORIN

AT	+	CITRON PHARMA LLC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N060613	001			Jun CMS2

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

HYDROMORPHONE HYDROCHLORIDE

AB		PADDOCK LLC	8MG	A204278	001	Apr 06, 2015	Mar	NEWA
AB			12MG	A204278	002	Apr 06, 2015	Mar	NEWA
AB			16MG	A204278	003	Apr 06, 2015	Mar	NEWA

HYDROXOCOBALAMIN

INJECTABLE;INJECTION

CYANOKIT

	@	SERB SAS	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Apr	CAHN
	+		5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Apr	CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

PLAQUENIL

AB	+	CONCORDIA PHARMS INC	200MG	N009768	001			Jun CAHN

HYDROXYPROGESTERONE CAPROATE

INJECTABLE;INJECTION

HYDROXYPROGESTERONE CAPROATE

	@	ACTAVIS LABS UT INC	125MG/ML	N017439	001			Mar CAHN
	@		250MG/ML	N017439	002			Mar CAHN
	+	MCGUFF	250MG/ML	A200271	001	Aug 24, 2015	Aug	NEWA

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

AB		ELITE LABS INC	10MG	A040600	001	Dec 28, 2004	Jun	CAHN
AB			25MG	A040602	001	Dec 28, 2004	Jun	CAHN
AB			50MG	A040604	001	Dec 28, 2004	Jun	CAHN
AB		HERITAGE PHARMA	10MG	A204279	001	Aug 20, 2014	Mar	CAHN
AB			25MG	A204279	002	Aug 20, 2014	Mar	CAHN
AB			50MG	A204279	003	Aug 20, 2014	Mar	CAHN
AB		MIKAH PHARMA	10MG	A040600	001	Dec 28, 2004	Mar	CMFD
AB			25MG	A040602	001	Dec 28, 2004	Mar	CMFD
AB			50MG	A040604	001	Dec 28, 2004	Mar	CMFD
	@	MUTUAL PHARM	10MG	A089381	001	May 19, 1986	Jul	DISC
	@		25MG	A089382	001	May 19, 1986	Jul	DISC
	@		50MG	A089383	001	May 19, 1986	Jul	DISC
	@	WATSON LABS	10MG	A088348	001	Sep 15, 1983	Jul	DISC
	@		25MG	A088349	001	Sep 15, 1983	Jul	DISC
	@		50MG	A088350	001	Sep 15, 1983	Jul	DISC

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

AB		HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Mar	CAHN
AB			EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Mar	CAHN

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

IBANDRONATE SODIUM

AP		AUROBINDO PHARMA LTD	EQ 3MG BASE/3ML	A205332	001	Aug 19, 2015	Aug	NEWA

IBUPROFEN

TABLET;ORAL

IBUPROFEN

AB		GRANULES INDIA LTD	400MG	A091625	001	Sep 15, 2015	Aug	NEWA
AB			600MG	A091625	002	Sep 15, 2015	Aug	NEWA
AB			800MG	A091625	003	Sep 15, 2015	Aug	NEWA
	@	VINTAGE PHARMS	300MG	A071230	001	Oct 22, 1986	Jul	DISC
	@		400MG	A071231	001	Oct 22, 1986	Jul	DISC
	@		600MG	A071232	001	Oct 22, 1986	Jul	DISC
	@		800MG	A072004	001	Nov 18, 1987	Jul	DISC

ILOPERIDONE
TABLET;ORAL
FANAPT
+ VANDA PHARMS INC 1MG N022192 001 May 06, 2009 Jan CAHN
2MG N022192 002 May 06, 2009 Jan CAHN
4MG N022192 003 May 06, 2009 Jan CAHN
6MG N022192 004 May 06, 2009 Jan CAHN
8MG N022192 005 May 06, 2009 Jan CAHN
10MG N022192 006 May 06, 2009 Jan CAHN
12MG N022192 007 May 06, 2009 Jan CAHN

IMIQUIMOD
CREAM;TOPICAL
IMIQUIMOD
AB G AND W LABS INC 5% A200481 001 Apr 18, 2011 Apr CAHN

INDAPAMIDE
TABLET;ORAL
INDAPAMIDE
AB ANI PHARMS INC 1.25MG A074299 002 Apr 29, 1996 Jul CAHN
@ 1.25MG A074498 002 Feb 12, 1998 Jul CAHN
AB 2.5MG A074299 001 Jul 27, 1995 Jul CAHN
@ 2.5MG A074498 001 Oct 31, 1996 Jul CAHN

INDOMETHACIN
CAPSULE, EXTENDED RELEASE;ORAL
INDOMETHACIN
>A> AB JUBILANT GENERICS 75MG A202706 001 Oct 05, 2015 Sep NEWA

INGENOL MEBUTATE
GEL;TOPICAL
PICATO
+ LEO PHARMA AS 0.015% N202833 001 Jan 23, 2012 May CRLD

>A> INSULIN DEGLUDEC
>A> SOLUTION;SUBCUTANEOUS
>A> RYZODEG 70/30
>A> + NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N203313 001 Sep 25, 2015 Sep NEWA
>A> TRESIBA
>A> NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N203314 001 Sep 25, 2015 Sep NEWA
>A> + 600 UNITS/3ML (200 UNITS/ML) N203314 002 Sep 25, 2015 Sep NEWA

INSULIN GLARGINE RECOMBINANT
SOLUTION;SUBCUTANEOUS
TOUJEO SOLOSTAR
+ SANOFI US SERVICES 300 UNITS/ML (300 UNITS/ML) N206538 001 Feb 25, 2015 Feb NEWA

INSULIN LISPRO RECOMBINANT
SOLUTION;SUBCUTANEOUS
HUMALOG KWIKPEN
+ ELI LILLY AND CO 200 UNITS/ML N205747 001 May 26, 2015 May NEWA

INSULIN RECOMBINANT HUMAN
POWDER;INHALATION
AFREZZA
SANOFI AVENTIS 12 UNITS/INH N022472 003 Apr 17, 2015 Apr NEWA

IOHEXOL
FOR SOLUTION;ORAL
ORALTAG
INTERPHARMA PRAHA AS 9.7GM/BOT N205383 001 Mar 26, 2015 Mar NEWA

IOPAMIDOL
INJECTABLE;INJECTION
IOPAMIDOL-250
@ FRESENIUS KABI USA 51% A074679 001 Apr 02, 1997 Jan DISC
IOPAMIDOL-300
@ FRESENIUS KABI USA 61% A074679 002 Apr 02, 1997 Jan DISC
IOPAMIDOL-370
@ FRESENIUS KABI USA 76% A074679 003 Apr 02, 1997 Jan DISC

	INJECTABLE;INJECTION						
	ISOVUE-200						
+	BRACCO	41%	N018735	006	Jul 07, 1987		Feb CTEC
	ISOVUE-250						
+	BRACCO	51%	N018735	007	Jul 06, 1992		Feb CTEC
+		51%	N020327	002	Oct 12, 1994		Feb CTEC
	ISOVUE-300						
+	BRACCO	61%	N020327	003	Oct 12, 1994		Feb CTEC
	ISOVUE-370						
+	BRACCO	76%	N020327	004	Oct 12, 1994		Feb CTEC
	SCANLUX-300						
AP	MYLAN INSTITUTIONAL	61%	A090394	001	Jun 18, 2010		Aug CAHN
	SCANLUX-370						
AP	MYLAN INSTITUTIONAL	76%	A090394	002	Jun 18, 2010		Aug CAHN
	IOTHALAMATE MEGLUMINE						
	INJECTABLE;INJECTION						
	CONRAY						
+	LIEBEL-FLARSHEIM	60%	N013295	001			Feb CAHN
	CONRAY 30						
+	LIEBEL-FLARSHEIM	30%	N016983	001			Feb CAHN
	CONRAY 43						
+	LIEBEL-FLARSHEIM	43%	N013295	002			Feb CAHN
	SOLUTION;INTRAVESICAL						
	CYSTO-CONRAY II						
	LIEBEL-FLARSHEIM	17.2%	N017057	002			Feb CAHN
	IOVERSOL						
	INJECTABLE;INJECTION						
	OPTIRAY 160						
	@ LIEBEL-FLARSHEIM	34%	N019710	003	Dec 30, 1988		Feb CAHN
	OPTIRAY 240						
+	LIEBEL-FLARSHEIM	51%	N019710	002	Dec 30, 1988		Feb CAHN
	@	51%	N020923	001	May 28, 1998		Feb CAHN
	OPTIRAY 300						
+	LIEBEL-FLARSHEIM	64%	N019710	004	Jan 22, 1992		Feb CAHN
+		64%	N020923	004	May 13, 1999		Feb CAHN
	OPTIRAY 320						
+	LIEBEL-FLARSHEIM	68%	N019710	001	Dec 30, 1988		Feb CAHN
	@	68%	N020923	002	May 29, 1998		Feb CAHN
	OPTIRAY 350						
+	LIEBEL-FLARSHEIM	74%	N019710	005	Jan 22, 1992		Feb CAHN
+		74%	N020923	003	May 28, 1998		Feb CAHN
	IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM						
	INJECTABLE;INJECTION						
	HEXABRIX						
	@ GUERBET	39.3%;19.6%	N018905	002	Jul 26, 1985		May DISC
	IRBESARTAN						
	TABLET;ORAL						
	IRBESARTAN						
AB	JUBILANT GENERICS	75MG	A203534	001	Feb 23, 2015		Feb NEWA
AB		150MG	A203534	002	Feb 23, 2015		Feb NEWA
AB		300MG	A203534	003	Feb 23, 2015		Feb NEWA
	IRON DEXTRAN						
	INJECTABLE;INJECTION						
	INFED						
BP +	ACTAVIS LABS UT INC	EQ 50MG IRON/ML	N017441	001			Mar CAHN
	ISAVUCONAZONIUM SULFATE						
	CAPSULE;ORAL						
	CRESEMBA						
+	ASTELLAS	186MG	N207500	001	Mar 06, 2015		Mar NEWA
	POWDER;IV (INFUSION)						
	CRESEMBA						
+	ASTELLAS	372MG	N207501	001	Mar 06, 2015		Mar NEWA

ISOSORBIDE DINITRATE

TABLET;ORAL

ISORDIL

AB		VALEANT PHARMS NORTH	5MG	N012093	007	Jul 29, 1988	Feb CAHN
	+		40MG	N012093	001	Jul 29, 1988	Feb CAHN

ISOTRETINOIN

CAPSULE;ORAL

ABSORICA

		RANBAXY	25MG	N021951	005	Aug 15, 2014	Feb NEWA
			35MG	N021951	006	Aug 15, 2014	Feb NEWA

MYORISAN

AB		DOUGLAS PHARMS	30MG	A076485	004	Aug 25, 2015	Aug NEWA

SOTRET

AB		SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002	Apr CAHN
AB			20MG	A076041	002	Dec 24, 2002	Apr CAHN
AB			30MG	A076503	001	Jun 20, 2003	Apr CAHN
AB			40MG	A076041	003	Dec 24, 2002	Apr CAHN

ZENATANE

AB		DR REDDYS LABS LTD	30MG	A202099	004	Feb 23, 2015	Feb NEWA

ISRADIPINE

CAPSULE;ORAL

ISRADIPINE

AB		ELITE LABS INC	2.5MG	A077169	001	Apr 24, 2006	Mar CAHN
AB			5MG	A077169	002	Apr 24, 2006	Mar CAHN

IVABRADINE HYDROCHLORIDE

TABLET;ORAL

CORLANOR

		AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015	Apr NEWA
	+		EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Apr NEWA

IVACAFTOR

GRANULE;ORAL

KALYDECO

		VERTEX PHARMS INC	50MG/PACKET	N207925	001	Mar 17, 2015	Mar NEWA
	+		75MG/PACKET	N207925	002	Mar 17, 2015	Mar NEWA

IVACAFTOR; LUMACAFTOR

TABLET;ORAL

ORKAMBI

	+	VERTEX PHARMS INC	125MG;200MG	N206038	001	Jul 02, 2015	Jul NEWA

IXABEPILONE

INJECTABLE;IV (INFUSION)

IXEMPRA KIT

	+	R-PHARM US LLC	15MG/VIAL	N022065	001	Oct 16, 2007	Jun CAHN
	+		45MG/VIAL	N022065	002	Oct 16, 2007	Jun CAHN

KANAMYCIN SULFATE

INJECTABLE;INJECTION

KANAMYCIN

	@	EUROHLTH INTL SARL	EQ 75MG BASE/2ML	A062324	001		Jun CAHN
	@		EQ 500MG BASE/2ML	A062324	002		Jun CAHN
	@		EQ 1GM BASE/3ML	A062324	003		Jun CAHN

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

>A> AP		BD RX	15MG/ML	A203242	001	Oct 07, 2015	Sep NEWA
>A> AP			30MG/ML	A203242	002	Oct 07, 2015	Sep NEWA
	@	CLARIS PHARMASERVICE	15MG/ML	A075631	002	Jun 29, 2001	Apr CAHN
	@		30MG/ML	A075631	001	Jun 29, 2001	Apr CAHN
	@	EUROHLTH INTL SARL	15MG/ML	A075772	001	Jul 21, 2004	Jun CAHN
	@		30MG/ML	A075772	002	Jul 21, 2004	Jun CAHN

SPRAY, METERED;NASAL

SPRIX

	+	EGALET US INC	15.75MG/SPRAY	N022382	001	May 14, 2010	Jan CAHN

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

	SOLUTION;IRRIGATION						
	OMIDRIA						
+	OMEROS	EQ 4.24MG BASE/ML;EQ 12.4MG BASE/ML	N205388	001	May 30, 2014	Feb	CPOT

LABETALOL HYDROCHLORIDE

	INJECTABLE;INJECTION						
	LABETALOL HYDROCHLORIDE						
@	CLARIS PHARMASERVICE	5MG/ML	A076051	001	Jul 05, 2002	Apr	CAHN
	TABLET;ORAL						
	LABETALOL HYDROCHLORIDE						
AB	MUTUAL PHARM	100MG	A075215	001	Jul 29, 1999	Jan	CMFD
AB		200MG	A075215	002	Jul 29, 1999	Jan	CMFD
AB		300MG	A075215	003	Jul 29, 1999	Jan	CMFD

LACTULOSE

	SOLUTION;ORAL, RECTAL						
	LACTULOSE						
AA	BIO-PHARM INC	10GM/15ML	A203762	001	Mar 27, 2015	Mar	NEWA

LAMIVUDINE; RALTEGRAVIR POTASSIUM

	TABLET;ORAL						
	DUTREBIS						
@	MERCK SHARP DOHME	150MG;EQ 300MG BASE	N206510	001	Feb 06, 2015	Aug	DISC
+		150MG;EQ 300MG BASE	N206510	001	Feb 06, 2015	Feb	NEWA

LAMIVUDINE; ZIDOVUDINE

	TABLET;ORAL						
	LAMIVUDINE AND ZIDOVUDINE						
AB	HETERO LABS LTD III	150MG;300MG	A079124	001	Sep 17, 2015	Aug	NEWA
AB	STRIDES ARCOLAB LTD	150MG;300MG	A079128	001	May 13, 2015	Apr	NEWA
AB	STRIDES PHARMA	150MG;300MG	A079128	001	May 13, 2015	Aug	CAHN

LAMOTRIGINE

	TABLET;ORAL						
	LAMOTRIGINE						
@	HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011	May	DISC
@		100MG	A078134	002	Apr 19, 2011	May	DISC
@		150MG	A078134	003	Apr 19, 2011	May	DISC
@		200MG	A078134	004	Apr 19, 2011	May	DISC

LAPATINIB DITOSYLATE

	TABLET;ORAL						
	TYKERB						
+	NOVARTIS PHARMS CORP	EQ 250MG BASE	N022059	001	Mar 13, 2007	Mar	CAHN

LENVATINIB MESYLATE

	CAPSULE;ORAL						
	LENVIMA						
	EISAI INC	EQ 4MG BASE	N206947	001	Feb 13, 2015	Feb	NEWA
+		EQ 10MG BASE	N206947	002	Feb 13, 2015	Feb	NEWA

LEVETIRACETAM

	INJECTABLE;IV (INFUSION)						
	LEVETIRACETAM						
AP	FRESENIUS KABI USA	500MG/5ML (100MG/ML)	A090876	001	Aug 13, 2015	Jul	NEWA
	SOLUTION;ORAL						
	LEVETIRACETAM						
AA	PHARM ASSOC	100MG/ML	A201157	001	Jun 04, 2015	May	NEWA
	TABLET;ORAL						
	SPRITAM						
	APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015	Jul	NEWA
		500MG	N207958	002	Jul 31, 2015	Jul	NEWA
		750MG	N207958	003	Jul 31, 2015	Jul	NEWA
		1GM	N207958	004	Jul 31, 2015	Jul	NEWA
	TABLET, EXTENDED RELEASE;ORAL						
	LEVETIRACETAM						
	APOTEX INC	1GM	A202958	001	Feb 25, 2015	Feb	NEWA
AB	DEXCEL PHARMA	500MG	A202167	001	Sep 04, 2015	Aug	NEWA
AB		750MG	A202167	002	Sep 04, 2015	Aug	NEWA

TABLET, EXTENDED RELEASE;ORAL
LEVETIRACETAM

AB	PHARMADAX INC	500MG	A201464	001	May 25, 2012	Aug	CAHN
AB		750MG	A201464	002	May 25, 2012	Aug	CAHN
AB	PRINSTON INC	500MG	A203468	001	May 21, 2015	May	NEWA
AB		750MG	A203468	002	May 21, 2015	May	NEWA

LEVOCARNITINE

INJECTABLE;INJECTION
LEVOCARNITINE

	@ TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	Apr	DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE

AB	APOTEX INC	5MG	A203027	001	Feb 13, 2015	Feb	NEWA
AB	SUN PHARM INDS LTD	5MG	A201653	001	Jun 26, 2015	Jun	NEWA

LEVOFLOXACIN

INJECTABLE;INJECTION
LEVOFLOXACIN

AP	CLARIS PHARMASERVICE	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Apr	CAHN
AP	HOSPIRA INC	EQ 500MG/20ML (EQ 25MG/ML)	A078577	001	Aug 12, 2015	Jul	NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A078577	002	Aug 12, 2015	Jul	NEWA

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	CLARIS PHARMASERVICE	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Apr	CAHN
AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Apr	CAHN
AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Apr	CAHN
AP	HOSPIRA INC	EQ 250MG/50ML (EQ 5MG/ML)	A078579	001	Sep 03, 2015	Aug	NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A078579	002	Sep 03, 2015	Aug	NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A078579	003	Sep 03, 2015	Aug	NEWA

SOLUTION/DROPS;OPHTHALMIC
LEVOFLOXACIN

AT +	NEXUS PHARMS	0.5%	A077700	001	Dec 20, 2010	Jul	CRLD

QUIXIN

	@ SANTEN	0.5%	N021199	001	Aug 18, 2000	Jul	DISC

TABLET;ORAL
LEVOFLOXACIN

AB	JUBILANT GENERICS	250MG	A203613	001	Jun 19, 2015	Jun	NEWA
AB		500MG	A203613	002	Jun 19, 2015	Jun	NEWA

LEVOLEUCOVORIN CALCIUM

SOLUTION;IV (INFUSION)
LEVOLEUCOVORIN CALCIUM

	SANDOZ	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Feb	NEWA
	SANDOZ INC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	Feb	NEWA
+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Mar	CRLD

LEVONORGESTREL

INTRAUTERINE DEVICE;INTRAUTERINE
LILETTA

	MEDICINES360	52MG	N206229	001	Feb 26, 2015	Feb	NEWA

LEVORPHANOL TARTRATE

TABLET;ORAL
LEVORPHANOL TARTRATE

+	SENTYNL THERAPS INC	2MG	A074278	001	Mar 31, 2000	Apr	CAHN

LIDOCAINE

OINTMENT;TOPICAL
LIDOCAINE

AT	AMNEAL PHARMS	5%	A206297	001	Aug 07, 2015	Jul	NEWA
>A>	@ BELMORA LLC	5%	A080210	001		Sep	CAHN
>D>	@ GRAHAM CHEM	5%	A080210	001		Sep	CAHN

PATCH;TOPICAL
LIDOCAINE

AB	ACTAVIS LABS UT INC	5%	A200675	001	Aug 23, 2012	Mar	CAHN
AB	MYLAN TECHNOLOGIES	5%	A202346	001	Aug 07, 2015	Jul	NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

	@	EUROHLTH INTL SARL	1%	A080407	001		Mar CAHN
	@		2%	A080407	002		Mar CAHN
AP		LUITPOLD	1%	A091564	001	Aug 14, 2015	Aug NEWA

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

	@	EUROHLTH INTL SARL	1%	A084625	001		Feb CAHN
	@		2%	A084625	002		Feb CAHN

JELLY;TOPICAL

ANESTACON

	@	BANNER LIFE SCIENCES	2%	A080429	001		Jan CAHN

LIDOCAINE HYDROCHLORIDE

	@	G AND W LABS INC	2%	A081318	001	Apr 29, 1993	Apr CAHN

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL

EMLA

AB	+	ACTAVIS LABS UT INC	2.5%;2.5%	N019941	001	Dec 30, 1992	Feb CAHN

LINACLOTIDE

CAPSULE;ORAL

LINZESS

		FOREST LABS LLC	145MCG	N202811	001	Aug 30, 2012	Mar CAHN
	+		290MCG	N202811	002	Aug 30, 2012	Mar CAHN

LINCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

LINCOCIN

AP	+	PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N050317	001		May CFTG

LINCOMYCIN

AP		X-GEN PHARMS INC	EQ 300MG BASE/ML	A201746	001	Jun 04, 2015	May NEWA

LINEZOLID

FOR SUSPENSION;ORAL

LINEZOLID

AB		ROXANE	100MG/5ML	A200068	001	Jun 03, 2015	May NEWA

ZYVOX

AB	+	PHARMACIA AND UPJOHN	100MG/5ML	N021132	001	Apr 18, 2000	May CFTG

SOLUTION;IV (INFUSION)

LINEZOLID

AP		HOSPIRA INC	600MG/300ML (2MG/ML)	A205442	001	Jul 07, 2015	Jun NEWA
AP		SANDOZ INC	200MG/100ML (2MG/ML)	A200904	001	Jul 16, 2015	Jul NEWA
AP			600MG/300ML (2MG/ML)	A200904	002	Jul 16, 2015	Jul NEWA
AP		TEVA PHARMS	600MG/300ML (2MG/ML)	A200222	001	Jun 27, 2012	May CDFR

LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	+	HOSPIRA INC	600MG/300ML (2MG/ML)	N206473	001	Jun 18, 2015	Jun NEWA

ZYVOX

AP		PHARMACIA AND UPJOHN	200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000	Jul CTEC
			200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000	May CDFR
			400MG/200ML (2MG/ML)	N021131	002	Apr 18, 2000	May NEWA
AP	+		600MG/300ML (2MG/ML)	N021131	003	Apr 18, 2000	May NEWA

TABLET;ORAL

LINEZOLID

AB		TEVA PHARMS USA	600MG	A078061	001	May 18, 2015	May NEWA

ZYVOX

AB	+	PHARMACIA AND UPJOHN	600MG	N021130	002	Apr 18, 2000	May CFTG

LISINOPRIL

TABLET;ORAL

LISINOPRIL

AB		SUN PHARM INDS LTD	2.5MG	A075944	001	Jul 01, 2002	Apr CAHN
AB			5MG	A075944	002	Jul 01, 2002	Apr CAHN
AB			10MG	A075944	003	Jul 01, 2002	Apr CAHN
AB			20MG	A075944	004	Jul 01, 2002	Apr CAHN
AB			30MG	A075944	006	Feb 11, 2003	Apr CAHN
AB			40MG	A075944	005	Jul 01, 2002	Apr CAHN

ZESTRIL

AB		ALVOGEN IPCO SARL	2.5MG	N019777	005	Apr 29, 1993	Feb CAHN
AB			5MG	N019777	001	May 19, 1988	Feb CAHN

TABLET;ORAL
ZESTRIL

AB		10MG	N019777	002	May 19, 1988	Feb	CAHN
AB		20MG	N019777	003	May 19, 1988	Feb	CAHN
AB		30MG	N019777	006	Jan 20, 1999	Feb	CAHN
AB	+	40MG	N019777	004	May 19, 1988	Feb	CAHN

LITHIUM CARBONATE
TABLET, EXTENDED RELEASE;ORAL
LITHIUM CARBONATE

AB	ALEMBIC PHARMS LTD	300MG	A204445	001	Jun 10, 2015	May	NEWA
	@ HIKMA INTL PHARMS	450MG	A076490	001	Jun 17, 2003	Feb	DISC
AB	UNIQUE PHARM LABS	300MG	A204779	001	Jul 27, 2015	Jul	NEWA

LOMITAPIDE MESYLATE
CAPSULE;ORAL
JUXTAPID

	AEGERION	EQ 30MG BASE	N203858	004	Apr 23, 2015	Apr	NEWA
		EQ 40MG BASE	N203858	005	Apr 23, 2015	Apr	NEWA
		EQ 60MG BASE	N203858	006	Apr 23, 2015	Apr	NEWA

LOMUSTINE
CAPSULE;ORAL
GLEOSTINE

	CORDEN PHARMA	5MG	N017588	004	Dec 19, 2014	Jan	NEWA

LOPERAMIDE HYDROCHLORIDE
CAPSULE;ORAL
IMODIUM

	@ J AND J CONSUMER INC	2MG	N017690	001		Jul	CAHN
AB	+	2MG	N017694	001		Jul	CAHN

LOPINAVIR; RITONAVIR
CAPSULE;ORAL
KALETRA

	@ ABBVIE	133.3MG;33.3MG	N021226	001	Sep 15, 2000	Jun	DISC

LORAZEPAM
INJECTABLE;INJECTION
ATIVAN

AP	+ EUROHLTH INTL SARL	2MG/ML	N018140	001		Jun	CAHN
AP	+	4MG/ML	N018140	002		Jun	CAHN

TABLET;ORAL
LORAZEPAM

AB	SUN PHARM INDS LTD	0.5MG	A076045	001	Aug 29, 2001	Apr	CAHN
AB		1MG	A076045	002	Aug 29, 2001	Apr	CAHN
AB		2MG	A076045	003	Aug 29, 2001	Apr	CAHN

LOSARTAN POTASSIUM
TABLET;ORAL
LOSARTAN POTASSIUM

AB	HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015	Jul	NEWA
AB		50MG	A203835	002	Aug 12, 2015	Jul	NEWA
AB		100MG	A203835	003	Aug 12, 2015	Jul	NEWA
AB	WATSON LABS	25MG	A091129	001	Oct 06, 2010	Feb	CMFD
AB		50MG	A091129	002	Oct 06, 2010	Feb	CMFD
AB		100MG	A091129	003	Oct 06, 2010	Feb	CMFD

LOVASTATIN
TABLET, EXTENDED RELEASE;ORAL
ALTOPREV

	@ COVIS PHARMA SARL	10MG	N021316	001	Jun 26, 2002	May	CAHN
		20MG	N021316	002	Jun 26, 2002	May	CAHN
		40MG	N021316	003	Jun 26, 2002	May	CAHN
	+	60MG	N021316	004	Jun 26, 2002	May	CAHN

LOXAPINE HYDROCHLORIDE
CONCENTRATE;ORAL
LOXITANE C

	@ ACTAVIS LABS UT INC	EQ 25MG BASE/ML	N017658	001		Mar	CAHN

		INJECTABLE;INJECTION						
		LOXITANE IM						
		@ ACTAVIS LABS UT INC	EQ 50MG BASE/ML	N018039	001			Mar CAHN
		LOXAPINE SUCCINATE						
		CAPSULE;ORAL						
		LOXAPINE SUCCINATE						
AB		ELITE LABS INC	EQ 5MG BASE	A076868	001	Aug 04, 2005		May CAHN
AB			EQ 10MG BASE	A076868	002	Aug 04, 2005		May CAHN
AB			EQ 25MG BASE	A076868	003	Aug 04, 2005		May CAHN
AB			EQ 50MG BASE	A076868	004	Aug 04, 2005		May CAHN
		LOXITANE						
		@ ACTAVIS LABS UT INC	EQ 5MG BASE	N017525	001			Mar CAHN
		@	EQ 10MG BASE	N017525	002			Mar CAHN
		@	EQ 25MG BASE	N017525	003			Mar CAHN
		@	EQ 50MG BASE	N017525	004			Mar CAHN
		TABLET;ORAL						
		LOXITANE						
		@ ACTAVIS LABS UT INC	EQ 10MG BASE	N017525	006			Mar CAHN
		@	EQ 25MG BASE	N017525	007			Mar CAHN
		@	EQ 50MG BASE	N017525	008			Mar CAHN
		LUCINACTANT						
		SUSPENSION;INTRATRACHEAL						
		SURFAXIN						
		@ DISCOVERY LABS	8.5ML	N021746	001	Mar 06, 2012		May DISC
		MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE						
		INJECTABLE;INJECTION						
		PLASMA-LYTE 56 IN PLASTIC CONTAINER						
		@ BAXTER HLTHCARE	32MG/100ML;128MG/100ML;234MG/100ML	N019047	001	Jun 15, 1984		Mar DISC
		MAGNESIUM SULFATE						
		SOLUTION;INTRAMUSCULAR, INTRAVENOUS						
		MAGNESIUM SULFATE						
AP		EXELA PHARMA SCS LLC	5GM/10ML (500MG/ML)	A206039	001	Dec 18, 2014		Apr CDFR
AP	+	FRESENIUS KABI USA	5GM/10ML (500MG/ML)	N019316	001	Sep 08, 1986		Apr CPOT
AP	+	HOSPIRA	5GM/10ML (500MG/ML)	A075151	001	Apr 25, 2000		Apr CDFR
		HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015		Apr NEWA
		MAGNESIUM SULFATE						
		SOLUTION;INTRAMUSCULAR, INTRAVENOUS						
		MAGNESIUM SULFATE						
	+	FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986		Apr NEWA
		MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE						
		SOLUTION;ORAL						
		SUCLEAR						
		@ BRAINTREE LABS	1.6GM/BOT,3.13GM/BOT,17.5GM/BOT,N/A,N/A,N/A,N/A;N/A,N/A,N/A,210GM,0.74GM,2.86GM,5.6GM	N203595	001	Jan 18, 2013		Aug DISC
		MANNITOL						
		INJECTABLE;INJECTION						
		MANNITOL 25%						
		@ IGI LABS INC	12.5GM/50ML	A089239	001	May 06, 1987		Mar CAHN
		@	12.5GM/50ML	A089240	001	May 06, 1987		Mar CAHN
		MECLIZINE HYDROCHLORIDE						
		TABLET;ORAL						
		MECLIZINE HYDROCHLORIDE						
		@ ANI PHARMS INC	12.5MG	A084975	001			Aug CAHN
		@	25MG	A084657	001			Aug CAHN
		@ VINTAGE PHARMS	12.5MG	A040179	001	Jan 30, 1997		Jun DISC
		@	25MG	A040179	002	Jan 30, 1997		Jun DISC

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

NAMENDA XR

			FOREST LABS LLC	7MG	N022525	001	Jun 21, 2010	Mar CAHN
				14MG	N022525	002	Jun 21, 2010	Mar CAHN
				21MG	N022525	003	Jun 21, 2010	Mar CAHN
		+		28MG	N022525	004	Jun 21, 2010	Mar CAHN

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

>A>			MACLEODS PHARMS LTD	2MG/ML	A202790	001	Oct 13, 2015	Sep NEWA
>A>	AA		SILARX PHARMS INC	2MG/ML	A204033	001	Oct 13, 2015	Sep NEWA

NAMENDA

>D>		+	FOREST LABS LLC	2MG/ML	N021627	001	Apr 18, 2005	Sep CFTG
>A>	AA	+		2MG/ML	N021627	001	Apr 18, 2005	Sep CFTG
		+		2MG/ML	N021627	001	Apr 18, 2005	Mar CAHN

TABLET;ORAL

MEMANTINE

	AB		SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	Mar CMFD
	AB			10MG	A090058	002	May 05, 2010	Mar CMFD

MEMANTINE HYDROCHLORIDE

>A>	AB		ALEMBIC PHARMS LTD	5MG	A200891	001	Oct 13, 2015	Sep NEWA
>A>	AB			10MG	A200891	002	Oct 13, 2015	Sep NEWA
	AB		AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015	Mar NEWA
	AB			10MG	A090041	002	Apr 10, 2015	Mar NEWA
>A>	AB		AUROBINDO PHARMA LTD	5MG	A203175	001	Oct 13, 2015	Sep NEWA
>A>	AB			10MG	A203175	002	Oct 13, 2015	Sep NEWA
	AB		DR REDDYS LABS LTD	5MG	A090048	001	Apr 14, 2010	Jun CMFD
	AB			10MG	A090048	002	Apr 14, 2010	Jun CMFD
>A>	AB		JUBILANT GENERICS	5MG	A091585	001	Oct 13, 2015	Sep NEWA
>A>	AB			10MG	A091585	002	Oct 13, 2015	Sep NEWA
	AB		LUPIN LTD	5MG	A090051	001	Apr 10, 2015	Mar NEWA
	AB			10MG	A090051	002	Apr 10, 2015	Mar NEWA
>A>	AB		MACLEODS PHARMS LTD	5MG	A202840	001	Oct 13, 2015	Sep NEWA
>A>	AB			10MG	A202840	002	Oct 13, 2015	Sep NEWA
	AB		MYLAN PHARMS INC	5MG	A079225	001	Jan 30, 2015	Jun CMFD
		@		5MG	A079225	001	Jan 30, 2015	Mar DISC
	AB			5MG	A079225	001	Jan 30, 2015	Jan NEWA
	AB			10MG	A079225	002	Jan 30, 2015	Jun CMFD
		@		10MG	A079225	002	Jan 30, 2015	Mar DISC
	AB			10MG	A079225	002	Jan 30, 2015	Jan NEWA
	AB		TEVA PHARMS	5MG	A090052	001	Oct 25, 2011	May CMFD
	AB			10MG	A090052	002	Oct 25, 2011	May CMFD
>A>	AB		TORRENT PHARMS LTD	5MG	A200155	001	Oct 13, 2015	Sep NEWA
>A>	AB			10MG	A200155	002	Oct 13, 2015	Sep NEWA
>A>	AB		UNICHEM LABS LTD	5MG	A200022	001	Oct 13, 2015	Sep NEWA
>A>	AB			10MG	A200022	002	Oct 13, 2015	Sep NEWA
	AB		UPSHER SMITH	5MG	A090043	001	Jul 31, 2015	Jul NEWA
	AB			10MG	A090043	002	Jul 31, 2015	Jul NEWA
	AB		WOCKHARDT LTD	5MG	A090073	001	Sep 04, 2015	Aug NEWA
	AB			10MG	A090073	002	Sep 04, 2015	Aug NEWA

NAMENDA

	AB		FOREST LABS LLC	5MG	N021487	001	Oct 16, 2003	Mar CAHN
	AB	+		10MG	N021487	002	Oct 16, 2003	Mar CAHN

MENOTROPINS (FSH;LH)

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

REPRONEX

		@	FERRING	75 IU/VIAL;75 IU/VIAL	N021047	001	Aug 27, 1999	May DISC

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERIDINE HYDROCHLORIDE

	AP		EUROHLTH INTL SARL	25MG/ML	A080445	001		Feb CAHN
	AP			50MG/ML	A080445	002		Feb CAHN
	AP			75MG/ML	A080445	003		Feb CAHN
	AP			100MG/ML	A080445	004		Feb CAHN
		@	IGI LABS INC	25MG/ML	A089781	001	Mar 31, 1989	May CAHN
		@		50MG/ML	A089782	001	Mar 31, 1989	Mar CAHN
		@		50MG/ML	A089783	001	Mar 31, 1989	Mar CAHN
		@		50MG/ML	A089784	001	Mar 31, 1989	Mar CAHN
		@		75MG/ML	A089785	001	Mar 31, 1989	Mar CAHN
		@		100MG/ML	A089786	001	Mar 31, 1989	Mar CAHN

INJECTABLE;INJECTION
MEPERIDINE HYDROCHLORIDE

	@		100MG/ML	A089787	001	Mar 31, 1989	Mar CAHN
	@		100MG/ML	A089788	001	Mar 31, 1989	Mar CAHN

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
MEPERGAN

	@	EUROHLTH INTL SARL	25MG/ML;25MG/ML	N011730	001		Jun CAHN

MEROPENEM

POWDER;IV (INFUSION)
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

		B BRAUN MEDICAL INC	500MG/VIAL	N202106	001	Apr 30, 2015	Apr NEWA
			1GM/VIAL	N202106	002	Apr 30, 2015	Apr NEWA

MESALAMINE

CAPSULE, EXTENDED RELEASE;ORAL
APRISO

	+	VALEANT PHARMS INTL	375MG	N022301	001	Oct 31, 2008	Jul CAHN

ENEMA;RECTAL
MESALAMINE

AB		G AND W LABS INC	4GM/60ML	A076841	001	Sep 30, 2004	Aug CAHN

SUPPOSITORY;RECTAL
CANASA

	@	FOREST LABS LLC	500MG	N021252	001	Jan 05, 2001	Aug CAHN
	+		1GM	N021252	002	Nov 05, 2004	Aug CAHN

MESTRANOL; NORETHINDRONE

TABLET;ORAL-20
NORINYL

	@	ACTAVIS LABS UT INC	0.1MG;2MG	N013625	004		Mar CAHN

TABLET;ORAL-21
NORINYL 1+50 21-DAY

	@	ACTAVIS LABS UT INC	0.05MG;1MG	N013625	002		Mar CAHN

TABLET;ORAL-28
NORINYL 1+50 28-DAY

	+	ACTAVIS LABS UT INC	0.05MG;1MG	N016659	001		Mar CAHN

METAPROTERENOL SULFATE

SOLUTION;INHALATION
METAPROTERENOL SULFATE

	@	MYLAN SPECLT	0.4%	A071786	001	Aug 05, 1988	Apr DISC
	@		0.6%	A070804	001	Aug 17, 1987	Apr DISC
	@	WOCKHARDT	0.4%	A075586	001	May 30, 2002	Apr DISC
	@		0.6%	A075586	002	May 30, 2002	Apr DISC

SYRUP;ORAL
METAPROTERENOL SULFATE

	@	G AND W LABS INC	10MG/5ML	A072761	001	Feb 27, 1992	Apr CAHN
	@		10MG/5ML	A073034	001	Aug 30, 1991	Apr CAHN

METAXALONE

TABLET;ORAL
METAXALONE

		COREPHARMA	400MG	A040486	001	Feb 27, 2015	Feb NEWA
			640MG	N022503	001	Jun 01, 2015	Jun NEWA

METFORMIN HYDROCHLORIDE

SOLUTION;ORAL
RIOMET

	+	SUN PHARM INDS LTD	500MG/5ML	N021591	001	Sep 11, 2003	Apr CAHN

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET;ORAL
PRANDIMET

AB		NOVO NORDISK INC	500MG;1MG	N022386	001	Jun 23, 2008	Jun CFTG
AB	+		500MG;2MG	N022386	002	Jun 23, 2008	Jun CFTG

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

AB		LUPIN LTD	500MG;1MG	A200624	001	Jul 15, 2015	Jun NEWA
AB			500MG;2MG	A200624	002	Jul 15, 2015	Jun NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDAMET

@	SB PHARMCO	500MG;EQ 2MG BASE	N021410	002	Oct 10, 2002	May DISC
@		500MG;EQ 4MG BASE	N021410	003	Oct 10, 2002	May DISC
@		1GM;EQ 2MG BASE	N021410	004	Aug 25, 2003	May DISC
@		1GM;EQ 4MG BASE	N021410	005	Aug 25, 2003	May DISC

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

	TEVA	500MG;EQ 2MG BASE	A077337	001	May 07, 2014	May CTEC
		500MG;EQ 4MG BASE	A077337	002	May 07, 2014	May CTEC
+		1GM;EQ 4MG BASE	A077337	004	May 07, 2014	May CRLD
		1GM;EQ 2MG BASE	A077337	003	May 07, 2014	May CTEC

METHADONE HYDROCHLORIDE

TABLET;ORAL

METHADONE HYDROCHLORIDE

AA	AUROLIFE PHARMA LLC	5MG	A203502	001	Aug 31, 2015	Aug NEWA
AA		10MG	A203502	002	Aug 31, 2015	Aug NEWA
AA	COREPHARMA	5MG	A090065	001	Aug 18, 2015	Aug NEWA
AA		10MG	A090065	002	Aug 18, 2015	Aug NEWA

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB	HERITAGE PHARMA	5MG	A040734	001	Dec 14, 2007	Mar CAHN
AB		10MG	A040734	002	Dec 14, 2007	Mar CAHN

METHOCARBAMOL

SOLUTION;IM-IV

ROBAXIN

AP	+ EUROHLTH INTL SARL	1GM/10ML (100MG/ML)	N011790	001		Jun CAHN

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE PRESERVATIVE FREE

AP	FRESENIUS KABI USA	EQ 25MG BASE/ML	A040265	001	Feb 26, 1999	May CMFD

METHOXSALEN

CAPSULE;ORAL

METHOXSALEN

AB	ACTAVIS INC	10MG	A202603	001	Jun 09, 2015	May NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

APTENSIO XR

	RHODES PHARMS	10MG	N205831	001	Apr 17, 2015	Apr NEWA
		15MG	N205831	002	Apr 17, 2015	Apr NEWA
		20MG	N205831	003	Apr 17, 2015	Apr NEWA
		30MG	N205831	004	Apr 17, 2015	Apr NEWA
		40MG	N205831	005	Apr 17, 2015	Apr NEWA
		50MG	N205831	006	Apr 17, 2015	Apr NEWA
+		60MG	N205831	007	Apr 17, 2015	Apr NEWA

METHYLPHENIDATE HYDROCHLORIDE

>A> AB2	MALLINCKRODT INC	10MG	A203583	001	Sep 29, 2015	Sep NEWA
>A> AB2		20MG	A203583	002	Sep 29, 2015	Sep NEWA
>A> AB2		30MG	A203583	003	Sep 29, 2015	Sep NEWA
>A> AB2		40MG	A203583	004	Sep 29, 2015	Sep NEWA
>A> AB2		50MG	A203583	005	Sep 29, 2015	Sep NEWA
>A> AB2		60MG	A203583	006	Sep 29, 2015	Sep NEWA

RITALIN LA

AB1	NOVARTIS	40MG	N021284	003	Jun 05, 2002	Feb CRLD
+		60MG	N021284	005	Oct 27, 2014	Feb CRLD

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	NOVEL LABS INC	5MG/5ML	A204602	001	Aug 14, 2015	Aug NEWA
AA		10MG/5ML	A204602	002	Aug 14, 2015	Aug NEWA

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A> AB	ASCENT PHARMS INC	5MG	A207416	001	Sep 22, 2015	Sep NEWA
>A> AB		10MG	A207416	002	Sep 22, 2015	Sep NEWA
>A> AB		20MG	A207416	003	Sep 22, 2015	Sep NEWA

		TABLET, CHEWABLE;ORAL						
		METHYLIN						
	AB	MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003	Feb	CFTG
	AB		5MG	N021475	002	Apr 15, 2003	Feb	CFTG
	AB +		10MG	N021475	003	Apr 15, 2003	Feb	CFTG
		METHYLPHENIDATE HYDROCHLORIDE						
	AB	NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015	Feb	NEWA
	AB		5MG	A204115	002	Feb 25, 2015	Feb	NEWA
	AB		10MG	A204115	003	Feb 25, 2015	Feb	NEWA
		TABLET, EXTENDED RELEASE;ORAL						
		METHYLIN ER						
	AB	MALLINCKRODT INC	10MG	A075629	001	May 09, 2000	May	CTEC
		METHYLPHENIDATE HYDROCHLORIDE						
	AB	ABHAI	10MG	A207488	001	Jun 09, 2015	May	NEWA
	AB		20MG	A207488	002	Jun 09, 2015	May	NEWA
		METHYLTESTOSTERONE						
		CAPSULE;ORAL						
		METHYLTESTOSTERONE						
>A>	AB	IMPAX LABS INC	10MG	A204851	001	Sep 21, 2015	Sep	NEWA
		TESTRED						
>D>	+	VALEANT PHARM INTL	10MG	A083976	001		Sep	CTEC
>A>	AB +		10MG	A083976	001		Sep	CTEC
		METOPROLOL TARTRATE						
		INJECTABLE;INJECTION						
		METOPROLOL TARTRATE						
	AP	CLARIS PHARMASERVICE	1MG/ML	A078950	001	Apr 29, 2013	Apr	CAHN
		TABLET;ORAL						
		METOPROLOL TARTRATE						
		MYLAN	37.5MG	A076704	004	Mar 18, 2015	Mar	NEWA
			75MG	A076704	005	Mar 18, 2015	Mar	NEWA
		METRONIDAZOLE						
		CREAM;TOPICAL						
		NORITATE						
	+	VALEANT PHARMS NORTH	1%	N020743	001	Sep 26, 1997	Feb	CAHN
		GEL;VAGINAL						
		METRONIDAZOLE						
	+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb	CAHN
		NUVESSA						
	+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb	CTNA
		INJECTABLE;INJECTION						
		METRONIDAZOLE						
		@ EUROHLTH INTL SARL	500MG/100ML	N018907	001	Mar 30, 1984	Aug	CAHN
		METRONIDAZOLE IN PLASTIC CONTAINER						
	AP	CLARIS PHARMASERVICE	500MG/100ML	A078084	001	Mar 31, 2008	Apr	CAHN
		TABLET;ORAL						
		METRONIDAZOLE						
>A>	AB	APPCO PHARMA LLC	250MG	A205245	001	Sep 23, 2015	Sep	NEWA
>A>	AB		500MG	A205245	002	Sep 23, 2015	Sep	NEWA
	AB	AUROBINDO PHARMA LTD	250MG	A203974	001	May 29, 2015	May	NEWA
	AB		500MG	A203974	002	May 29, 2015	May	NEWA
		MICONAZOLE						
		TABLET;BUCCAL						
		ORAVIG						
	+	DARA BIOSCIENCES	50MG	N022404	001	Apr 16, 2010	Apr	CAHN
		MIDAZOLAM HYDROCHLORIDE						
		INJECTABLE;INJECTION						
		MIDAZOLAM HYDROCHLORIDE						
		@ CLARIS PHARMASERVICE	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Apr	CAHN
		@	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Apr	CAHN
	AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jun	CAHN
	AP		EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jun	CAHN
		@ IGI LABS INC	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000	Apr	CAHN
		@ WOCKHARDT	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Mar	DISC
		@	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Mar	DISC
		@	EQ 5MG BASE/ML	A078141	002	May 30, 2008	Mar	DISC
		@	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Mar	DISC

SYRUP;ORAL
MIDAZOLAM HYDROCHLORIDE

AA		SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058	001	Mar 15, 2002	Apr	CAHN

MIGLITOL

TABLET;ORAL
GLYSET

AB		PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Mar	CTEC
AA			25MG	N020682	001	Dec 18, 1996	Feb	CFTG
AB			50MG	N020682	002	Dec 18, 1996	Mar	CTEC
AA			50MG	N020682	002	Dec 18, 1996	Feb	CFTG
AB	+		100MG	N020682	003	Dec 18, 1996	Mar	CTEC
AA	+		100MG	N020682	003	Dec 18, 1996	Feb	CFTG

MIGLITOL

AB		ORIENT PHARMA CO LTD	25MG	A203965	001	Feb 24, 2015	Mar	CTEC
AA			25MG	A203965	001	Feb 24, 2015	Feb	NEWA
AB			50MG	A203965	002	Feb 24, 2015	Mar	CTEC
AA			50MG	A203965	002	Feb 24, 2015	Feb	NEWA
AB			100MG	A203965	003	Feb 24, 2015	Mar	CTEC
AA			100MG	A203965	003	Feb 24, 2015	Feb	NEWA

MILRINONE LACTATE

INJECTABLE;INJECTION
MILRINONE LACTATE

AP		BEDFORD	EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan	CRLD
AP		EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jun	CAHN
>A>		@	EQ 1MG BASE/ML	A075852	001	May 28, 2002	Sep	CAHN
AP	+	HIKMA FARMACEUTICA	EQ 1MG BASE/ML	A077966	001	Dec 03, 2010	Jan	CRLD
>D>		@ HIKMA MAPLE	EQ 1MG BASE/ML	A075852	001	May 28, 2002	Sep	CAHN

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL
MINOCYCLINE HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 50MG BASE	A065062	001	Nov 30, 2000	Apr	CAHN
AB			EQ 75MG BASE	A065062	002	Nov 30, 2000	Apr	CAHN
AB			EQ 100MG BASE	A065062	003	Nov 30, 2000	Apr	CAHN
AB		TORRENT PHARMA INC	EQ 50MG BASE	A065062	001	Nov 30, 2000	Jun	CAHN
AB			EQ 75MG BASE	A065062	002	Nov 30, 2000	Jun	CAHN
AB			EQ 100MG BASE	A065062	003	Nov 30, 2000	Jun	CAHN

CAPSULE, EXTENDED RELEASE;ORAL
XIMINO

		@ SUN PHARM INDS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Apr	CAHN
		@	EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Apr	CAHN
		@	EQ 90MG BASE	N201922	003	Jul 11, 2012	Apr	CAHN
		@	EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Apr	CAHN
		@	EQ 135MG BASE	N201922	005	Jul 11, 2012	Apr	CAHN

TABLET;ORAL
MINOCYCLINE HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 50MG BASE	A065156	001	Jan 06, 2004	Apr	CAHN
AB			EQ 75MG BASE	A065156	002	Jan 06, 2004	Apr	CAHN
AB			EQ 100MG BASE	A065156	003	Jan 06, 2004	Apr	CAHN
AB		TORRENT PHARMA INC	EQ 50MG BASE	A065156	001	Jan 06, 2004	Jun	CAHN
AB			EQ 75MG BASE	A065156	002	Jan 06, 2004	Jun	CAHN
AB			EQ 100MG BASE	A065156	003	Jan 06, 2004	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL
MINOCYCLINE HYDROCHLORIDE

>D>	AB	SANDOZ	EQ 135MG BASE	A090422	003	Aug 13, 2009	Sep	CRLD
>A>	AB +		EQ 135MG BASE	A090422	003	Aug 13, 2009	Sep	CRLD
	AB	SUN PHARM INDS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Apr	CAHN
	AB		EQ 80MG BASE	A091118	004	Sep 25, 2014	Apr	CAHN
	AB		EQ 90MG BASE	A091118	005	Sep 25, 2014	Apr	CAHN
	AB		EQ 105MG BASE	A091118	006	Sep 25, 2014	Apr	CAHN
	AB		EQ 135MG BASE	A091118	008	Sep 25, 2014	Apr	CAHN

SOLODYN

>D>	+	MEDICIS	EQ 55MG BASE	N050808	008	Aug 27, 2010	Sep	CRLD
>A>			EQ 55MG BASE	N050808	008	Aug 27, 2010	Sep	CRLD
>D>	AB +		EQ 80MG BASE	N050808	007	Aug 27, 2010	Sep	CRLD
>A>	AB		EQ 80MG BASE	N050808	007	Aug 27, 2010	Sep	CRLD
>D>	AB		EQ 115MG BASE	N050808	005	Jul 23, 2009	Sep	CRLD
>A>	AB +		EQ 115MG BASE	N050808	005	Jul 23, 2009	Sep	CRLD

MIVACURIUM CHLORIDE

SOLUTION;INTRAVENOUS

MIVACRON

		ABBVIE	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22, 1992	Jan NEWA
	+		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098	005	Jan 22, 1992	Jan NEWA

MOLINDONE HYDROCHLORIDE

TABLET;ORAL

MOLINDONE HYDROCHLORIDE

		COREPHARMA	5MG	A090453	001	Mar 20, 2015	Mar NEWA
			10MG	A090453	002	Mar 20, 2015	Mar NEWA
	+		25MG	A090453	003	Mar 20, 2015	Mar NEWA

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

	AB	AJANTA PHARMA LTD	EQ 4MG BASE/PACKET	A203438	001	Jul 31, 2015	Jul NEWA

TABLET;ORAL

MONTELUKAST SODIUM

	AB	AJANTA PHARMA LTD	EQ 10MG BASE	A203432	001	Jul 31, 2015	Jul NEWA
	AB	AMNEAL PHARMS	EQ 10MG BASE	A204604	001	Sep 04, 2015	Aug NEWA
	AB	KREMERS URBAN PHARMS	EQ 10MG BASE	A201522	001	Aug 03, 2012	Mar CAHN
>A>	AB	UNICHEM LABS LTD	EQ 10MG BASE	A204290	001	Oct 08, 2015	Sep NEWA

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

	AB	AJANTA PHARMA LTD	EQ 4MG BASE	A203328	001	Jul 31, 2015	Jul NEWA
	AB		EQ 5MG BASE	A203328	002	Jul 31, 2015	Jul NEWA
	AB	HETERO LABS LTD V	EQ 4MG BASE	A204093	001	May 22, 2015	May NEWA
	AB		EQ 5MG BASE	A204093	002	May 22, 2015	May NEWA
	AB	JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015	Feb NEWA
	AB		EQ 5MG BASE	A203795	002	Feb 27, 2015	Feb NEWA
	AB	KREMERS URBAN PHARMS	EQ 4MG BASE	A200405	001	Aug 03, 2012	Mar CAHN
	AB		EQ 5MG BASE	A200405	002	Aug 03, 2012	Mar CAHN
	AB	MACLEODS PHARMS LTD	EQ 4MG BASE	A203582	001	Mar 12, 2015	Feb NEWA
	AB		EQ 5MG BASE	A203582	002	Mar 12, 2015	Feb NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

AVINZA

>D>								
>D>	AB2	KING PHARMS LLC	30MG	N021260	001	Mar 20, 2002	Sep DISC
>A>		@	30MG	N021260	001	Mar 20, 2002	Sep DISC
>D>	AB2		45MG	N021260	005	Dec 18, 2008	Sep DISC
>A>		@	45MG	N021260	005	Dec 18, 2008	Sep DISC
>D>	AB2		60MG	N021260	002	Mar 20, 2002	Sep DISC
>A>		@	60MG	N021260	002	Mar 20, 2002	Sep DISC
>D>	AB2		75MG	N021260	006	Dec 18, 2008	Sep DISC
>A>		@	75MG	N021260	006	Dec 18, 2008	Sep DISC
>D>	AB2		90MG	N021260	003	Mar 20, 2002	Sep DISC
>A>		@	90MG	N021260	003	Mar 20, 2002	Sep DISC
>D>	AB2	+	120MG	N021260	004	Mar 20, 2002	Sep DISC
>A>		@	120MG	N021260	004	Mar 20, 2002	Sep DISC

KADIAN

	AB1	+ ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Mar CAHN
	AB1		20MG	N020616	001	Jul 03, 1996	Mar CAHN
	AB1		30MG	N020616	004	Mar 09, 2001	Mar CAHN
	AB1		40MG	N020616	009	Jul 09, 2012	May CTEC
			40MG	N020616	009	Jul 09, 2012	Mar CAHN
	AB1		50MG	N020616	002	Jul 03, 1996	Mar CAHN
	AB1		60MG	N020616	005	Mar 09, 2001	Mar CAHN
	AB1		70MG	N020616	010	Jul 09, 2012	May CTEC
			70MG	N020616	010	Jul 09, 2012	Mar CAHN
	AB1		80MG	N020616	006	Oct 27, 2006	Mar CAHN
	AB1	+	100MG	N020616	003	Jul 03, 1996	Mar CAHN
			130MG	N020616	011	Jul 09, 2012	Mar CAHN
			150MG	N020616	012	Jul 09, 2012	Mar CAHN
	AB1	+	200MG	N020616	007	Feb 27, 2007	Mar CAHN

MORPHINE SULFATE

>D>	AB2	ACTAVIS ELIZABETH	30MG	A079040	001	Jan 16, 2013	Sep CTEC
>A>			30MG	A079040	001	Jan 16, 2013	Sep CTEC
>D>	AB2		45MG	A079040	002	Jan 16, 2013	Sep CTEC
>A>			45MG	A079040	002	Jan 16, 2013	Sep CTEC
>D>	AB2		60MG	A079040	003	Jan 16, 2013	Sep CTEC

		CAPSULE, EXTENDED RELEASE;ORAL						
		MORPHINE SULFATE						
>A>			60MG	A079040	003	Jan 16, 2013	Sep	CTEC
>D>	AB2		75MG	A079040	004	Jan 16, 2013	Sep	CTEC
>A>			75MG	A079040	004	Jan 16, 2013	Sep	CTEC
>D>	AB2		90MG	A079040	005	Jan 16, 2013	Sep	CTEC
>A>			90MG	A079040	005	Jan 16, 2013	Sep	CTEC
>D>	AB2		120MG	A079040	006	Jan 16, 2013	Sep	CTEC
>A>		+	120MG	A079040	006	Jan 16, 2013	Sep	CTEC
	AB1	TEVA PHARMS USA	40MG	A202718	007	Jun 03, 2015	May	NEWA
	AB1		70MG	A202718	008	Jun 03, 2015	May	NEWA
		INJECTABLE;INJECTION						
		DURAMORPH PF						
	AP	+ EUROHLTH INTL SARL	0.5MG/ML	N018565	001	Sep 18, 1984	Jun	CAHN
	AP	+	1MG/ML	N018565	002	Sep 18, 1984	Jun	CAHN
		INFUMORPH						
		+ EUROHLTH INTL SARL	10MG/ML	N018565	003	Jul 19, 1991	Jun	CAHN
		+	25MG/ML	N018565	004	Jul 19, 1991	Jun	CAHN
		MORPHINE SULFATE						
	AP	EUROHLTH INTL SARL	4MG/ML	A205758	001	May 21, 2015	May	NEWA
	AP		8MG/ML	A205758	002	May 21, 2015	May	NEWA
	AP		10MG/ML	A205758	003	May 21, 2015	May	NEWA
	AP	+ HOSPIRA INC	4MG/ML	N202515	002	Nov 14, 2011	May	CFTG
	AP	+	8MG/ML	N202515	003	Nov 14, 2011	May	CFTG
	AP	+	10MG/ML	N202515	004	Nov 14, 2011	May	CFTG
		SOLUTION;ORAL						
		MORPHINE SULFATE						
	AA	TRIS PHARMA INC	10MG/5ML	A203518	001	May 12, 2015	May	NEWA
	AA		100MG/5ML	A203518	002	May 12, 2015	May	NEWA
		TABLET, EXTENDED RELEASE;ORAL						
		MORPHINE SULFATE						
	AB	ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Mar	NEWA
	AB		30MG	A203849	002	Apr 06, 2015	Mar	NEWA
	AB		60MG	A203849	003	Apr 06, 2015	Mar	NEWA
	AB		100MG	A203849	004	Apr 06, 2015	Mar	NEWA
	AB		200MG	A203849	005	Apr 06, 2015	Mar	NEWA
	AB	SUN PHARM INDS LTD	15MG	A078761	001	May 11, 2012	Apr	CAHN
	AB		30MG	A078761	002	May 11, 2012	Apr	CAHN
	AB		60MG	A078761	003	May 11, 2012	Apr	CAHN
	AB		100MG	A078761	004	May 11, 2012	Apr	CAHN
	AB		200MG	A078761	005	May 11, 2012	Apr	CAHN
		MOXIFLOXACIN HYDROCHLORIDE						
		SOLUTION;IV (INFUSION)						
		MOXIFLOXACIN HYDROCHLORIDE						
		+ FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015	Apr	NEWA
		SOLUTION/DROPS;OPHTHALMIC						
		MOXEZA						
	AT2	+ ALCON PHARMS LTD	EQ 0.5% BASE	N022428	001	Nov 19, 2010	May	CFTG
		MOXIFLOXACIN HYDROCHLORIDE						
	AT1	LUPIN LTD	EQ 0.5% BASE	A202867	001	Sep 04, 2014	May	CTEC
	AT2		EQ 0.5% BASE	A204079	001	May 28, 2015	May	NEWA
	AT1	WATSON LABS INC	EQ 0.5% BASE	A202525	001	Mar 06, 2015	May	CTEC
	AT		EQ 0.5% BASE	A202525	001	Mar 06, 2015	Feb	NEWA
		VIGAMOX						
	AT1	+ ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003	May	CTEC
		TABLET;ORAL						
		MOXIFLOXACIN HYDROCHLORIDE						
	AB	MYLAN PHARMS INC	EQ 400MG BASE	A204635	001	Aug 31, 2015	Aug	NEWA
		NADOLOL						
		TABLET;ORAL						
		NADOLOL						
	AB	ORION CORP ORION	40MG	A201893	001	Sep 16, 2015	Aug	NEWA
	AB		80MG	A201893	002	Sep 16, 2015	Aug	NEWA

NALBUPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

NALBUPHINE HYDROCHLORIDE

@	IGI LABS INC	10MG/ML	A	072070	001	Apr 10, 1989	Mar CAHN
@		10MG/ML	A	072071	001	Apr 10, 1989	Mar CAHN
@		10MG/ML	A	072072	001	Apr 10, 1989	Mar CAHN
@		20MG/ML	A	072073	001	Apr 10, 1989	Mar CAHN
@		20MG/ML	A	072074	001	Apr 10, 1989	Mar CAHN
@		20MG/ML	A	072075	001	Apr 10, 1989	Mar CAHN

NALMEFENE HYDROCHLORIDE

INJECTABLE;INJECTION

REVEX

@	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML	N	020459	001	Apr 17, 1995	Jun CAHN
@		EQ 1MG BASE/ML	N	020459	002	Apr 17, 1995	Jun CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE

@	EUROHLTH INTL SARL	0.4MG/ML	A	070299	001	Sep 24, 1986	Mar CAHN

NALOXONE HYDROCHLORIDE

@	IGI LABS INC	0.02MG/ML	A	072082	001	Apr 11, 1989	Mar CAHN
@		0.02MG/ML	A	072083	001	Apr 11, 1989	Mar CAHN
@		0.02MG/ML	A	072084	001	Apr 11, 1989	Mar CAHN
@		0.02MG/ML	A	072085	001	Apr 11, 1989	Mar CAHN
@		0.4MG/ML	A	072086	001	Apr 11, 1989	Mar CAHN
@		0.4MG/ML	A	072087	001	Apr 11, 1989	Mar CAHN
@		0.4MG/ML	A	072088	001	Apr 11, 1989	Mar CAHN
@		0.4MG/ML	A	072089	001	Apr 11, 1989	Mar CAHN
@		0.4MG/ML	A	072090	001	Apr 11, 1989	Mar CAHN
@		1MG/ML	A	072091	001	Apr 11, 1989	Mar CAHN
@		1MG/ML	A	072092	001	Apr 11, 1989	Mar CAHN
@		1MG/ML	A	072093	001	Apr 11, 1989	Mar CAHN

NARCAN

@	ADAPT	0.02MG/ML	N	016636	002		Aug CAHN
@		0.4MG/ML	N	016636	001		Aug CAHN
@		1MG/ML	N	016636	003	Jun 14, 1982	Aug CAHN

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 0.5MG BASE;EQ 50MG BASE	A	075523	001	Mar 17, 2000	Apr CAHN

NAPROXEN

SUSPENSION;ORAL

NAPROSYN

AB	+	PEDIAPHARM INC	25MG/ML	N	018965	001	Mar 23, 1987	Apr CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

TREXIMET

	PERNIX IRELAND LTD	60MG;EQ 10MG BASE	N	021926	002	May 14, 2015	Jun NEWA

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

@	ALKEM LABS LTD	EQ 2.5MG BASE	A	203741	001	Jun 24, 2015	Jun DISC
		EQ 2.5MG BASE	A	203741	001	Jun 24, 2015	Jun NEWA
@		EQ 5MG BASE	A	203741	002	Jun 24, 2015	Jun DISC
		EQ 5MG BASE	A	203741	002	Jun 24, 2015	Jun NEWA
@		EQ 10MG BASE	A	203741	003	Jun 24, 2015	Jun DISC
		EQ 10MG BASE	A	203741	003	Jun 24, 2015	Jun NEWA
@		EQ 20MG BASE	A	203741	004	Jun 24, 2015	Jun DISC
		EQ 20MG BASE	A	203741	004	Jun 24, 2015	Jun NEWA
@	AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A	203659	001	Apr 16, 2015	Apr DISC
AB		EQ 2.5MG BASE	A	203659	001	Apr 16, 2015	Mar NEWA
@		EQ 5MG BASE	A	203659	002	Apr 16, 2015	Apr DISC
AB		EQ 5MG BASE	A	203659	002	Apr 16, 2015	Mar NEWA
@		EQ 10MG BASE	A	203659	003	Apr 16, 2015	Apr DISC
AB		EQ 10MG BASE	A	203659	003	Apr 16, 2015	Mar NEWA
@		EQ 20MG BASE	A	203659	004	Apr 16, 2015	Apr DISC

TABLET;ORAL
NEBIVOLOL HYDROCHLORIDE

AB		EQ 20MG BASE	A203659	004	Apr 16, 2015	Mar	NEWA
	@ INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828	001	Jul 29, 2015	Jul	DISC
		EQ 2.5MG BASE	A203828	001	Jul 29, 2015	Jul	NEWA
	@	EQ 5MG BASE	A203828	002	Jul 29, 2015	Jul	DISC
		EQ 5MG BASE	A203828	002	Jul 29, 2015	Jul	NEWA
	@	EQ 10MG BASE	A203828	003	Jul 29, 2015	Jul	DISC
		EQ 10MG BASE	A203828	003	Jul 29, 2015	Jul	NEWA
	@	EQ 20MG BASE	A203828	004	Jul 29, 2015	Jul	DISC
		EQ 20MG BASE	A203828	004	Jul 29, 2015	Jul	NEWA

NEFAZODONE HYDROCHLORIDE
TABLET;ORAL
NEFAZODONE HYDROCHLORIDE

	@ IDT AUSTRALIA LTD	50MG	A076072	001	Sep 16, 2003	Apr	CAHN
	@	100MG	A076072	002	Sep 16, 2003	Apr	CAHN
	@	150MG	A076072	003	Sep 16, 2003	Apr	CAHN
	@	200MG	A076072	004	Sep 16, 2003	Apr	CAHN
	@	250MG	A076072	005	Sep 16, 2003	Apr	CAHN
AB	SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003	Apr	CAHN
AB		100MG	A076409	002	Sep 16, 2003	Apr	CAHN
AB		150MG	A076409	003	Sep 16, 2003	Apr	CAHN
AB		200MG	A076409	004	Sep 16, 2003	Apr	CAHN
AB		250MG	A076409	005	Sep 16, 2003	Apr	CAHN

NELARABINE
INJECTABLE;IV (INFUSION)
ARRANON

+	NOVARTIS PHARMS CORP	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	Mar	CAHN

NEOSTIGMINE METHYLSULFATE
SOLUTION;INTRAVENOUS
NEOSTIGMINE METHYLSULFATE

	FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015	Jan	NEWA
		10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015	Jan	NEWA

NEVIRAPINE
TABLET, EXTENDED RELEASE;ORAL
NEVIRAPINE

AB	ALVOGEN PINE BROOK	400MG	A204621	001	Jul 10, 2015	Jun	NEWA

NIACIN
TABLET, EXTENDED RELEASE;ORAL
NIACIN

AB	AMNEAL PHARMS	500MG	A203578	001	Jul 24, 2015	Jul	NEWA
AB		1GM	A203578	002	Jul 24, 2015	Jul	NEWA

NIFEDIPINE
CAPSULE;ORAL
NIFEDIPINE

AB	HERITAGE PHARMA	10MG	A202644	001	Apr 25, 2013	Mar	CAHN
AB		20MG	A202644	002	Apr 25, 2013	Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL
NIFEDIPINE

AB2	VALEANT PHARMS NORTH	30MG	A075289	002	Feb 06, 2001	Aug	CAHN
AB2		60MG	A075289	001	Sep 27, 2000	Aug	CAHN

NILUTAMIDE
TABLET;ORAL
NILANDRON

	@ CONCORDIA PHARMS INC	50MG	N020169	001	Sep 19, 1996	Apr	CAHN
+		150MG	N020169	002	Apr 30, 1999	Apr	CAHN

NIMODIPINE
CAPSULE;ORAL
NIMODIPINE

AB	+ BANNER LIFE SCIENCES	30MG	A076740	001	Jan 17, 2008	Jan	CAHN
AB	SOFGEN PHARMS	30MG	A201832	001	Jul 24, 2015	Jul	NEWA

NINTEDANIB ESYLATE

CAPSULE;ORAL

OFEV

	BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832	001	Oct 15, 2014	Mar	CAIN
+		EQ 150MG BASE	N205832	002	Oct 15, 2014	Mar	CAIN

NITRIC OXIDE

GAS;INHALATION

INOMAX

@	INO	100PPM	N020845	002	Dec 23, 1999	Jun	DISC

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACRODANTIN

AB	ALVOGEN INC	25MG	N016620	003		Jun	CTEC

NITROFURANTOIN

AB	ACTAVIS LABS FL INC	25MG	A091095	001	Jun 18, 2015	Jun	NEWA
AB		50MG	A091095	002	Jun 18, 2015	Jun	NEWA
AB		100MG	A091095	003	Jun 18, 2015	Jun	NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB	WATSON LABS INC	75MG;25MG	A202250	001	Jul 08, 2015	Jun	NEWA

NORETHINDRONE

TABLET;ORAL-28

NOR-QD

AB1	+ ACTAVIS LABS UT INC	0.35MG	N017060	001		Mar	CAHN

NORGESTREL

TABLET;ORAL

OVRETTE

@	LABORATOIRE HRA	0.075MG	N017031	001		Jun	CAHN

NYSTATIN

CREAM;TOPICAL

NYSTATIN

AT	G AND W LABS INC	100,000 UNITS/GM	A061966	001		Jun	CMFD

SUSPENSION;ORAL

NYSTATIN

AA	G AND W LABS INC	100,000 UNITS/ML	A062349	001	Jul 14, 1982	Apr	CAHN
@		100,000 UNITS/ML	A062776	001	Dec 17, 1987	Apr	CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYKACET

AT	G AND W LABS INC	100,000 UNITS/GM;0.1%	A062367	001	May 28, 1985	Mar	CMFD

OINTMENT;TOPICAL

MYKACET

AT	G AND W LABS INC	100,000 UNITS/GM;0.1%	A062733	001	Mar 09, 1987	Mar	CMFD

OFLOXACIN

TABLET;ORAL

OFLOXACIN

AB	LARKEN LABS	400MG	A076093	003	Sep 02, 2003	Jul	CMFD

OLANZAPINE

TABLET;ORAL

OLANZAPINE

AB	IVAX PHARMS INC	20MG	A077301	001	Apr 29, 2015	Apr	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB	MACLEODS PHARMS LTD	5MG	A203044	001	Feb 20, 2015	Feb	NEWA
AB		10MG	A203044	002	Feb 20, 2015	Feb	NEWA
AB		15MG	A203044	003	Feb 20, 2015	Feb	NEWA
AB		20MG	A203044	004	Feb 20, 2015	Feb	NEWA
AB	ORCHID HLTHCARE	5MG	A202937	001	Mar 02, 2015	Feb	NEWA
AB		10MG	A202937	002	Mar 02, 2015	Feb	NEWA
AB		15MG	A202937	003	Mar 02, 2015	Feb	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

AB		20MG	A202937	004	Mar 02, 2015	Feb	NEWA

OLAPARIB

CAPSULE;ORAL
LYNPARZA

	ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014	Jan	CTNA

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED;INHALATION
STIOLTO RESPIMAT

+	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH	N206756	001	May 21, 2015	May	NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

AT	BARR LABS INC	EQ 0.2% BASE	A090848	001	Jul 13, 2015	Jun	NEWA

PATADAY

AT +	ALCON PHARMS LTD	EQ 0.2% BASE	N021545	001	Dec 22, 2004	Jun	CFTG

PAZEO

+	ALCON RES LTD	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Jan	NEWA

OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET;ORAL
TECHNIVIE

+	ABBVIE INC	12.5MG;75MG;50MG	N207931	001	Jul 24, 2015	Aug	CMS1
+		12.5MG;75MG;50MG	N207931	001	Jul 25, 2015	Jul	NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

AB	AUROBINDO PHARMA USA	10MG	A203270	001	Aug 19, 2015	Aug	NEWA
AB		20MG	A203270	002	Aug 19, 2015	Aug	NEWA
AB		40MG	A203270	003	Aug 19, 2015	Aug	NEWA
AB	LUPIN LTD	40MG	A202384	001	Aug 25, 2015	Aug	NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

AB	SUN PHARM INDS LTD	4MG	A078602	001	Feb 24, 2011	Apr	CAHN
AB		8MG	A078602	002	Feb 24, 2011	Apr	CAHN

ZOFRAN ODT

AB	NOVARTIS PHARMS CORP	4MG	N020781	001	Jan 27, 1999	Mar	CAHN
AB +		8MG	N020781	002	Jan 27, 1999	Mar	CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A206846	001	Jul 13, 2015	Jun	NEWA
AP	CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Apr	CAHN
AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077365	001	Dec 26, 2006	Jun	CAHN

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AP	CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Apr	CAHN
AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jun	CAHN
@	TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014	001	Mar 21, 2008	Jan	DISC

ZOFRAN

AP +	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Mar	CAHN

ZOFRAN PRESERVATIVE FREE

AP +	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Mar	CAHN

SOLUTION;ORAL
ZOFRAN

AA +	NOVARTIS PHARMS CORP	EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	Mar	CAHN

TABLET;ORAL
ZOFRAN

AB	NOVARTIS PHARMS CORP	EQ 4MG BASE	N020103	001	Dec 31, 1992	Mar	CAHN
AB		EQ 8MG BASE	N020103	002	Dec 31, 1992	Mar	CAHN
AB +		EQ 24MG BASE	N020103	003	Aug 27, 1999	Mar	CAHN

ORPHENADRINE CITRATE

INJECTABLE;INJECTION

NORFLEX

		@ IGI LABS INC	30MG/ML	N013055	001		Apr CAHN
		@ MEDICIS	30MG/ML	N013055	001		Mar DISC

ORPHENADRINE CITRATE

AP	+	AKORN	30MG/ML	A040484	001	May 24, 2006	Mar CRLD

OXACILLIN SODIUM

CAPSULE;ORAL

OXACILLIN SODIUM

		@ ANI PHARMS INC	EQ 250MG BASE	A062222	001		Aug CAHN
		@	EQ 500MG BASE	A062222	002		Aug CAHN

OXANDROLONE

TABLET;ORAL

OXANDRIN

AB		GEMINI LABS LLC	2.5MG	N013718	001		Aug CAHN
AB	+		10MG	N013718	002	Nov 05, 2001	Aug CAHN

OXCARBAZEPINE

SUSPENSION;ORAL

OXCARBAZEPINE

AB		SUN PHARM INDS LTD	300MG/5ML	A078734	001	Jun 26, 2009	Apr CAHN

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL

AB	+	ACTAVIS LABS UT INC	3.9MG/24HR	N021351	002	Feb 26, 2003	Mar CAHN

GEL, METERED;TRANSDERMAL

GELNIQUE 3%

	+	ACTAVIS LABS UT INC	3%	N202513	001	Dec 07, 2011	Mar CAHN

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

GELNIQUE

	+	ACTAVIS LABS UT INC	10%(100MG/PACKET)	N022204	001	Jan 27, 2009	Mar CAHN

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

AB		AVANTHI INC	5MG	A202773	001	Aug 17, 2015	Aug NEWA
AB		NOVEL LABS INC	5MG	A204752	001	Aug 24, 2015	Aug NEWA

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA		ANI PHARMS INC	5MG/5ML	A204979	001	Jun 01, 2015	May NEWA
AA		NOVEL LABS INC	100MG/5ML	A204603	001	Apr 29, 2015	Apr NEWA
AA		WOCKHARDT BIO AG	5MG/5ML	A206456	001	Jun 16, 2015	Jun NEWA

TABLET;ORAL

OXAYDO

		ACURA PHARMS INC	5MG	N202080	001	Jun 17, 2011	Mar CTNA
			7.5MG	N202080	002	Jun 17, 2011	Mar CTNA
		EGALET LTD	5MG	N202080	001	Jun 17, 2011	May CAHN
			7.5MG	N202080	002	Jun 17, 2011	May CAHN
		EGALET US INC	5MG	N202080	001	Jun 17, 2011	Jul CAHN
			7.5MG	N202080	002	Jun 17, 2011	Jul CAHN

OXYCODONE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	5MG	A076636	003	Apr 07, 2015	Mar NEWA
>A> AB		EPIC PHARMA LLC	5MG	A202662	001	Sep 22, 2015	Sep NEWA
>A> AB			10MG	A202662	002	Sep 22, 2015	Sep NEWA
>A> AB			15MG	A202662	003	Sep 22, 2015	Sep NEWA
>A> AB			30MG	A202662	004	Sep 22, 2015	Sep NEWA
AB		VINTAGE PHARMS	10MG	A077712	004	Apr 13, 2015	Mar NEWA
AB			20MG	A077712	005	Apr 13, 2015	Mar NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

	AB		SUN PHARM INDS LTD	5MG	A203506	001	Apr 24, 2015	Apr NEWA
	AB			7.5MG	A203506	002	Apr 24, 2015	Apr NEWA
	AB			10MG	A203506	003	Apr 24, 2015	Apr NEWA
	AB			15MG	A203506	004	Apr 24, 2015	Apr NEWA
	AB			20MG	A203506	005	Apr 24, 2015	Apr NEWA
	AB			30MG	A203506	006	Apr 24, 2015	Apr NEWA
	AB			40MG	A203506	007	Apr 24, 2015	Apr NEWA

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

	AP	+	EUROHLTH INTL SARL	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Feb CAHN
	AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Feb CAHN

PALBOCICLIB

CAPSULE;ORAL

IBRANCE

			PFIZER INC	75MG	N207103	001	Feb 03, 2015	Feb NEWA
				100MG	N207103	002	Feb 03, 2015	Feb NEWA
		+		125MG	N207103	003	Feb 03, 2015	Feb NEWA

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

INVEGA

	AB		JANSSEN PHARMS	1.5MG	N021999	006	Aug 26, 2008	Jul CFTG
	AB			3MG	N021999	001	Dec 19, 2006	Jul CFTG
	AB	+		6MG	N021999	002	Dec 19, 2006	Jul CFTG
	AB			9MG	N021999	003	Dec 19, 2006	Jul CFTG

PALIPERIDONE

	AB		ACTAVIS LABS FL INC	1.5MG	A202645	001	Aug 03, 2015	Jul NEWA
	AB			3MG	A202645	002	Aug 03, 2015	Jul NEWA
	AB			6MG	A202645	003	Aug 03, 2015	Jul NEWA
	AB			9MG	A202645	004	Aug 03, 2015	Jul NEWA
>A>	AB		MYLAN PHARMS INC	1.5MG	A203802	001	Sep 24, 2015	Sep NEWA
>A>	AB			3MG	A203802	002	Sep 24, 2015	Sep NEWA
>A>	AB			6MG	A203802	003	Sep 24, 2015	Sep NEWA
>A>	AB			9MG	A203802	004	Sep 24, 2015	Sep NEWA

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA TRINZA

			JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015	May NEWA
				410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015	May NEWA
				546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015	May NEWA
		+		819MG/2.625ML (312MG/ML)	N207946	004	May 18, 2015	May NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

ALOXI

>D>		+	HELSINN HLTHCARE	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N021372	002	Feb 29, 2008	Sep CFTG
>A>	AP	+		EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N021372	002	Feb 29, 2008	Sep CFTG
>D>		+		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N021372	001	Jul 25, 2003	Sep CFTG
>A>	AP	+		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N021372	001	Jul 25, 2003	Sep CFTG

>A> PALONOSETRON HYDROCHLORIDE

>A>	AP		SANDOZ INC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202521	001	Oct 13, 2015	Sep NEWA
>A>	AP		TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Oct 13, 2015	Sep NEWA
>A>	AP			EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A090713	001	Oct 13, 2015	Sep NEWA

PANCURONIUM BROMIDE

INJECTABLE;INJECTION

PANCURONIUM BROMIDE

	@	IGI LABS INC	1MG/ML	A072210	001	Mar 31, 1988	Mar CAHN
	@		2MG/ML	A072211	001	Mar 31, 1988	Mar CAHN
	@		2MG/ML	A072212	001	Mar 31, 1988	Mar CAHN
	@		2MG/ML	A072213	001	Mar 31, 1988	Mar CAHN

PANOBINOSTAT

CAPSULE;ORAL

FARYDAK

		NOVARTIS PHARMS CORP	10MG	N205353	001	Feb 23, 2015	Feb NEWA
			15MG	N205353	002	Feb 23, 2015	Feb NEWA
	+		20MG	N205353	003	Feb 23, 2015	Feb NEWA

PANOBINOSTAT LACTATE

CAPSULE;ORAL

FARYDAK

		NOVARTIS PHARMS CORP	EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar CAIN
			EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar CPOT
			EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar CAIN
			EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar CPOT
	+		EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar CAIN
	+		EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar CPOT

PANTOPRAZOLE SODIUM

INJECTABLE;IV (INFUSION)

PANTOPRAZOLE SODIUM

AP		SANDOZ INC	EQ 40MG BASE/VIAL	A090296	001	Jul 14, 2015	Jun NEWA

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB		KREMERS URBAN PHARMS	EQ 20MG BASE	A078281	001	Jan 20, 2011	Mar CAHN
AB			EQ 40MG BASE	A078281	002	Jan 20, 2011	Mar CAHN
AB		SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr CAHN
AB			EQ 40MG BASE	A200794	002	May 02, 2012	Apr CAHN

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

AB		BANNER LIFE SCIENCES	1MCG	A202539	001	Mar 27, 2014	Jan CAHN
AB			2MCG	A202539	002	Mar 27, 2014	Jan CAHN
AB			4MCG	A202539	003	Mar 27, 2014	Jan CAHN

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL

VOTRIENT

	+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N022465	001	Oct 19, 2009	Mar CAHN
	@		EQ 400MG BASE	N022465	002	Oct 19, 2009	Aug DISC
			EQ 400MG BASE	N022465	002	Oct 19, 2009	Mar CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIFYLLINE

AB		VALEANT PHARMS	400MG	A075028	001	Jul 20, 1998	Feb CAHN

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

BONTRIL

	@	VALEANT	105MG	A088021	001	Sep 21, 1982	Jan DISC

PHENDIMETRAZINE TARTRATE

	+	SANDOZ	105MG	N018074	001		Jan CTEC

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

DIBENZYLINE

AB	+	CONCORDIA PHARMS INC	10MG	N008708	001		Jun CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

AA		MIKAH PHARMA LLC	37.5MG	A040228	001	Jun 19, 1997	Jun CMFD

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

>D>		AKORN INC	2.5%	N207926	001	Jan 15, 2015	Sep CRLD
>A>	+		2.5%	N207926	001	Jan 15, 2015	Sep CRLD
			2.5%	N207926	001	Jan 15, 2015	Jan NEWA
>D>			10%	N207926	002	Jan 15, 2015	Sep CRLD
>A>	+		10%	N207926	002	Jan 15, 2015	Sep CRLD
			10%	N207926	002	Jan 15, 2015	Jan NEWA
>D>		PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013	Sep CRLD
>A>	+		2.5%	N203510	001	Mar 21, 2013	Sep CRLD

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH VC PLAIN

AA	+	G AND W LABS INC	5MG/5ML;6.25MG/5ML	A088761	001	Nov 08, 1984	Jul CAHN

PHENYTOIN SODIUM

CAPSULE;ORAL

EXTENDED PHENYTOIN SODIUM

	@	WOCKHARDT	30MG EXTENDED	A040759	001	Dec 18, 2007	Jun DISC
	@	WOCKHARDT USA	100MG EXTENDED	A040732	001	Jan 30, 2008	Jun DISC

PHENYTOIN SODIUM

AB		AUROBINDO PHARMA LTD	100MG EXTENDED	A204309	001	Jun 10, 2015	May NEWA

INJECTABLE;INJECTION

PHENYTOIN SODIUM

AP	+	EUROHLTH INTL SARL	50MG/ML	A084307	001		Feb CAHN

PHYTONADIONE

INJECTABLE;INJECTION

AQUAMEPHYTON

	@	IGI LABS INC	1MG/0.5ML	N012223	002		Apr CAHN
	@		10MG/ML	N012223	001		Apr CAHN

PILOCARPINE HYDROCHLORIDE

GEL;OPHTHALMIC

PILOPINE HS

	@	ALCON	4%	N018796	001	Oct 01, 1984	Aug DISC

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

AB		ELAN PHARMA INTL LTD	5MG	A076746	001	Nov 16, 2004	Mar CAHN

PIMOZIDE

TABLET;ORAL

ORAP

>D>		TEVA	1MG	N017473	003	Aug 27, 1997	Sep CFTG
>A>	AB		1MG	N017473	003	Aug 27, 1997	Sep CFTG
>D>	+		2MG	N017473	001	Jul 31, 1984	Sep CFTG
>A>	AB +		2MG	N017473	001	Jul 31, 1984	Sep CFTG

>A> PIMOZIDE

>A>	AB	PAR PHARM	1MG	A204521	001	Sep 28, 2015	Sep NEWA
>A>	AB		2MG	A204521	002	Sep 28, 2015	Sep NEWA

PINDOLOL

TABLET;ORAL

PINDOLOL

	@	G AND W LABS INC	5MG	A073661	001	Oct 31, 1993	Apr CAHN
	@		5MG	A073687	001	Feb 26, 1993	Apr CAHN
	@		5MG	A074123	001	Apr 17, 1997	Apr CAHN
	@		10MG	A073661	002	Oct 31, 1993	Apr CAHN
	@		10MG	A073687	002	Feb 26, 1993	Apr CAHN
	@		10MG	A074123	002	Apr 17, 1997	Apr CAHN

PIRBUTEROL ACETATE

AEROSOL, METERED;INHALATION

MAXAIR

	@	MEDICIS	EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992	Jan DISC

PIRFENIDONE

CAPSULE;ORAL

ESBRIET

	+	GENENTECH INC	267MG	N022535	001	Oct 15, 2014	Feb CAHN

PIROXICAM

CAPSULE;ORAL

PIROXICAM

AB		MYLAN PHARMS INC	10MG	A074116	001	Jun 15, 1993	May CAHN
AB			20MG	A074118	001	Jun 15, 1993	May CAHN

PODOFILOX

GEL;TOPICAL

CONDYLOX

	+	ACTAVIS LABS UT INC	0.5%	N020529	001	Mar 13, 1997	Feb CAHN

SOLUTION;TOPICAL

CONDYLOX

AT	+	ACTAVIS LABS UT INC	0.5%	N019795	001	Dec 13, 1990	Jan CAHN

PODOFILOX

AT		BAUSCH AND LOMB INC	0.5%	A090184	001	Jul 21, 2010	May CAHN

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT		ALCON RES LTD	10,000 UNITS/ML;EQ 1MG BASE/ML	A064211	001	Apr 13, 1998	Jan CAHN

PONATINIB HYDROCHLORIDE

TABLET;ORAL

ICLUSIG

		ARIAD	EQ 30MG BASE	N203469	003	Apr 23, 2015	Apr NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

KLOR-CON

AB		UPSHER SMITH	8MEQ	A203106	001	Jul 10, 2015	Jun NEWA
AB			10MEQ	A203106	002	Jul 10, 2015	Jun NEWA

FOR SOLUTION;ORAL

POTASSIUM CHLORIDE

		PHARMA RES SOFTWARE	20MEQ	N208019	001	Aug 19, 2015	Aug NEWA

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB1		ADARE PHARMS INC	20MEQ	A076368	001	Aug 18, 2004	Jul CAHN
AB2		MYLAN PHARMS INC	8MEQ	A204662	001	Aug 21, 2014	Feb CPOT
AB2			10MEQ	A204662	002	Aug 21, 2014	Feb CPOT

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		GLENMARK GENERICS	0.75MG	A090781	006	Sep 11, 2015	Aug NEWA

TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		DR REDDYS LABS LTD	0.375MG	A203354	001	Aug 07, 2015	Jul NEWA
AB			0.75MG	A203354	002	Aug 07, 2015	Jul NEWA
AB			1.5MG	A203354	003	Aug 07, 2015	Jul NEWA
AB			3MG	A203354	004	Aug 07, 2015	Jul NEWA
AB			4.5MG	A203354	005	Aug 07, 2015	Jul NEWA

PREDNICARBATE

OINTMENT;TOPICAL

DERMATOP

AB	+	VALEANT PHARMS NORTH	0.1%	N019568	001	Sep 23, 1991	Apr CAHN

PREDNISONE

TABLET;ORAL

PREDNISONE

@	HIKMA PHARMS	1MG	A040890	001	Nov 01, 2010	Aug	DISC

PREGABALIN

CAPSULE;ORAL

LYRICA

	PF PRISM CV	25MG	N021446	001	Dec 30, 2004	Apr	CTEC
		50MG	N021446	002	Dec 30, 2004	Apr	CTEC
		75MG	N021446	003	Dec 30, 2004	Apr	CTEC
		100MG	N021446	004	Dec 30, 2004	Apr	CTEC
		150MG	N021446	005	Dec 30, 2004	Apr	CTEC
		200MG	N021446	006	Dec 30, 2004	Apr	CTEC
		225MG	N021446	007	Dec 30, 2004	Apr	CTEC
+		300MG	N021446	008	Dec 30, 2004	Apr	CTEC

PROCAINAMIDE HYDROCHLORIDE

CAPSULE;ORAL

PROCAINAMIDE HYDROCHLORIDE

@	IDT AUSTRALIA LTD	250MG	A089219	001	Jul 01, 1986	Jun	CAHN
@		500MG	A089221	001	Jul 01, 1986	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL

PROCAINAMIDE HYDROCHLORIDE

@	IDT AUSTRALIA LTD	250MG	A089369	001	Aug 14, 1987	Jun	CAHN
@		500MG	A089370	001	Jan 09, 1987	Jun	CAHN
@		750MG	A089371	001	Aug 14, 1987	Jun	CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION

PROCHLORPERAZINE EDISYLATE

AP	+	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Feb	CAHN

PROGESTERONE

CAPSULE;ORAL

PROGESTERONE

AB		BANNER LIFE SCIENCES	100MG	A200900	001	Aug 16, 2013	Jan	CAHN
AB			200MG	A200900	002	Aug 16, 2013	Jan	CAHN

GEL;VAGINAL

CRINONE

		ACTAVIS LABS UT INC	4%	N020701	001	Jul 31, 1997	Feb	CAHN
	+		8%	N020701	002	Jul 31, 1997	Feb	CAHN

INJECTABLE;INJECTION

PROGESTERONE

AO	+	ACTAVIS LABS UT INC	50MG/ML	N017362	002		Mar	CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

PROMETHAZINE HYDROCHLORIDE

AP	+	EUROHLTH INTL SARL	25MG/ML	A083312	001		Jun	CAHN
AP	+		50MG/ML	A083312	002		Jun	CAHN

SUPPOSITORY;RECTAL

PHENERGAN

@	DELCOR ASSET CORP	12.5MG	N010926	002		Apr	CAHN
@		25MG	N010926	001		Apr	CAHN

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

AB		HERITAGE PHARMA	12.5MG	A040673	001	Mar 05, 2008	Mar	CAHN
AB			25MG	A040673	002	Mar 05, 2008	Mar	CAHN
AB			50MG	A040673	003	Mar 05, 2008	Mar	CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPAFENONE HYDROCHLORIDE

AB		WATSON LABS INC	225MG	A202688	001	Aug 24, 2015	Aug	NEWA
AB			325MG	A202688	002	Aug 24, 2015	Aug	NEWA
AB			425MG	A202688	003	Aug 24, 2015	Aug	NEWA

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

	@	ANI PHARMS INC	30MG	A040512	002	Jul 20, 2005	Aug CAHN
	@		60MG	A040512	001	Oct 08, 2003	Aug CAHN
AB		ZYDUS PHARMS USA INC	60MG	A205650	001	Jun 22, 2015	Jun NEWA

TABLET, EXTENDED RELEASE;ORAL

MESTINON

AB	+	VALEANT PHARMS LLC	180MG	N011665	001		Jun CFTG

PYRIDOSTIGMINE BROMIDE

AB		ALVOGEN INC	180MG	A204737	001	Jun 26, 2015	Jun NEWA
AB		IMPAX LABS INC	180MG	A203184	001	Sep 15, 2015	Aug NEWA

PYRIMETHAMINE

TABLET;ORAL

DARAPRIM

	+	TURING PHARMS AG	25MG	N008578	001		Aug CAHN

QUAZEPAM

TABLET;ORAL

DORAL

	@	SCIECURE PHARMA INC	15MG	N018708	001	Dec 27, 1985	Jun DISC

QUETIAPINE FUMARATE

TABLET;ORAL

SEROQUEL

AB	+	ASTRAZENECA PHARMS	EQ 25MG BASE	N020639	001	Sep 26, 1997	May CAHN
AB			EQ 50MG BASE	N020639	007	Oct 04, 2005	May CAHN
AB			EQ 100MG BASE	N020639	002	Sep 26, 1997	May CAHN
	@		EQ 150MG BASE	N020639	004	Dec 20, 1998	May CAHN
AB			EQ 200MG BASE	N020639	003	Sep 26, 1997	May CAHN
AB	+		EQ 300MG BASE	N020639	005	Jul 26, 2000	May CAHN
AB			EQ 400MG BASE	N020639	006	Oct 04, 2005	May CAHN

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004	Apr CAHN
AB			EQ 10MG BASE	A076607	002	Dec 15, 2004	Apr CAHN
AB			EQ 20MG BASE	A076607	003	Dec 15, 2004	Apr CAHN
AB			EQ 40MG BASE	A076607	004	Dec 15, 2004	Apr CAHN

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

	@	CYCLE PHARMS LTD	324MG	A088431	001	Jan 06, 1984	Jun CAHN

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

	@	CYCLE PHARMS LTD	200MG	A083640	001		Jun CAHN
	@		300MG	A085632	001		Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE SULFATE

	+	G AND W LABS INC	300MG	A040045	001	Jun 30, 1994	Apr CAHN

QUININE SULFATE

CAPSULE;ORAL

QUININE SULFATE

AB		AMNEAL PHARMS	324MG	A203729	001	Jul 15, 2015	Jun NEWA
AB		LUPIN LTD	324MG	A203112	001	Apr 24, 2015	Apr NEWA
AB		RICONPHARMA LLC	324MG	A204372	001	Jul 22, 2015	Jul NEWA

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

RABEPRAZOLE SODIUM

AB		AMNEAL PHARMS	20MG	A204179	001	Jul 31, 2015	Jul NEWA

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

RALOXIFENE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	60MG	A204310	001	Aug 28, 2015	Aug NEWA
AB		WATSON LABS INC	60MG	A200825	001	Jan 21, 2015	Jan NEWA

RAMELTEON

TABLET;ORAL

RAMELTEON

AB		ACTAVIS LABS FL INC	8MG	A091610	001	Aug 19, 2015	Aug NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

ZANTAC

AP	+	CONCORDIA PHARMS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jun CAHN

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

	@	SUN PHARM INDS LTD	EQ 150MG BASE	A075439	001	Apr 19, 2000	Apr CAHN
	@		EQ 300MG BASE	A075439	002	Apr 19, 2000	Apr CAHN

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

AB		STANDARD CHEM PHARM	0.5MG	A091517	001	Apr 24, 2015	Apr NEWA
AB			1MG	A091517	002	Apr 24, 2015	Apr NEWA
AB			2MG	A091517	003	Apr 24, 2015	Apr NEWA

RIBAVIRIN

CAPSULE;ORAL

REBETOL

	@	MERCK SHARP DOHME	200MG	N020903	001	Jun 03, 1998	Jun DISC

RISEDRONATE SODIUM

TABLET, DELAYED RELEASE;ORAL

ATELVIA

AB	+	WARNER CHILCOTT LLC	35MG	N022560	001	Oct 08, 2010	May CFTG

RISEDRONATE SODIUM

AB		TEVA PHARMS USA	35MG	A203217	001	May 18, 2015	May NEWA

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

AB		SUN PHARM INDS LTD	0.5MG	A077542	001	Aug 06, 2010	Apr CAHN
AB			1MG	A077542	002	Aug 06, 2010	Apr CAHN
AB			2MG	A077542	003	Aug 06, 2010	Apr CAHN
AB			3MG	A078474	001	Aug 06, 2010	Apr CAHN
AB			4MG	A078474	002	Aug 06, 2010	Apr CAHN

RIVAROXABAN

TABLET;ORAL

XARELTO

		JANSSEN PHARMS	10MG	N022406	001	Jul 01, 2011	Apr CRLD

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

EXELON

AB		NOVARTIS	4.6MG/24HR	N022083	001	Jul 06, 2007	Aug CFTG
AB	+		9.5MG/24HR	N022083	002	Jul 06, 2007	Aug CFTG
AB			13.3MG/24HR	N022083	005	Aug 31, 2012	Aug CFTG

RIVASTIGMINE

AB		ALVOGEN INC	4.6MG/24HR	A204403	001	Sep 03, 2015	Aug NEWA
AB			9.5MG/24HR	A204403	002	Sep 03, 2015	Aug NEWA
AB			13.3MG/24HR	A204403	003	Aug 31, 2015	Aug NEWA
AB		ALVOGEN PINE BROOK	4.6MG/24HR	A204403	001	Sep 03, 2015	Aug CAHN
AB			9.5MG/24HR	A204403	002	Sep 03, 2015	Aug CAHN
AB			13.3MG/24HR	A204403	003	Aug 31, 2015	Aug CAHN

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB	ORCHID HLTHCARE	EQ 1.5MG BASE	A090879	001	Jun 10, 2015	May	NEWA
AB		EQ 3MG BASE	A090879	002	Jun 10, 2015	May	NEWA
AB		EQ 4.5MG BASE	A090879	003	Jun 10, 2015	May	NEWA
AB		EQ 6MG BASE	A090879	004	Jun 10, 2015	May	NEWA

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP	SAGENT PHARMS	50MG/5ML (10MG/ML)	A091458	001	Jul 28, 2010	Aug	CAHN
AP		100MG/10ML (10MG/ML)	A091458	002	Jul 28, 2010	Aug	CAHN

ROFLUMILAST

TABLET;ORAL

DALIRESP

+	ASTRAZENECA PHARMS	500MCG	N022522	001	Feb 28, 2011	Mar	CAHN

>A> ROLAPITANT HYDROCHLORIDE

>A> TABLET;ORAL

>A> VARUBI

>A> +	TESARO INC	EQ 90MG BASE	N206500	001	Sep 01, 2015	Sep	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB	G AND W LABS INC	EQ 0.25MG BASE	A077460	001	May 05, 2008	Apr	CAHN
AB		EQ 0.5MG BASE	A077460	002	May 05, 2008	Apr	CAHN
AB		EQ 1MG BASE	A077460	003	May 05, 2008	Apr	CAHN
AB		EQ 2MG BASE	A077460	004	May 05, 2008	Apr	CAHN
AB		EQ 3MG BASE	A077460	005	May 05, 2008	Apr	CAHN
AB		EQ 4MG BASE	A077460	006	May 05, 2008	Apr	CAHN
AB		EQ 5MG BASE	A077460	007	May 19, 2008	Apr	CAHN

SACUBITRIL; VALSARTAN

TABLET;ORAL

ENTRESTO

	NOVARTIS PHARMS CORP	24MG;26MG	N207620	001	Jul 07, 2015	Jul	NEWA
		49MG;51MG	N207620	002	Jul 07, 2015	Jul	NEWA
+		97MG;103MG	N207620	003	Jul 07, 2015	Jul	NEWA

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

SCOPOLAMINE

AB	PERRIGO PHARMS CO	1MG/72HR	A078830	001	Jan 30, 2015	Mar	CAHN
AB	PERRIGO R AND D	1MG/72HR	A078830	001	Jan 30, 2015	Jan	NEWA

TRANSDERM SCOP

AB +	NOVARTIS	1MG/72HR	N017874	001		Jan	CFTG

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

@	G AND W LABS INC	5MG	A074537	001	Aug 02, 1996	Apr	CAHN
@		5MG	A074744	001	Jan 27, 1997	Apr	CAHN
@		5MG	A074756	001	Nov 25, 1998	Apr	CAHN

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@	HIKMA PHARMS	EQ 25MG BASE	A077864	001	Aug 10, 2009	May	DISC
@		EQ 50MG BASE	A077864	002	Aug 10, 2009	May	DISC
@		EQ 100MG BASE	A077864	003	Aug 10, 2009	May	DISC
AB	SUN PHARM INDS LTD	EQ 25MG BASE	A077977	001	Feb 06, 2007	Apr	CAHN
AB		EQ 50MG BASE	A077977	002	Feb 06, 2007	Apr	CAHN
AB		EQ 100MG BASE	A077977	003	Feb 06, 2007	Apr	CAHN
		EQ 150MG BASE	A077977	004	Feb 06, 2007	Apr	CAHN
		EQ 200MG BASE	A077977	005	Feb 06, 2007	Apr	CAHN

SILDENAFIL CITRATE

SOLUTION;INTRAVENOUS

REVATIO

AP	+	PFIZER	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Mar	CFTG

SILDENAFIL CITRATE

AP		AUROBINDO PHARMA LTD	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	A203988	001	Apr 01, 2015	Mar	NEWA

SILODOSIN

CAPSULE;ORAL

RAPAFLO

	+	ACTAVIS LABS UT INC	4MG	N022206	001	Oct 08, 2008	Mar	CAHN
			8MG	N022206	002	Oct 08, 2008	Mar	CAHN

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

AB		SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Apr	CAHN
AB			10MG	A076285	002	Dec 20, 2006	Apr	CAHN
AB			20MG	A076285	003	Dec 20, 2006	Apr	CAHN
AB			40MG	A076285	004	Dec 20, 2006	Apr	CAHN
AB			80MG	A076285	005	Jun 23, 2006	Apr	CAHN

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.9%

AP		EUROHLTH INTL SARL	9MG/ML	A201850	001	Jan 20, 2012	Feb	CAHN

SODIUM CHLORIDE 0.9%

		EUROHLTH INTL SARL	9MG/ML	A201833	001	Sep 24, 2013	Feb	CAHN

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	+	LIEBEL-FLARSHEIM	45MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb	CAHN
			112.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb	CAHN
	+		405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb	CPOT
			1012.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb	CPOT

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE;INJECTION

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB		EUROHLTH INTL SARL	62.5MG/5ML	A078215	001	Mar 31, 2011	Jun	CAHN

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

>A> AP		PETNAT SOLUTIONS IN	10-200mCi/ML	A203890	001	Sep 28, 2015	Sep	NEWA
AP		CARDINAL HEALTH 414	10-200mCi/ML	A203780	001	Jul 30, 2015	Jul	NEWA
AP		HOT SHOTS NM LLC	10-200mCi/ML	A204530	001	Jul 29, 2015	Jul	NEWA
AP		IBA MOLECULAR N AM	10-200mCi/ML	A203592	001	Aug 18, 2015	Aug	NEWA
AP		MIPS CRF	10-200mCi/ML	A204517	001	Jul 21, 2015	Jul	NEWA
AP		PRECISION NUCLEAR	10-200mCi/ML	A204542	001	Feb 27, 2015	Feb	NEWA
AP		SPECTRON MRC LLC	10-200mCi/ML	A203912	001	Apr 22, 2015	Apr	NEWA
AP		UNIV UTAH CYCLOTRON	10-200mCi/ML	A204497	001	Apr 20, 2015	Apr	NEWA

SODIUM IODIDE I-123

CAPSULE;ORAL

SODIUM IODIDE I 123

AA	+	CARDINAL HEALTH 418	100uCi	N018671	001	May 27, 1982	Apr	CAHN
AA	+		200uCi	N018671	002	May 27, 1982	Apr	CAHN
	@		400uCi	N018671	003	May 27, 1982	Apr	CAHN

SODIUM LACTATE

INJECTABLE;INJECTION

>D> SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

>D> AP		BAXTER HLTHCARE	1.87GM/100ML	N016692	001			Sep DISC
>A>	@		1.87GM/100ML	N016692	001			Sep DISC

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

>D> AP		B BRAUN	1.87GM/100ML	N020004	001	Apr 21, 1992	Sep	CTEC
>A>			1.87GM/100ML	N020004	001	Apr 21, 1992	Sep	CTEC

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

KALEXATE

		KVK TECH	15GM/BOT	A040905	002	Apr 03, 2015	Mar	NEWA

KAYEXALATE

AA	+	CONCORDIA PHARMS INC	453.6GM/BOT	N011287	001		Apr	CAHN

SODIUM TETRADECYL SULFATE

INJECTABLE;INJECTION

SOTRADECOL

	+	MYLAN INSTITUTIONAL	20MG/2ML (10MG/ML)	A040541	001	Nov 12, 2004	Jul	CRLD

SOMATROPIN RECOMBINANT

INJECTABLE;INJECTION

NORDITROPIN FLEXPRO

		NOVO NORDISK INC	30MG/3ML	N021148	011	Jan 23, 2015	Jan	NEWA

NORDITROPIN NORDIFLEX

	@	NOVO NORDISK INC	30MG/3ML	N021148	007	Mar 10, 2009	Jul	DISC
			30MG/3ML	N021148	007	Mar 10, 2009	Mar	CMFD
	@		30MG/3ML	N021148	007	Mar 10, 2009	Jan	DISC

NUTROPIN

	@	GENENTECH	5MG/VIAL	N020168	001	Nov 17, 1993	Jun	DISC
	@		10MG/VIAL	N020168	002	Nov 17, 1993	Jun	DISC
BX	+		10MG/VIAL	N020168	002	Nov 17, 1993	Mar	CTEC

NUTROPIN AQ

	@	GENENTECH	10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995	Jun	DISC

NUTROPIN AQ NUSPIN

	+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008	Jun	CTNA
	+		10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008	Jun	NEWA
	+		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008	Jun	CTNA

NUTROPIN AQ PEN

	+	GENENTECH	20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008	Jun	NEWA

ZOMACTON

BX	+	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Mar	CTNA
BX			10MG/VIAL	N019774	003	Mar 07, 2012	Apr	CRLD
BX	+		10MG/VIAL	N019774	003	Mar 07, 2012	Mar	NEWA

SONIDEGIB PHOSPHATE

CAPSULE;ORAL

ODOMZO

	+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N205266	001	Jul 24, 2015	Jul	NEWA

SOTALOL HYDROCHLORIDE

SOLUTION;INTRAVENOUS

SOTALOL HYDROCHLORIDE

	+	ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009	Apr	CAHN

TABLET;ORAL

BETAPACE

AB1		COVIS PHARMA SARL	80MG	N019865	001	Oct 30, 1992	Mar	CAHN
AB1			120MG	N019865	005	Apr 20, 1994	Mar	CAHN
AB1	+		160MG	N019865	002	Oct 30, 1992	Mar	CAHN
AB1			240MG	N019865	003	Oct 30, 1992	Mar	CAHN
	@		320MG	N019865	004	Oct 30, 1992	Mar	CAHN

STERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION

AP		EUROHLTH INTL SARL	100%	A206369	001	Sep 02, 2015	Aug	NEWA

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

QUELICIN PRESERVATIVE FREE

	@	HOSPIRA	100MG/ML	N008845	004		Jun	DISC

SUCRALFATE

TABLET;ORAL

SUCRALFATE

AB		MYLAN PHARMS INC	1GM	A074415	001	Jun 08, 1998	May	CAHN

SUFENTANIL CITRATE

INJECTABLE;INJECTION

SUFENTANIL CITRATE

AP		EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Jun	CAHN

SULFACETAMIDE SODIUM

LOTION;TOPICAL

KLARON

AB	+	VALEANT PHARMS NORTH	10%	N019931	001	Dec 23, 1996	Mar	CAHN

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM

AT		AKORN	10%	A040215	001	May 25, 1999	Mar	CMFD

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

		@ ANI PHARMS INC	200MG/5ML;40MG/5ML	A070028	001	Jun 02, 1987	Jul	CAHN

SULFANILAMIDE

CREAM;VAGINAL

SULFANILAMIDE

		@ G AND W LABS INC	15%	A088718	001	Sep 19, 1985	Apr	CAHN

SULINDAC

TABLET;ORAL

SULINDAC

		@ ANI PHARMS INC	150MG	A072972	001	Feb 28, 1992	Aug	CAHN
		@	200MG	A072973	001	Feb 28, 1992	Aug	CAHN

SUMATRIPTAN SUCCINATE

TABLET;ORAL

SUMATRIPTAN SUCCINATE

>D>	AB	SANDOZ	EQ 25MG BASE	A076976	001	Aug 10, 2009	Sep	DISC
>A>		@	EQ 25MG BASE	A076976	001	Aug 10, 2009	Sep	DISC
>D>	AB		EQ 50MG BASE	A076976	002	Aug 10, 2009	Sep	DISC
>A>		@	EQ 50MG BASE	A076976	002	Aug 10, 2009	Sep	DISC
>D>	AB		EQ 100MG BASE	A076976	003	Aug 10, 2009	Sep	DISC
>A>		@	EQ 100MG BASE	A076976	003	Aug 10, 2009	Sep	DISC
	AB	SUN PHARM INDS LTD	EQ 25MG BASE	A076554	001	Aug 10, 2009	Apr	CAHN
	AB		EQ 50MG BASE	A076554	002	Aug 10, 2009	Apr	CAHN
	AB		EQ 100MG BASE	A076572	001	Feb 09, 2009	Apr	CAHN

TACROLIMUS

TABLET, EXTENDED RELEASE;ORAL

ENVARSUS XR

		VELOXIS PHARMS INC	EQ 0.75MG BASE	N206406	001	Jul 10, 2015	Jul	NEWA
			EQ 1MG BASE	N206406	002	Jul 10, 2015	Jul	NEWA
	+		EQ 4MG BASE	N206406	003	Jul 10, 2015	Jul	NEWA

TAPENTADOL HYDROCHLORIDE

SOLUTION;ORAL

NUCYNTA

	+	DEPOMED INC	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012	May	CAHN

TABLET;ORAL

NUCYNTA

		DEPOMED INC	EQ 50MG BASE	N022304	001	Nov 20, 2008	May	CAHN
			EQ 75MG BASE	N022304	002	Nov 20, 2008	May	CAHN
	+		EQ 100MG BASE	N022304	003	Nov 20, 2008	May	CAHN

TABLET, EXTENDED RELEASE;ORAL

NUCYNTA ER

		DEPOMED INC	EQ 50MG BASE	N200533	001	Aug 25, 2011	May	CAHN
			EQ 100MG BASE	N200533	002	Aug 25, 2011	May	CAHN
			EQ 150MG BASE	N200533	003	Aug 25, 2011	May	CAHN
			EQ 200MG BASE	N200533	004	Aug 25, 2011	May	CAHN
	+		EQ 250MG BASE	N200533	005	Aug 25, 2011	May	CAHN

TEDIZOLID PHOSPHATE

POWDER;IV (INFUSION)

SIVEXTRO

>D>		+	CUBIST PHARMS INC	200MG/VIAL	N205436	001	Jun 20, 2014	Sep CAHN
>A>		+	CUBIST PHARMS LLC	200MG/VIAL	N205436	001	Jun 20, 2014	Sep CAHN

TABLET;ORAL

SIVEXTRO

>D>		+	CUBIST PHARMS INC	200MG	N205435	001	Jun 20, 2014	Sep CAHN
>A>		+	CUBIST PHARMS LLC	200MG	N205435	001	Jun 20, 2014	Sep CAHN

TELAPREVIR

TABLET;ORAL

INCIVEK

		@	VERTEX PHARMS	375MG	N201917	001	May 23, 2011	Jan DISC

TELMISARTAN

TABLET;ORAL

TELMISARTAN

	AB		AMNEAL PHARMS	20MG	A204415	001	Sep 08, 2015	Aug NEWA
	AB			40MG	A204415	002	Sep 08, 2015	Aug NEWA
	AB			80MG	A204415	003	Sep 08, 2015	Aug NEWA
	AB		AUROBINDO PHARMA LTD	20MG	A206511	001	Sep 03, 2015	Aug NEWA
	AB			40MG	A206511	002	Sep 03, 2015	Aug NEWA
	AB			80MG	A206511	003	Sep 03, 2015	Aug NEWA

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

	AB		VINTAGE PHARMS	7.5MG	A201781	001	Jun 04, 2015	May NEWA
	AB			15MG	A201781	002	Jun 04, 2015	May NEWA
	AB			22.5MG	A201781	003	Jun 04, 2015	May NEWA
	AB			30MG	A201781	004	Jun 04, 2015	May NEWA

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

	AB		AMNEAL PHARMS	5MG	A203691	001	May 08, 2015	Apr NEWA
	AB			20MG	A203691	002	May 08, 2015	Apr NEWA
	AB			100MG	A203691	003	May 08, 2015	Apr NEWA
	AB			140MG	A203691	004	May 08, 2015	Apr NEWA
	AB			180MG	A203691	005	May 08, 2015	Apr NEWA
	AB			250MG	A203691	006	May 08, 2015	Apr NEWA

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

	AB		TEVA PHARMS USA	300MG	A091612	001	Mar 18, 2015	Mar NEWA

VIREAD

	AB	+	GILEAD SCIENCES INC	300MG	N021356	001	Oct 26, 2001	Mar CFTG

TERBINAFINE

GEL;TOPICAL

LAMISIL

		@	GLAXOSMITHKLINE CONS	1%	N020846	001	Apr 29, 1998	Aug CAHN

TERBINAFINE HYDROCHLORIDE

SOLUTION;TOPICAL

LAMISIL

		@	GLAXOSMITHKLINE CONS	1%	N020749	001	Oct 17, 1997	Aug CAHN

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

		@	WOCKHARDT	EQ 250MG BASE	A078229	001	Jul 02, 2007	Feb DISC

TERCONAZOLE

SUPPOSITORY;VAGINAL

TERCONAZOLE

>D>		@	TARO	80MG	A077553	001	Mar 09, 2007	Sep CMFD
>A>	AB			80MG	A077553	001	Mar 09, 2007	Sep CMFD

TESTOSTERONE

GEL;TRANSDERMAL

ANDROGEL

AB1		ABBVIE	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jan CTEC
AB1	+		50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jan CTEC

TESTIM

AB2	+	AUXILIUM PHARMS	50MG/5GM PACKET	N021454	001	Oct 31, 2002	Jan CTEC

TESTOSTERONE

	@	ACTAVIS LABS UT INC	1% (2.5GM/PACKET)	A076737	001	Jan 27, 2006	Mar CAHN
	@		1% (5GM/PACKET)	A076737	002	Jan 27, 2006	Mar CAHN
AB1			25MG/2.5GM PACKET	A076737	001	Jan 27, 2006	Jul CMFD
AB1			50MG/5GM PACKET	A076737	002	Jan 27, 2006	Jul CMFD
BX		ANI PHARMS INC	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	May CAHN
BX			50MG/5GM PACKET	N202763	002	Feb 14, 2012	May CAHN
AB1		PAR PHARM	25MG/2.5GM PACKET	A076744	001	May 23, 2007	Aug CMFD
AB1			50MG/5GM PACKET	A076744	002	May 23, 2007	Aug CMFD
AB1		PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jan CTEC
AB1			50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jan CTEC

VOGELXO

AB2		UPSHER SMITH	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jan CTEC

GEL, METERED;TRANSDERMAL

ANDROGEL

AB	+	ABBVIE	1.62% (20.25MG/1.25GM ACTUATION)	N022309	001	Apr 29, 2011	Jul CFTG

FORTESTA

AB	+	ENDO PHARMS	10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Jul CFTG

TESTOSTERONE

AB		ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jul NEWA
AB			12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Aug NEWA
AB		PERRIGO ISRAEL	1.62% (20.25MG/1.25GM ACTUATION)	A204268	001	Aug 04, 2015	Jul NEWA

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

AB		SUN PHARMA GLOBAL	12.5MG	A206129	001	Aug 17, 2015	Aug NEWA
AB			25MG	A206129	002	Aug 17, 2015	Aug NEWA

XENAZINE

AB		VALEANT PHARMS NORTH	12.5MG	N021894	001	Aug 15, 2008	Aug CFTG
			12.5MG	N021894	001	Aug 15, 2008	Feb CAHN
AB	+		25MG	N021894	002	Aug 15, 2008	Aug CFTG
	+		25MG	N021894	002	Aug 15, 2008	Feb CAHN

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

ACHROMYCIN V

AB	+	HERITAGE PHARMS INC	500MG	N050278	001		Apr CRLD

TETRACYCLINE HYDROCHLORIDE

>A>		@ CHARTWELL CIENCA	250MG	A062752	001	Aug 12, 1988	Sep CAHN
>A>		@	500MG	A062752	002	Aug 12, 1988	Sep CAHN
		@ IVAX SUB TEVA PHARMS	250MG	A060704	001		Apr DISC
		@	500MG	A060704	002		Apr DISC
>D>		@ LABS ATRAL	250MG	A062752	001	Aug 12, 1988	Sep CAHN
>D>		@	500MG	A062752	002	Aug 12, 1988	Sep CAHN

THEOPHYLLINE

TABLET;ORAL

THEOLAIR

	@	MEDICIS	125MG	A086399	001		Mar DISC
	@		250MG	A086399	002		Mar DISC

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

AB		MYLAN PHARMS INC	400MG	A040595	001	Apr 21, 2006	May CAHN
AB	+		600MG	A040560	002	Apr 21, 2006	May CAHN

THIOTEPA

INJECTABLE;INJECTION

THIOTEPA

	+	EUROHLTH INTL SARL	15MG/VIAL	A075547	001	Apr 02, 2001	May CRLD

TICAGRELOR

TABLET;ORAL

BRILINTA

>A>		ASTRAZENECA LP	60MG	N022433	002	Sep 03, 2015	Sep NEWA

TIGECYCLINE

INJECTABLE;IV (INFUSION)

TIGECYCLINE

AP		SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	May NEWA

TYGACIL

AP	+	PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	May CFTG

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

ISTALOL

AT2	+	BAUSCH AND LOMB	EQ 0.5% BASE	N021516	001	Jun 04, 2004	Apr CFTG

TIMOLOL MALEATE

AT1		AKORN	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Apr CTEC
AT1			EQ 0.5% BASE	A074516	001	Mar 25, 1997	Apr CTEC
AT1		ALCON RES LTD	EQ 0.5% BASE	A074262	001	Apr 28, 1995	Apr CTEC
AT2		APOTEX INC	EQ 0.5% BASE	A204936	001	Apr 17, 2015	Apr NEWA
AT1		BAUSCH AND LOMB	EQ 0.5% BASE	A074776	001	Mar 25, 1997	Apr CTEC
AT1		FDC LTD	EQ 0.5% BASE	A077259	002	Apr 30, 2008	Apr CTEC
AT1		HI TECH PHARMA	EQ 0.5% BASE	A075163	001	Sep 10, 2002	Apr CTEC
AT1		PACIFIC PHARMA	EQ 0.5% BASE	A074747	001	Mar 25, 1997	Apr CTEC
AT1		WOCKHARDT	EQ 0.5% BASE	A078771	002	Sep 28, 2009	Apr CTEC

TIMOPTIC

AT1	+	ATON	EQ 0.5% BASE	N018086	002		Apr CTEC

TINIDAZOLE

TABLET;ORAL

TINIDAZOLE

AB		EDENBRIDGE PHARMS	250MG	A203808	001	Aug 04, 2015	Jul NEWA
AB			500MG	A203808	002	Aug 04, 2015	Jul NEWA

TIOTROPIUM BROMIDE

SPRAY, METERED;INHALATION

SPIRIVA RESPIMAT

>A>		BOEHRINGER INGELHEIM	EQ 0.00125MG BASE/INH	N021936	002	Sep 15, 2015	Sep NEWA

>A> TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE

>A> TABLET;ORAL

>A> LONSURF

>A>		TAIHO ONCOLOGY	EQ 6.14MG BASE;15MG	N207981	001	Sep 22, 2015	Sep NEWA
>A>	+		EQ 8.19MG BASE;20MG	N207981	002	Sep 22, 2015	Sep NEWA

TOBRAMYCIN

SOLUTION;INHALATION

KITABIS PAK

AN		PULMOFLOW INC	300MG/5ML	N205433	001	Dec 02, 2014	Feb CTEC

TOBRAMYCIN

AN		AMNEAL PHARMS	300MG/5ML	A205501	001	Jul 13, 2015	Jun NEWA

SOLUTION/DROPS;OPHTHALMIC

TOBREX

AT	+	ALCON LABS INC	0.3%	N050541	001		Mar CAHN

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

	@	IGI LABS INC	EQ 10MG BASE/ML	A063119	001	Oct 31, 1994	Mar CAHN
	@		EQ 40MG BASE/ML	A063120	001	Oct 31, 1994	Mar CAHN
	@		EQ 40MG BASE/ML	A063121	001	Oct 31, 1994	Mar CAHN
	@		EQ 40MG BASE/ML	A063122	001	Oct 31, 1994	Mar CAHN

TOBRAMYCIN SULFATE (PHARMACY BULK)

	+	FRESENIUS KABI USA	EQ 40MG BASE/ML	A065120	001	Nov 29, 2002	Jul CTEC
AP	+		EQ 40MG BASE/ML	A065120	001	Nov 29, 2002	Jul CRLD
	@	HOSPIRA	EQ 40MG BASE/ML	A063116	001	May 18, 1992	Jul DISC
AP			EQ 40MG BASE/ML	A063116	001	May 18, 1992	Jul CTNA

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

	@	G AND W LABS INC	100MG	N018894	001	Nov 02, 1984	Apr CAHN
	@		250MG	N018894	002	Nov 02, 1984	Apr CAHN
	@		500MG	N018894	003	Nov 02, 1984	Apr CAHN

TOLCAPONE

TABLET;ORAL

TASMAR

AB	+	VALEANT PHARMS LLC	100MG	N020697	001	Jan 29, 1998	Mar CFTG

TOLCAPONE

AB		PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar NEWA

TOLMETIN SODIUM

TABLET;ORAL

TOLMETIN SODIUM

	@	G AND W LABS INC	EQ 600MG BASE	A074399	001	Mar 28, 1996	May CAHN
	@		EQ 600MG BASE	A074729	001	Feb 27, 1997	Apr CAHN

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

TOLTERODINE TARTRATE

AB		TORRENT PHARMS LTD	2MG	A203016	001	Aug 11, 2015	Jul NEWA
AB			4MG	A203016	002	Aug 11, 2015	Jul NEWA

TABLET;ORAL

TOLTERODINE TARTRATE

AB		IVAX SUB TEVA PHARMS	1MG	A077006	001	Feb 23, 2015	Feb NEWA
AB			2MG	A077006	002	Feb 23, 2015	Feb NEWA
AB		MACLEODS PHARMS LTD	1MG	A203409	001	Aug 31, 2015	Aug NEWA
AB			2MG	A203409	002	Aug 31, 2015	Aug NEWA

TOPIRAMATE

TABLET;ORAL

TOPIRAMATE

AB		SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Apr CAHN
AB			100MG	A076327	002	Mar 27, 2009	Apr CAHN
AB			200MG	A076327	003	Mar 27, 2009	Apr CAHN
	@	WOCKHARDT USA	25MG	A090353	001	Sep 01, 2010	Apr DISC
	@		50MG	A090353	002	Sep 01, 2010	Apr DISC
	@		100MG	A090353	003	Sep 01, 2010	Apr DISC
	@		200MG	A090353	004	Sep 01, 2010	Apr DISC

TOPIRAMATE

	@	HIKMA PHARMS	25MG	A091185	001	Nov 25, 2013	May DISC
	@		50MG	A091185	002	Nov 25, 2013	May DISC
	@		100MG	A091185	003	Nov 25, 2013	May DISC
	@		200MG	A091185	004	Nov 25, 2013	May DISC

TOPOTECAN HYDROCHLORIDE

CAPSULE;ORAL

HYCAMTIN

		NOVARTIS PHARMS CORP	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	Mar CAHN
	+		EQ 1MG BASE	N020981	002	Oct 11, 2007	Mar CAHN

INJECTABLE;INJECTION

HYCAMTIN

AP	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	Mar CAHN

TOPOTECAN HYDROCHLORIDE

AP		CHEM WERTH INC	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	May CAHN

TORSEMIDE

INJECTABLE;INJECTION

TORSEMIDE

	@	EUROHLTH INTL SARL	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Jan DISC
	@		50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Jan DISC
	@	LUITPOLD	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Jan DISC
	@		50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Jan DISC

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

>A>	AB		MACLEODS PHARMS LTD	50MG	A205702	001	Sep 25, 2015	Sep NEWA

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL

MEKINIST

			NOVARTIS PHARMS CORP	EQ 0.5MG NON-SOLVATED PARENT	N204114	001	May 29, 2013	Mar CAHN
				EQ 1MG NON-SOLVATED PARENT	N204114	002	May 29, 2013	Mar CAHN
		+		EQ 2MG NON-SOLVATED PARENT	N204114	003	May 29, 2013	Mar CAHN

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

	AP		FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Apr CMFD

TABLET;ORAL

TRANEXAMIC ACID

>A>	AB		MYLAN	650MG	A205133	001	Sep 21, 2015	Sep NEWA

TRANYLCYPROMINE SULFATE

TABLET;ORAL

PARNATE

	AB	+	CONCORDIA PHARMS INC	EQ 10MG BASE	N012342	003	Aug 16, 1985	Jun CAHN

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

IZBA

		@	ALCON LABS INC	0.003%	N204822	001	May 15, 2014	Jul DISC

TRAVATAN Z

	AT	+	ALCON PHARMS LTD	0.004%	N021994	001	Sep 21, 2006	Jun CTEC

TRAVOPROST

	AT		APOTEX INC	0.004%	A203431	001	Jul 10, 2015	Jun NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

DESYREL

		@	PRAGMA PHARMS LLC	50MG	N018207	001		May CAHN
		@		100MG	N018207	002		May CAHN
		@		150MG	N018207	003	Mar 25, 1985	May CAHN
		@		300MG	N018207	004	Nov 07, 1988	May CAHN

TABLET, EXTENDED RELEASE;ORAL

OLEPTRO

		@	ANGELINI PHARMA	150MG	N022411	001	Feb 02, 2010	Mar DISC
		@		300MG	N022411	002	Feb 02, 2010	Mar DISC

TRETINOIN

CREAM;TOPICAL

RENOVA

		+	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000	Apr CAHN
	AB2	+		0.05%	N019963	001	Dec 29, 1995	Apr CAHN

RETIN-A

	AB	+	VALEANT PHARMS NORTH	0.1%	N017340	001		Apr CAHN

GEL;TOPICAL

ATRALIN

	AB	+	DOW PHARM	0.05%	N022070	001	Jul 26, 2007	Jul CTEC

TRETINOIN

	AB		SPEAR PHARMS INC	0.05%	A207955	001	Aug 13, 2015	Jul NEWA

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

	AT		G AND W LABS	0.025%	A089797	001	May 31, 1991	Apr CMFD
	AT			0.1%	A089798	001	May 31, 1991	Apr CMFD

TRIDERM

	AT		CROWN LABS	0.025%	A088042	002	Mar 25, 2015	Mar NEWA
	AT			0.5%	A088042	003	Mar 25, 2015	Mar NEWA

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

	AT		G AND W LABS INC	0.1%	A089129	001	Aug 14, 1986	Mar CMFD

		OINTMENT;TOPICAL						
		KENALOG						
AT		DELCOR ASSET CORP	0.025%	N011600	003			Mar CMFD
AT			0.1%	N011600	001			Mar CMFD
		TRIAMCINOLONE ACETONIDE						
AT		G AND W LABS	0.025%	A089795	001	Dec 23, 1988		Aug CMFD
AT			0.1%	A089796	001	Dec 23, 1988		Aug CMFD
		SPRAY;TOPICAL						
		KENALOG						
AT	+	RANBAXY	0.147MG/GM	N012104	001			Mar CFTG
AT	+	SUN PHARM INDS LTD	0.147MG/GM	N012104	001			Aug CAHN
		TRIAMCINOLONE ACETONIDE						
AT		PERRIGO UK FINCO	0.147MG/GM	A205782	001	Apr 13, 2015		Mar NEWA
		TRIAMTERENE						
		CAPSULE;ORAL						
		DYRENIUM						
		CONCORDIA PHARMS INC	50MG	N013174	001			Apr CAHN
	+		100MG	N013174	002			Apr CAHN
		TRIMIPRAMINE MALEATE						
		CAPSULE;ORAL						
		SURMONTIL						
AB	+	ODYSSEY PHARMS	EQ 50MG BASE	N016792	002			Jun CRLD
AB			EQ 100MG BASE	N016792	003	Sep 15, 1982		Jun CRLD
		TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)						
		CREAM;VAGINAL						
		VAGILIA						
	@	G AND W LABS INC	3.7%;2.86%;3.42%	A088821	001	Nov 09, 1987		Jul CAHN
		TRIPTORELIN PAMOATE						
		INJECTABLE;INTRAMUSCULAR						
		TRELSTAR						
	+	ACTAVIS LABS UT INC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000		Jan CAHN
	+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001		Jan CAHN
	+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010		Jan CAHN
		TROSPIUM CHLORIDE						
		CAPSULE, EXTENDED RELEASE;ORAL						
		SANCTURA XR						
	@	ALLERGAN	60MG	N022103	001	Aug 03, 2007		May DISC
		TROSPIUM CHLORIDE						
AB		ACTAVIS LABS FL INC	60MG	A091289	001	Oct 12, 2012		Jun CRLD
AB	+		60MG	A091289	001	Oct 12, 2012		May CRLD
AB		SANDOZ INC	60MG	A091635	001	Apr 29, 2015		Apr NEWA
		TABLET;ORAL						
		SANCTURA						
	@	ALLERGAN	20MG	N021595	001	May 28, 2004		May DISC
		TROSPIUM CHLORIDE						
AB		GLENMARK GENERICS	20MG	A091575	001	Aug 13, 2010		Jun CRLD
AB	+		20MG	A091575	001	Aug 13, 2010		May CRLD
		UNOPROSTONE ISOPROPYL						
		SOLUTION/DROPS;OPHTHALMIC						
		RESCULA						
	+	R-TECH UENO LTD	0.15%	N021214	001	Aug 03, 2000		May CAHN
	+	SUCAMPO PHARMA LLC	0.15%	N021214	001	Aug 03, 2000		Jan CAHN
>A>		URIDINE TRIACETATE						
>A>		GRANULE;ORAL						
>A>		XURIDEN						
>A>	+	WELLSTAT THERAP	2GM/PACKET	N208169	001	Sep 04, 2015		Sep NEWA
		URSODIOL						
		CAPSULE;ORAL						
		ACTIGALL						
	@	ACTAVIS LABS UT INC	150MG	N019594	001	Dec 31, 1987		Mar CAHN
AB	+		300MG	N019594	002	Dec 31, 1987		Mar CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	HETERO LABS LTD V	EQ 500MG BASE	A203047	001	Apr 08, 2015	Mar	NEWA
AB		EQ 1GM BASE	A203047	002	Apr 08, 2015	Mar	NEWA
AB	SUN PHARM INDS LTD	EQ 500MG BASE	A076588	001	Jan 31, 2007	Apr	CAHN
AB		EQ 1GM BASE	A076588	002	Jan 31, 2007	Apr	CAHN

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

AB	BANNER LIFE SCIENCES	250MG	A073484	001	Jun 29, 1993	Jan	CAHN

CAPSULE, DELAYED RELEASE;ORAL

STAVZOR

@	BANNER LIFE SCIENCES	125MG	N022152	001	Jul 29, 2008	Jan	CAHN
@		250MG	N022152	002	Jul 29, 2008	Jan	CAHN
@		500MG	N022152	003	Jul 29, 2008	Jan	CAHN

VALSARTAN

TABLET;ORAL

VALSARTAN

AB	PRINSTON INC	40MG	A204821	001	Jun 09, 2015	May	NEWA
AB		80MG	A204821	002	Jun 09, 2015	May	NEWA
AB		160MG	A204821	003	Jun 09, 2015	May	NEWA
AB		320MG	A204821	004	Jun 09, 2015	May	NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

AB	LUPIN LTD	EQ 125MG BASE	A090439	001	Jan 28, 2015	Jan	NEWA
AB		EQ 250MG BASE	A090439	002	Jan 28, 2015	Jan	NEWA

INJECTABLE;INJECTION

VANCOLED

@	EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A062682	001	Jul 22, 1986	Jun	CAHN
@		EQ 1GM BASE/VIAL	A062682	002	Mar 30, 1988	Jun	CAHN
@		EQ 2GM BASE/VIAL	A062682	003	May 11, 1988	Jun	CAHN
@		EQ 5GM BASE/VIAL	A062682	004	May 11, 1988	Jun	CAHN
@		EQ 10GM BASE/VIAL	A062682	005	May 11, 1988	Jun	CAHN

VANCOMYCIN HYDROCHLORIDE

AP	XELLIA PHARMS APS	EQ 500MG BASE/VIAL	A091377	001	Sep 09, 2015	Aug	NEWA
AP		EQ 1GM BASE/VIAL	A091377	002	Sep 09, 2015	Aug	NEWA

VARDENAFIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL

STAXYN

AB	+ BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	Apr	CFTG

VARDENAFIL HYDROCHLORIDE

AB	WATSON LABS INC	10MG	A203689	001	Apr 22, 2015	Apr	NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Feb	CAHN
AB		EQ 75MG BASE	A090071	002	Apr 15, 2011	Feb	CAHN
AB		EQ 150MG BASE	A090071	003	Apr 15, 2011	Feb	CAHN

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	YAOPHARMA CO LTD	EQ 25MG BASE	A202036	001	May 28, 2015	May	NEWA
AB		EQ 37.5MG BASE	A202036	002	May 28, 2015	May	NEWA
AB		EQ 50MG BASE	A202036	003	May 28, 2015	May	NEWA
AB		EQ 75MG BASE	A202036	004	May 28, 2015	May	NEWA
AB		EQ 100MG BASE	A202036	005	May 28, 2015	May	NEWA

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERELAN

AB	RECRO GAINESVILLE	120MG	N019614	001	May 29, 1990	Apr	CAHN
AB		180MG	N019614	003	Jan 09, 1992	Apr	CAHN
AB		240MG	N019614	002	May 29, 1990	Apr	CAHN
+		360MG	N019614	004	May 10, 1996	Apr	CAHN

		CAPSULE, EXTENDED RELEASE;ORAL						
		VERELAN PM						
	AB	RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Apr	CAHN
	AB		200MG	N020943	002	Nov 25, 1998	Apr	CAHN
	AB	+	300MG	N020943	003	Nov 25, 1998	Apr	CAHN
		INJECTABLE;INJECTION						
		CALAN						
		@ EXELA PHARMA SCS LLC	2.5MG/ML	N018925	001	Mar 30, 1984	Aug	CAHN
		ISOPTIN						
		@ MT ADAMS	2.5MG/ML	N018485	001		Apr	CAHN
		TABLET;ORAL						
		ISOPTIN						
		@ MT ADAMS	40MG	N018593	003	Nov 23, 1987	Apr	CAHN
		@	80MG	N018593	001	Mar 08, 1982	Apr	CAHN
		@	120MG	N018593	002	Mar 08, 1982	Apr	CAHN
		VERTEPORFIN						
		INJECTABLE;INJECTION						
		VISUDYNE						
	+	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000	Mar	CAHN
		VILAZODONE HYDROCHLORIDE						
		TABLET;ORAL						
		VIIBRYD						
	+	FOREST LABS LLC	10MG	N022567	001	Jan 21, 2011	Mar	CAHN
			20MG	N022567	002	Jan 21, 2011	Mar	CAHN
			40MG	N022567	003	Jan 21, 2011	Mar	CAHN
		VINORELBINE TARTRATE						
		INJECTABLE;INJECTION						
		VINORELBINE TARTRATE						
>A>	AP	EUROHLTH INTL SARL	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003	Sep	CAHN
>D>	AP	HIKMA MAPLE	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003	Sep	CAHN
		VORICONAZOLE						
		TABLET;ORAL						
		VORICONAZOLE						
	AB	GLENMARK PHARMS LTD	50MG	A203503	001	Sep 02, 2015	Aug	NEWA
	AB		200MG	A203503	002	Sep 02, 2015	Aug	NEWA
		ZAFIRLUKAST						
		TABLET;ORAL						
		ACCOLATE						
	AB	PAR PHARM INC	10MG	N020547	003	Sep 17, 1999	Feb	CAHN
	AB	+	20MG	N020547	001	Sep 26, 1996	Feb	CAHN
		ZOLEDRONIC ACID						
		INJECTABLE;IV (INFUSION)						
		ZOLEDRONIC ACID						
	AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Apr	NEWA
	AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar	NEWA
	AP	MYLAN LABS LTD	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Jul	CAHN
	AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar	CPOT
		ZOLMITRIPTAN						
		TABLET;ORAL						
		ZOLMITRIPTAN						
>A>	AB	ALEMBIC PHARMS LTD	2.5MG	A204232	001	Sep 30, 2015	Sep	NEWA
>A>	AB		5MG	A204232	002	Sep 30, 2015	Sep	NEWA
>A>	AB	MACLEODS PHARMS LTD	2.5MG	A203772	001	Sep 30, 2015	Sep	NEWA
>A>	AB		5MG	A203772	002	Sep 30, 2015	Sep	NEWA
		TABLET, ORALLY DISINTEGRATING;ORAL						
		ZOLMITRIPTAN						
>A>	AB	JUBILANT GENERICS	2.5MG	A202956	001	Sep 17, 2015	Sep	NEWA
>A>	AB		5MG	A202956	002	Sep 17, 2015	Sep	NEWA

ZOLPIDEM TARTRATE

SPRAY, METERED;ORAL

ZOLPIMIST

>A>		+	AMHERST PHARMS LLC	5MG/SPRAY	N	022196	001	Dec 19, 2008	Sep CAHN
>D>		+	NOVADEL	5MG/SPRAY	N	022196	001	Dec 19, 2008	Sep CAHN

TABLET;ORAL

ZOLPIDEM TARTRATE

		@	HIKMA	5MG	A	078129	001	Apr 30, 2008	Mar DISC
		@		10MG	A	078129	002	Apr 30, 2008	Mar DISC
	AB		SUN PHARM INDS LTD	5MG	A	078055	001	Apr 23, 2007	Apr CAHN
	AB			10MG	A	078055	002	Apr 23, 2007	Apr CAHN

TABLET;SUBLINGUAL

INTERMEZZO

	AB		PURDUE PHARMA	1.75MG	N	022328	001	Nov 23, 2011	May CFTG
	AB	+		3.5MG	N	022328	002	Nov 23, 2011	May CFTG

ZOLPIDEM TARTRATE

	AB		NOVEL LABS INC	1.75MG	A	204299	001	Jun 03, 2015	May NEWA
	AB			3.5MG	A	204299	002	Jun 03, 2015	May NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

	AB		BANNER LIFE SCIENCES	25MG	A	077813	001	Aug 16, 2006	Jan CAHN
	AB			50MG	A	077813	002	Aug 16, 2006	Jan CAHN
	AB			100MG	A	077813	003	Aug 16, 2006	Jan CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL							
TYLENOL							
@	J AND J CONSUMER INC	120MG	N017756	002			Aug CAHN
@		650MG	N017756	001			Aug CAHN
TABLET, EXTENDED RELEASE;ORAL							
ACETAMINOPHEN							
	SUN PHARM INDS LTD	650MG	A078569	001	Dec 14, 2011		Apr CAHN
@		650MG	A090205	001	Nov 18, 2009		Apr CAHN
TYLENOL							
+	J AND J CONSUMER INC	650MG	N019872	001	Jun 08, 1994		Aug CAHN
+		650MG	N019872	002	Jan 11, 2001		Aug CAHN

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION;TOPICAL							
SHADE UVAGUARD							
+	BAYER HEALTHCARE LLC	3%;7.5%;3%	N020045	001	Dec 07, 1992		Mar CAHN

BUDESONIDE

SPRAY, METERED;NASAL							
RHINOCORT ALLERGY							
+	ASTRAZENECA PHARMS	0.032MG/SPRAY	N020746	003	Mar 23, 2015		Mar NEWA

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL							
LOTRIMIN ULTRA							
+	BAYER HEALTHCARE LLC	1%	N021307	001	Dec 07, 2001		Mar CAHN

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL							
PEPCID COMPLETE							
+	J AND J CONSUMER INC	800MG;10MG;165MG	N020958	001	Oct 16, 2000		Aug CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL							
CETIRIZINE HYDROCHLORIDE ALLERGY							
	BANNER LIFE SCIENCES	5MG	N022429	001	Jul 23, 2009		Jan CAHN
+		10MG	N022429	004	Jul 23, 2009		Jan CAHN
CETIRIZINE HYDROCHLORIDE HIVES RELIEF							
	BANNER LIFE SCIENCES	5MG	N022429	003	Jul 23, 2009		Jan CAHN
+		10MG	N022429	002	Jul 23, 2009		Jan CAHN
SYRUP;ORAL							
CHILDREN'S ZYRTEC ALLERGY							
+	J AND J CONSUMER INC	5MG/5ML	N022155	002	Nov 16, 2007		Aug CAHN
CHILDREN'S ZYRTEC HIVES RELIEF							
+	J AND J CONSUMER INC	5MG/5ML	N022155	001	Nov 16, 2007		Aug CAHN
TABLET;ORAL							
CETIRIZINE HYDROCHLORIDE ALLERGY							
	AUROBINDO PHARMA LTD	5MG	A090760	001	Aug 05, 2015		Jul NEWA
		10MG	A090760	003	Aug 05, 2015		Jul NEWA
	SUN PHARM INDS LTD	5MG	A077498	001	Dec 27, 2007		Apr CAHN
		10MG	A077498	002	Dec 27, 2007		Apr CAHN
CETIRIZINE HYDROCHLORIDE HIVES							
	SUN PHARM INDS LTD	5MG	A077498	003	Dec 27, 2007		Apr CAHN
		10MG	A077498	004	Dec 27, 2007		Apr CAHN
CETIRIZINE HYDROCHLORIDE HIVES RELIEF							
	AUROBINDO PHARMA LTD	5MG	A090760	002	Aug 05, 2015		Jul NEWA
		10MG	A090760	004	Aug 05, 2015		Jul NEWA
ZYRTEC ALLERGY							
	J AND J CONSUMER INC	5MG	N019835	003	Nov 16, 2007		Aug CAHN
+		10MG	N019835	004	Nov 16, 2007		Aug CAHN
ZYRTEC HIVES RELIEF							
	J AND J CONSUMER INC	5MG	N019835	005	Nov 16, 2007		Aug CAHN
+		10MG	N019835	006	Nov 16, 2007		Aug CAHN
TABLET, CHEWABLE;ORAL							
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY							
	JUBILANT GENERICS	5MG	A091116	001	Feb 19, 2015		Feb NEWA
		10MG	A091116	002	Feb 19, 2015		Feb NEWA
	SANDOZ	5MG	A078692	001	Feb 14, 2008		Feb CTNA

TABLET, CHEWABLE;ORAL							
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY							
+	10MG	A078692	002	Feb 14, 2008	Feb CTNA		
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF							
JUBILANT GENERICS	5MG	A091116	003	Feb 19, 2015	Feb NEWA		
	10MG	A091116	004	Feb 19, 2015	Feb NEWA		
CHILDREN'S ZYRTEC ALLERGY							
@ J AND J CONSUMER INC	5MG	N021621	003	Nov 16, 2007	Aug CAHN		
@	10MG	N021621	004	Nov 16, 2007	Aug CAHN		
CHILDREN'S ZYRTEC HIVES RELIEF							
@ J AND J CONSUMER INC	5MG	N021621	005	Nov 16, 2007	Aug CAHN		
@	10MG	N021621	006	Nov 16, 2007	Aug CAHN		
TABLET, ORALLY DISINTEGRATING;ORAL							
CETIRIZINE HYDROCHLORIDE ALLERGY							
PAR PHARM INC	10MG	A205490	001	Sep 02, 2015	Aug NEWA		
ZYRTEC ALLERGY							
+ J AND J CONSUMER INC	10MG	N022578	001	Sep 03, 2010	Aug CAHN		
CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE							
TABLET, EXTENDED RELEASE;ORAL							
ZYRTEC-D 12 HOUR							
+ J AND J CONSUMER INC	5MG;120MG	N021150	002	Nov 09, 2007	Aug CAHN		
CHLORPHENIRAMINE MALEATE							
TABLET, EXTENDED RELEASE;ORAL							
CHLOR-TRIMETON							
@ BAYER HEALTHCARE LLC	8MG	N007638	001		Mar CAHN		
+	12MG	N007638	002		Mar CAHN		
CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE							
TABLET, EXTENDED RELEASE;ORAL							
CHLOR-TRIMETON							
+ BAYER HEALTHCARE LLC	8MG;120MG	N018397	001		Mar CAHN		
CLEMASTINE FUMARATE							
TABLET;ORAL							
CLEMASTINE FUMARATE							
@ ANI PHARMS INC	1.34MG	A073282	002	Dec 03, 1992	Jul CAHN		
CLOTRIMAZOLE							
CREAM;VAGINAL							
GYNE-LOTRIMIN							
+ BAYER HEALTHCARE LLC	1%	N018052	002	Nov 30, 1990	Mar CAHN		
GYNE-LOTRIMIN 3							
+ BAYER HEALTHCARE LLC	2%	N020574	001	Nov 24, 1998	Mar CAHN		
CREAM, TABLET;TOPICAL, VAGINAL							
GYNE-LOTRIMIN COMBINATION PACK							
+ BAYER HEALTHCARE LLC	1%,100MG	N020289	002	Apr 26, 1993	Mar CAHN		
TABLET;VAGINAL							
GYNE-LOTRIMIN							
+ BAYER HEALTHCARE LLC	100MG	N017717	002	Nov 30, 1990	Mar CAHN		
DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN							
TABLET, EXTENDED RELEASE;ORAL							
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE							
ACTAVIS LABS FL INC	30MG;600MG	A091070	001	Aug 31, 2015	Aug NEWA		
	60MG;1.2GM	A091070	002	Aug 31, 2015	Aug NEWA		
DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN							
CAPSULE;ORAL							
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE							
BANNER LIFE SCIENCES	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010	Jan CAHN		
FAMOTIDINE							
TABLET;ORAL							
FAMOTIDINE							
SUN PHARM INDS LTD	10MG	A090283	001	Nov 17, 2009	Apr CAHN		
	20MG	A090283	002	Nov 17, 2009	Apr CAHN		
PEPCID AC							
J AND J CONSUMER INC	10MG	N020325	001	Apr 28, 1995	Jul CAHN		

TABLET;ORAL						
PEPCID AC						
+	20MG	N020325	002	Sep 23, 2003	Jul	CAHN
PEPCID AC						
J AND J CONSUMER INC	10MG	N020902	001	Aug 05, 1999	Aug	CAHN
TABLET, CHEWABLE;ORAL						
PEPCID AC						
@ J AND J CONSUMER INC	10MG	N020801	001	Sep 24, 1998	Aug	CAHN
+	20MG	N020801	002	Dec 17, 2007	Aug	CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL						
FEXOFENADINE HYDROCHLORIDE ALLERGY						
SCIEGEN PHARMS INC	60MG	A204507	002	Sep 16, 2015	Aug	NEWA
	180MG	A204507	003	Sep 16, 2015	Aug	NEWA
FEXOFENADINE HYDROCHLORIDE HIVES						
SCIEGEN PHARMS INC	60MG	A204507	004	Sep 16, 2015	Aug	NEWA
	180MG	A204507	005	Sep 16, 2015	Aug	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL						
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE						
SUN PHARMA GLOBAL	60MG;120MG	A090818	001	Jan 29, 2015	Jan	NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL						
GUAIFENESIN						
ACTAVIS LABS FL INC	1.2GM	A091009	002	Sep 03, 2015	Aug	NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL						
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE						
ACTAVIS LABS FL INC	600MG;60MG	A091071	001	May 27, 2015	May	NEWA
	1.2GM;120MG	A091071	002	May 27, 2015	May	NEWA

IBUPROFEN

CAPSULE;ORAL						
IBUPROFEN						
BANNER LIFE SCIENCES	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009	Jan	CAHN
MIDOL LIQUID GELS						
+ BANNER LIFE SCIENCES	200MG	N021472	001	Oct 18, 2002	Jan	CAHN
SUSPENSION;ORAL						
CHILDREN'S MOTRIN						
+ J AND J CONSUMER INC	100MG/5ML	N020516	001	Jun 16, 1995	Aug	CAHN
SUSPENSION/DROPS;ORAL						
CHILDREN'S MOTRIN						
+ J AND J CONSUMER INC	40MG/ML	N020603	001	Jun 10, 1996	Aug	CAHN
TABLET;ORAL						
IBUPROFEN						
@ ANI PHARMS INC	200MG	A072901	001	Dec 19, 1991	Aug	CAHN
@	200MG	A072903	001	Dec 19, 1991	Aug	CAHN
JUNIOR STRENGTH MOTRIN						
J AND J CONSUMER INC	100MG	N020602	001	Jun 10, 1996	Aug	CAHN
MOTRIN IB						
+ J AND J CONSUMER INC	200MG	N019012	003	Dec 17, 1990	Aug	CAHN
MOTRIN MIGRAINE PAIN						
+ J AND J CONSUMER INC	200MG	N019012	004	Feb 25, 2000	Aug	CAHN
NUPRIN						
@ J AND J CONSUMER INC	200MG	N019012	001	May 18, 1984	Aug	CAHN
@	200MG	N019012	002	Jul 29, 1987	Aug	CAHN
TABLET, CHEWABLE;ORAL						
CHILDREN'S MOTRIN						
J AND J CONSUMER INC	50MG	N020601	001	Nov 15, 1996	Aug	CAHN
JUNIOR STRENGTH MOTRIN						
+ J AND J CONSUMER INC	100MG	N020601	003	Nov 15, 1996	Aug	CAHN

IBUPROFEN SODIUM

TABLET;ORAL

IBUPROFEN SODIUM

	PERRIGO R AND D	EQ 200MG BASE	A206581	001	Aug 03, 2015	Jul	NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S MOTRIN COLD

+	J AND J CONSUMER INC	100MG/5ML;15MG/5ML	N021128	001	Aug 01, 2000	Aug	CAHN

TABLET;ORAL

SINE-AID IB

	J AND J CONSUMER INC	200MG;30MG	N019899	001	Dec 31, 1992	Aug	CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ALAWAY

	BAUSCH AND LOMB	EQ 0.035% BASE	N021996	002	Feb 11, 2015	Feb	NEWA

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

	LOTUS PHARM CO LTD	1.5MG	A202246	001	Jun 05, 2015	May	NEWA
	OC PHARMA	1.5MG	A202380	001	May 29, 2015	May	NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

	BANNER LIFE SCIENCES	1MG	N021855	001	Aug 04, 2005	Jan	CAHN
+		2MG	N021855	002	Aug 04, 2005	Jan	CAHN

SOLUTION;ORAL

IMODIUM A-D

+	J AND J CONSUMER INC	1MG/5ML	N019487	001	Mar 01, 1988	Aug	CAHN

SUSPENSION;ORAL

IMODIUM A-D

+	J AND J CONSUMER INC	1MG/7.5ML	N019487	002	Jul 08, 2004	Aug	CAHN

TABLET;ORAL

IMODIUM A-D

+	J AND J CONSUMER INC	2MG	N019860	001	Nov 22, 1989	Aug	CAHN

TABLET, CHEWABLE;ORAL

IMODIUM A-D EZ CHEWS

+	J AND J CONSUMER INC	2MG	N020448	001	Jul 24, 1997	Aug	CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+	J AND J CONSUMER INC	2MG;125MG	N021140	001	Nov 30, 2000	Aug	CAHN

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

	SUN PHARM INDS LTD	2MG;125MG	A077500	001	Sep 06, 2006	Apr	CAHN

TABLET, CHEWABLE;ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+	J AND J CONSUMER INC	2MG;125MG	N020606	001	Jun 26, 1996	Aug	CAHN

LORATADINE

CAPSULE;ORAL

CLARITIN

+	BAYER HEALTHCARE LLC	10MG	N021952	001	Jun 16, 2008	Mar	CAHN

SYRUP;ORAL

CLARITIN

+	BAYER HEALTHCARE LLC	1MG/ML	N020641	002	Nov 27, 2002	Mar	CAHN

CLARITIN HIVES RELIEF

@	BAYER HEALTHCARE LLC	1MG/ML	N020641	003	Nov 19, 2003	Mar	CAHN

LORATADINE

	TARO	1MG/ML	A201865	001	Jul 31, 2015	Jul	NEWA

TABLET;ORAL

LORATADINE

	SUN PHARM INDS LTD	10MG	A076134	001	Aug 18, 2003	Apr	CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CLARITIN

+	BAYER HEALTHCARE LLC	5MG	N021891	001	Aug 23, 2006	Mar	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
CLARITIN REDITABS
+ BAYER HEALTHCARE LLC 5MG N021993 001 Dec 12, 2006 Mar CAHN
LORATADINE REDIDOSE
SUN PHARM INDS LTD 10MG A077153 001 Apr 11, 2007 Apr CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE
TABLET, EXTENDED RELEASE;ORAL
CLARITIN-D
+ BAYER HEALTHCARE LLC 5MG;120MG N019670 002 Nov 27, 2002 Mar CAHN
CLARITIN-D 24 HOUR
+ BAYER HEALTHCARE LLC 10MG;240MG N020470 002 Nov 27, 2002 Mar CAHN
LORATADINE AND PSEUDOEPHEDRINE SULFATE
SUN PHARM INDS LTD 10MG;240MG A076557 001 Sep 22, 2004 Apr CAHN

NAPROXEN SODIUM
CAPSULE;ORAL
NAPROXEN SODIUM
+ BANNER LIFE SCIENCES EQ 200MG BASE N021920 001 Feb 17, 2006 Jan CAHN
CATALENT EQ 200MG BASE A202807 001 Feb 13, 2015 Feb NEWA
OHM LABS INC EQ 200MG BASE A202807 001 Feb 13, 2015 Jun CAHN
TABLET;ORAL
NAPROXEN SODIUM
SUN PHARM INDS LTD EQ 200MG BASE A091183 001 May 20, 2011 Apr CAHN

NICOTINE POLACRILEX
GUM, CHEWING;BUCCAL
NICOTINE POLACRILEX
@ IVAX SUB TEVA PHARMS EQ 2MG BASE A076880 001 Feb 18, 2009 Mar DISC
@ EQ 4MG BASE A077850 001 Feb 18, 2009 Mar DISC

OMEPRAZOLE MAGNESIUM
TABLET, DELAYED RELEASE;ORAL
OMEPRAZOLE MAGNESIUM
PERRIGO R AND D EQ 20MG BASE A204152 001 Jul 30, 2015 Jul NEWA

OMEPRAZOLE; SODIUM BICARBONATE
CAPSULE;ORAL
ZEGERID OTC
+ BAYER HEALTHCARE LLC 20MG;1.1GM N022281 001 Dec 01, 2009 Mar CAHN
FOR SUSPENSION;ORAL
ZEGERID OTC
+ BAYER HEALTHCARE LLC 20MG/PACKET;1.68GM/PACKET N022283 001 Jun 17, 2013 Mar CAHN

OXYMETAZOLINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
OCUCLEAR
BAYER HEALTHCARE LLC 0.025% N018471 001 May 30, 1986 Mar CAHN

POLYETHYLENE GLYCOL 3350
FOR SOLUTION;ORAL
MIRALAX
+ BAYER HEALTHCARE LLC 17GM/SCOOPFUL N022015 001 Oct 06, 2006 Mar CAHN
POLYETHYLENE GLYCOL 3350
RARITAN PHARMS INC 17GM/SCOOPFUL A202071 001 Dec 28, 2012 Jan CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
PSEUDOEPHEDRINE HYDROCHLORIDE
SUN PHARM INDS LTD 120MG A077442 001 Sep 28, 2005 Apr CAHN
SUDAFED 24 HOUR
+ J AND J CONSUMER INC 240MG N020021 002 Dec 15, 1992 Aug CAHN

RANITIDINE HYDROCHLORIDE
TABLET;ORAL
RANITIDINE HYDROCHLORIDE
@ SUN PHARM INDS LTD EQ 75MG BASE A075132 001 Jan 14, 2000 Apr CAHN
@ WOCKHARDT EQ 75MG BASE A078884 001 Jul 31, 2008 Jan DISC

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 9 SEPTEMBER 2015

NO SEPTEMBER 2015 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO SEPTEMBER 2015 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABACAVIR SULFATE - ZIAGEN						
N 020977 001					D-147	Mar 23, 2018
ABACAVIR SULFATE - ZIAGEN						
N 020978 001					D-147	Mar 23, 2018
ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ						
N 205551 001	6417191	Mar 28, 2016	DP U-1572			
	6417191*PED	Sep 28, 2016				
ABACAVIR SULFATE; LAMIVUDINE - EPZICOM						
N 021652 001	6417191	Mar 28, 2016	DP U-257			
	6417191*PED	Sep 28, 2016				
ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR						
N 204031 001	8980319	Dec 21, 2030	DP			
	8992975	May 16, 2032	DP			
	9050335	May 16, 2032	DP			
ACLIDINIUM BROMIDE - TUDORZA PRESSAIR						
N 202450 001	9056100	Jul 07, 2020	DP U-1263			
ACYCLOVIR; HYDROCORTISONE - XERESE						
N 022436 001	7223387	Jul 24, 2021	DP U-1006			
	7223387	Jul 24, 2021	DP U-1484			
ADAPALENE; BENZOYL PEROXIDE - EPIDUO						
N 022320 001	8936800	Dec 23, 2022	DP U-1078			
ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE						
N 207917 001	8445543	Jul 12, 2027	U-1078		NP	Jul 15, 2018
	8703820	Mar 12, 2023	U-1078			
	8729127	Mar 12, 2023	U-1078			
	8785420	Dec 23, 2022	U-1078			
	8909305	Dec 23, 2022	U-1078			
	8936800	Dec 23, 2022	DP U-1078			
ALBUTEROL SULFATE - PROAIR RESPICLICK						
N 205636 001	6446627	Dec 18, 2017	DP		NP	Mar 12, 2018
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT						
N 021747 001	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI						
N 022426 001	8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI						
N 022426 002	8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI						
N 022426 003	8637079	Jun 04, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426 004		8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426 005		8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426 006		8637079	Jun 04, 2029	DP			
ALVIMOPAN - ENTEREG							
N 021775 001		8946262	Feb 12, 2030	U-1655			
AMOXICILLIN - MOXATAG							
N 050813 001		8778924	Dec 08, 2026	DS DP U-897			
APIXABAN - ELIQUIS							
N 202155 001		6967208	Feb 03, 2023	DS DP U-1167			
		6967208	Feb 03, 2023	DS DP U-1200			
		6967208	Feb 03, 2023	DS DP U-1301			
		6967208	Feb 03, 2023	DS DP U-1302			
		6967208	Feb 03, 2023	DS DP U-1323			
		6967208	Feb 03, 2023	DS DP U-1501			
		6967208	Feb 03, 2023	DS DP U-1502			
		6967208	Feb 03, 2023	DS DP U-1729			
		6967208	Feb 03, 2023	DS DP U-1730			
APIXABAN - ELIQUIS							
N 202155 002		6413980	Dec 22, 2019	DS DP U-1200			
		6413980	Dec 22, 2019	DS DP U-1301			
		6413980	Dec 22, 2019	DS DP U-1302			
		6967208	Feb 03, 2023	DS DP U-1200			
		6967208	Feb 03, 2023	DS DP U-1301			
		6967208	Feb 03, 2023	DS DP U-1302			
		6967208	Feb 03, 2023	DS DP U-1323			
APREMILAST - OTEZLA							
N 205437 001		9018243	Mar 19, 2023	U-1505			
		9018243	Mar 19, 2023	U-1595			
APREMILAST - OTEZLA							
N 205437 002		9018243	Mar 19, 2023	U-1505			
		9018243	Mar 19, 2023	U-1595			
APREMILAST - OTEZLA							
N 205437 003		9018243	Mar 19, 2023	U-1505			
		9018243	Mar 19, 2023	U-1595			
APREPITANT - EMEND							
N 021549 001	>A>	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	>A>	6096742	Jul 01, 2018	DS DP U-1743			
	>A>	6096742	Jul 01, 2018	DS DP U-1744			
	>A>	8258132	Sep 26, 2027	DP U-901			
	>A>	8258132	Sep 26, 2027	DP U-1743			
APREPITANT - EMEND							
N 021549 002	>A>	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	>A>	6096742	Jul 01, 2018	DS DP U-1743			
	>A>	6096742	Jul 01, 2018	DS DP U-1744			
	>A>	8258132	Sep 26, 2027	DP U-901			
	>A>	8258132	Sep 26, 2027	DP U-1743			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APREPITANT - EMEND							
N 021549 003	>A>	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	>A>	6096742	Jul 01, 2018	DS DP U-1743			
	>A>	6096742	Jul 01, 2018	DS DP U-1744			
	>A>	8258132	Sep 26, 2027	DP U-901			
	>A>	8258132	Sep 26, 2027	DP U-1743			
ARIPIPRAZOLE - ABILIFY							
N 021436 001		9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	>A>	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY							
N 021436 002		9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	>A>	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY							
N 021436 003		9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	>A>	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY							
N 021436 004		9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	>A>	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY							
N 021436 005		9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	>A>	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY							
N 021436 006		9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	>A>	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY							
N 021713 001		5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
		5006528	Oct 20, 2014	DS DP U-761			
		5006528*PED	Apr 20, 2015				
		6977257	Apr 24, 2022	DP			
		6977257*PED	Oct 24, 2022				
ARIPIPRAZOLE - ABILIFY							
N 021729 002		9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	>A>	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY							
N 021729 003		9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	>A>	9125939	Jul 28, 2026	U-1749			
ARIPIPRAZOLE - ABILIFY							
N 021729 004						ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY							
N 021729 005						ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY							
N 021866 001		5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
		5006528	Oct 20, 2014	DS DP U-763			
		5006528*PED	Apr 20, 2015				
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971 001		5006528	Oct 20, 2014	DS DP U-543			
		5006528	Oct 20, 2014	DS DP U-1632			
		5006528*PED	Apr 20, 2015				
		8030313	Oct 19, 2024	U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 001	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 002	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 003	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 004	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
ASENAPINE MALEATE - SAPHRIS						
N 022117 001	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ASENAPINE MALEATE - SAPHRIS							
N 022117 001		8022228*PED	Oct 06, 2026				
ASENAPINE MALEATE - SAPHRIS							
N 022117 002		5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
		5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
		7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
		7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
		8022228	Apr 06, 2026	DS DP			
		8022228*PED	Oct 06, 2026				
ASPIRIN - ASPIRIN							
N 203697 001		9101637	Mar 23, 2022	U-1731			
		9101637	Mar 23, 2022	U-1732			
		9101637	Mar 23, 2022	U-1733			
ATAZANAVIR SULFATE - REYATAZ							
N 021567 001		5849911	Jun 20, 2017	DS DP U-167			
		5849911*PED	Dec 20, 2017				
		6087383	Dec 21, 2018	DS DP			
		6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ							
N 021567 002		5849911	Jun 20, 2017	DS DP U-167			
		5849911*PED	Dec 20, 2017				
		6087383	Dec 21, 2018	DS DP			
		6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ							
N 021567 003		5849911	Jun 20, 2017	DS DP U-167			
		5849911*PED	Dec 20, 2017				
		6087383	Dec 21, 2018	DS DP			
		6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ							
N 021567 004		5849911	Jun 20, 2017	DS DP U-167			
		5849911*PED	Dec 20, 2017				
		6087383	Dec 21, 2018	DS DP			
		6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ							
N 206352 001		5849911	Jun 20, 2017	DS DP U-167		NP	Jun 02, 2017
		5849911*PED	Dec 20, 2017			>A> NPP	Sep 24, 2018
	>A>	6087383	Dec 21, 2018	DS DP		PED	Dec 02, 2017
	>A>	6087383*PED	Jun 21, 2019			>A> PED	Mar 24, 2019
ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ							
N 206353 001		5849911	Jun 20, 2017	DS DP U-167			
		5849911*PED	Dec 20, 2017				
		6087383	Dec 21, 2018	DS DP			
		6087383*PED	Jun 21, 2019				
		8148374	Sep 03, 2029	DS DP U-1279			
AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ							
N 206494 001		7112592	Feb 24, 2022	DS DP U-282			
		7612087	Nov 12, 2026	DP			
		8178554	Jul 24, 2021	DS DP U-282			
		8471025	Aug 12, 2031	DS			
		8835455	Oct 08, 2030	DP			
		8969566	Jun 15, 2032	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AZELAIC ACID - FINACEA								
N 207071 001		6730288	Sep 08, 2019	DP			NP	Jul 29, 2018
		7700076	Sep 18, 2027	DP				
		8435498	Mar 01, 2024	U-1727				
		8722021	Oct 24, 2023	DP				
		8900554	Oct 24, 2023	DP				
AZELASTINE HYDROCHLORIDE - ASTEPRO								
N 022203 001							NPP	Feb 20, 2018
							NPP	Feb 20, 2018
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA								
N 202236 001		8163723	Aug 29, 2023	U-77			NPP	Feb 20, 2018
		8163723	Aug 29, 2023	U-81				
		8163723	Aug 29, 2023	U-644				
		8163723	Aug 29, 2023	U-707				
		8163723	Aug 29, 2023	U-1667				
AZILSARTAN KAMEDOXOMIL - EDARBI								
N 200796 001		9066936	Mar 26, 2028	DP				
AZILSARTAN KAMEDOXOMIL - EDARBI								
N 200796 002		9066936	Mar 26, 2028	DP				
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR								
N 202331 001		9066936	Mar 26, 2028	DP				
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR								
N 202331 002		9066936	Mar 26, 2028	DP				
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA								
N 050819 001		8895070	Jun 03, 2029	U-124				
	>A>	9078870	Jun 03, 2029	DP				
BESIFLOXACIN HYDROCHLORIDE - BESIVANCE								
N 022308 001		8937062	Nov 13, 2029	U-80				
BEXAROTENE - TARGRETIN								
N 021055 001						>A>	M-164	Jul 29, 2018
BIMATOPROST - LUMIGAN								
N 022184 001		8933120	Mar 16, 2025	DP				
		8933127	Mar 16, 2025	DP				
BIMATOPROST - LATISSE								
N 022369 001		7351404	May 25, 2024	U-939	Y			
		7388029	Jan 21, 2022	U-938	Y			
		8541466	Jan 31, 2021	U-1217				
		8986715	Jan 15, 2023	U-1217				
BORTEZOMIB - VELCADE								
N 021602 001		5780454	May 03, 2017	DS DP			D-141	Oct 08, 2017
		5780454*PED	Nov 03, 2017				D-142	Oct 08, 2017
		6713446	Jan 25, 2022	DS DP			I-695	Oct 08, 2017
		6713446*PED	Jul 25, 2022				M-139	Aug 08, 2017
		6958319	Jan 25, 2022	DS DP		>A>	M-165	Sep 14, 2018
		6958319*PED	Jul 25, 2022				ODE	Oct 08, 2021
							PED	Feb 08, 2018
							PED	Apr 08, 2018
							PED	Apr 08, 2018
							PED	Apr 08, 2018
						>A>	PED	Mar 14, 2019
							PED	Apr 08, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BORTEZOMIB - VELCADE						
N 021602 001	5780454	May 03, 2017	DS DP		D-141	Oct 08, 2017
	5780454*PED	Nov 03, 2017			D-142	Oct 08, 2017
	6713446	Jan 25, 2022	DS DP		I-695	Oct 08, 2017
	6713446*PED	Jul 25, 2022			M-139	Aug 08, 2017
	6958319	Jan 25, 2022	DS DP		>A> M-165	Sep 14, 2018
	6958319*PED	Jul 25, 2022			ODE	Oct 08, 2021
					PED	Feb 08, 2018
					PED	Apr 08, 2018
					PED	Apr 08, 2018
					PED	Apr 08, 2018
					>A> PED	Mar 14, 2019
					PED	Apr 08, 2022
BREXPIPRAZOLE - REXULTI						
N 205422 001	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
BREXPIPRAZOLE - REXULTI						
N 205422 002	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
BREXPIPRAZOLE - REXULTI						
N 205422 003	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
BREXPIPRAZOLE - REXULTI						
N 205422 004	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
BREXPIPRAZOLE - REXULTI						
N 205422 005	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
BREXPIPRAZOLE - REXULTI						
N 205422 006	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA						
N 204251 001	9044484	Oct 30, 2030	DP			
BROMOCRIPTINE MESYLATE - CYCLOSET						
N 020866 001	8877708	Jun 07, 2030	DP U-1706			
BUDESONIDE - UCERIS						
N 203634 001	9132093	Sep 07, 2031	DP			
BUDESONIDE - UCERIS						
N 205613 001	5914122	Dec 19, 2015	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 001	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 002	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 003	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 004	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV						
N 204242 005	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE						
N 200063 001	8916195	Feb 02, 2030	U-1639			
	9107837	Jun 04, 2027	U-1639			
CALCIUM ACETATE - PHOSLO GELCAPS						
N 021160 003	6875445	Jul 30, 2021	DP			
CALCIUM ACETATE - PHOSLYRA						
N 022581 001	9089528	Jul 20, 2027	U-1469			
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER						
N 207026 001					ODE	Jan 13, 2022
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER						
N 207026 002					ODE	Jan 13, 2022
CANGRELOR - KENGREAL						
N 204958 001	6114313	Dec 11, 2017	DP U-1715		NCE	Jun 22, 2020
	6130208	Jun 29, 2018	DP U-1715			
	8680052	Mar 09, 2033	U-1715			
	8759316	May 13, 2029	U-1715			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 001	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 002	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 002	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 003	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 004	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
CARBIDOPA; LEVODOPA - DUOPA						
N 203952 001					NP	Jan 09, 2018
					ODE	Jan 09, 2022
CARFILZOMIB - KYPROLIS						
N 202714 001					I-712	Jul 24, 2018
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 001					>A> NCE	Sep 17, 2020
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 002					>A> NCE	Sep 17, 2020
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 003					>A> NCE	Sep 17, 2020
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 004					>A> NCE	Sep 17, 2020
CEFTAROLINE FOSAMIL - TEFLARO						
N 200327 001	6417175	Apr 11, 2022	DS DP U-1676			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CEFTAROLINE FOSAMIL - TEFLARO						
N 200327 002	6417175	Apr 11, 2022	DS DP U-1676			
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA						
N 206829 001	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
CELECOXIB - CELECOXIB						
A 076898 002					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 076898 003					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 076898 004					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 078857 002					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 078857 003					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 078857 004					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 200562 002					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 200562 003					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 200562 004					PC	Jun 02, 2015
CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE						
N 206323 001	6248363	Nov 23, 2019	DP U-1716			
	6383471	Apr 06, 2019	DP U-1716			
	9066942	Jan 03, 2032	U-1716			
CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR						
N 207768 001	8062667	Mar 29, 2029	DP			
	8790700	Mar 15, 2027	DP			
CHOLIC ACID - CHOLBAM						
N 205750 001					ODE	Mar 17, 2022
CHOLIC ACID - CHOLBAM						
N 205750 002					ODE	Mar 17, 2022
CICLESONIDE - ALVESCO						
N 021658 002	8371292	Feb 01, 2028	U-1355			
CICLESONIDE - ALVESCO						
N 021658 003	8371292	Feb 01, 2028	U-1355			
CICLESONIDE - OMNARIS						
N 022004 001	8371292	Feb 01, 2028	U-1356			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CICLESONIDE - ZETONNA						
N 202129 001	8371292	Feb 01, 2028	U-1357			
CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE						
A 090898 001					PC	Jul 01, 2015
CLOBETASOL PROPIONATE - OLUX E						
N 022013 001	8962000	Aug 31, 2025	DP U-1410			
COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX						
N 205395 001	5843946	Dec 01, 2015	DP U-1660			
	5843946*PED	Jun 01, 2016				
	7470506	Jun 23, 2019	U-1660			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1660			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1660			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1660			
	RE43802*PED	Apr 19, 2017				
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD						
N 203100 001	8981103	Oct 26, 2026	DS DP		I-704	Dec 17, 2017
COLCHICINE - MITIGARE						
N 204820 001	8927607	Aug 22, 2033	U-1020			
CRIZOTINIB - XALKORI						
N 202570 001	7230098	Aug 26, 2025	DS		>A> M-163	Sep 14, 2018
CRIZOTINIB - XALKORI						
N 202570 002	7230098	Aug 26, 2025	DS		>A> M-163	Sep 14, 2018
CROFELEMER - FULYZAQ						
N 202292 001	8962680	Oct 31, 2031	U-1319			
CYANOCOBALAMIN - NASCOBAL						
N 021642 001	7229636	Aug 01, 2024	DP U-817			
	7879349	Aug 01, 2024	DP U-1152			
	8003353	Aug 01, 2024	U-817			
	8940714	Feb 26, 2024	U-1152			
CYSTEAMINE BITARTRATE - PROCYSBI						
N 203389 001					NPP	Aug 14, 2018
CYSTEAMINE BITARTRATE - PROCYSBI						
N 203389 002					NPP	Aug 14, 2018
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 001	8703781	Oct 15, 2030	DS DP U-1713			
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 002	8703781	Oct 15, 2030	DS DP U-1713			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA						
N 206843 001	8329159	Apr 13, 2028	DS		NCE	Jul 24, 2020
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA						
N 206843 002	8329159	Apr 13, 2028	DS		NCE	Jul 24, 2020
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
DANTROLENE SODIUM - RYANODEX						
N 205579 001					ODE	Jul 22, 2021
DAPAGLIFLOZIN PROPANEDIOL - FARXIGA						
N 202293 001					M-157	Mar 11, 2018
DAPAGLIFLOZIN PROPANEDIOL - FARXIGA						
N 202293 002					M-157	Mar 11, 2018
DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)						
N 206619 001	6037157	Jun 26, 2016	U-1635			
	6703403	Jun 26, 2016	U-1635			
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1637			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1637			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
DEFERASIROX - EXJADE						
N 021882 001					ODE	Jan 23, 2020
DEFERASIROX - EXJADE						
N 021882 002					ODE	Jan 23, 2020
DEFERASIROX - EXJADE						
N 021882 003					ODE	Jan 23, 2020
DEFERASIROX - JADENU						
N 206910 001	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			
DEFERASIROX - JADENU						
N 206910 002	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEFERASIROX - JADENU							
N 206910	003	6465504	Apr 05, 2019	DS DP			
		6596750	Jun 24, 2017	DS U-735			
DEFERIPRONE - FERRIPROX							
N 021825	001	>A> 7049328	Jun 28, 2021	U-735			
DEFERIPRONE - FERRIPROX							
N 208030	001	>A> 7049328	Jun 28, 2021	U-735		>A> NCE	Oct 14, 2016
		>A> 8703156	Oct 29, 2029	DP U-735		>A> ODE	Oct 14, 2016
DEOXYCHOLIC ACID - KYBELLA							
N 206333	001	7622130	Dec 10, 2027	U-1690			
		7754230	Dec 10, 2027	U-1690			
		8101593	Mar 02, 2030	DP			
		8242294	May 16, 2028	DS			
		8298556	Aug 03, 2025	U-1690			
		8367649	Mar 02, 2030	DP			
		8461140	Feb 21, 2028	DP			
		8546367	Feb 21, 2028	DP U-1690			
		8653058	Mar 02, 2030	DP			
		8846066	Feb 08, 2025	U-1690			
		8883770	Feb 21, 2028	DP			
DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE							
A 200653	001					PC	May 16, 2015
DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE							
A 200653	002					PC	May 16, 2015
DESONIDE - VERDESO							
N 021978	001	8962000	Aug 31, 2025	DP U-1412			
DESVENLAFAXINE SUCCINATE - PRISTIQ							
N 021992	003	6673838	Mar 01, 2022	DS U-860			
		6673838	Mar 01, 2022	DS U-1364			
		8269040	Jul 05, 2027	DS			
DEXAMETHASONE - OZURDEX							
N 022315	001	8043628	Oct 20, 2020	U-1205			
		8088407	Oct 20, 2020	U-1205			
		9012437	Oct 20, 2020	U-1205			
DEXLANSOPRAZOLE - DEXILANT							
N 022287	001	9011926	Feb 24, 2026	DP			
DEXLANSOPRAZOLE - DEXILANT							
N 022287	002	8784885	Oct 15, 2023	DP U-1552			
		8784885	Oct 15, 2023	DP U-1553			
		8784885	Oct 15, 2023	DP U-1554			
		8784885*PED	Apr 15, 2024				
		9011926	Feb 24, 2026	DP			
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX							
N 021038	004	6716867	Mar 31, 2019	U-1472			
		6716867*PED	Oct 01, 2019				
		8242158	Jan 04, 2032	DP			
		8242158*PED	Jul 04, 2032				
		8338470	Jan 04, 2032	DP			
		8338470*PED	Jul 04, 2032				
		8455527	Jan 04, 2032	U-421			
		8455527*PED	Jul 04, 2032				
		8648106	Jan 04, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 004	8648106*PED	Jul 04, 2032				
DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE						
A 078908 002					PC	Aug 01, 2015
DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE						
A 078908 003					PC	Dec 19, 2015
DICHLORPHENAMIDE - KEVEYIS						
N 011366 002					>A> ODE	Aug 07, 2022
DICLOFENAC - ZORVOLEX						
N 204592 001	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
DICLOFENAC - ZORVOLEX						
N 204592 002	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
DICLOFENAC POTASSIUM - CAMBIA						
N 022165 001	8927604	Jun 16, 2026	U-436			
DICLOFENAC SODIUM - DYLOJECT						
N 022396 001	6407079	Jun 18, 2019	DP			
	8946292	Mar 22, 2027	U-1659			
DICLOFENAC SODIUM - PENNSAID						
N 204623 001	9066913	Oct 17, 2027	DP U-1488			
	9101591	Oct 17, 2027	DP U-1488			
	9132110	Oct 17, 2027	U-1488			
DOLUTEGRAVIR SODIUM - TIVICAY						
N 204790 001					>A> M-166	Jul 30, 2018
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC						
N 206439 001	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC						
N 206439 002	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC						
N 206439 002	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
DOXEPIN HYDROCHLORIDE - SILENOR						
N 022036 001	9107898	May 01, 2028	DP U-620			
DOXEPIN HYDROCHLORIDE - SILENOR						
N 022036 002	9107898	May 01, 2028	DP U-620			
DOXYCYCLINE HYCLATE - DOXTERIC						
N 050795 006	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
DRONEDARONE HYDROCHLORIDE - MULTAQ						
N 022425 001	9107900	Apr 16, 2029	U-1726			
	9107900	Apr 16, 2029	U-1728			
DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE						
A 090694 003					PC	Jan 11, 2016
EDOXABAN TOSYLATE - SAVAYSA						
N 206316 001	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
EDOXABAN TOSYLATE - SAVAYSA						
N 206316 002	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
EDOXABAN TOSYLATE - SAVAYSA						
N 206316 003	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA						
N 021937 001	9018192	Jun 13, 2026	U-750			
	9018192	Jun 13, 2026	U-1170			
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 001	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 001	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-930			
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 002	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 002	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-930			
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-1575			
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 003	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-714			
	8062665	Aug 01, 2027	DP U-930			
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-1575			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 003	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 004	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-930			
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-1575			
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 005	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291 005		7160870	Nov 20, 2022	DS DP U-1575			
		7160870	Nov 20, 2022	DS DP U-1714			
		7160870*PED	May 20, 2023				
		7332481	May 24, 2021	U-930			
		7332481	May 24, 2021	U-1306			
		7332481	May 24, 2021	U-1575			
		7332481	May 24, 2021	U-1714			
		7332481*PED	Nov 24, 2021				
		7452874	May 24, 2021	DS DP U-1714			
		7452874*PED	Nov 24, 2021				
		7473686	May 24, 2021	DS DP U-930			
		7473686	May 24, 2021	DS DP U-1306			
		7473686	May 24, 2021	DS DP U-1575			
		7473686	May 24, 2021	DS DP U-1714			
		7473686*PED	Nov 24, 2021				
		7547719	Jul 13, 2025	DS DP U-930			
		7547719	Jul 13, 2025	DS DP U-1306			
		7547719	Jul 13, 2025	DS DP U-1575			
		7547719*PED	Jan 13, 2026				
		7790704	May 24, 2021	U-930			
		7790704	May 24, 2021	U-1306			
		7790704	May 24, 2021	U-1575			
		7790704*PED	Nov 24, 2021				
		7795293	May 21, 2023	U-930			
		7795293	May 21, 2023	U-1306			
		7795293	May 21, 2023	U-1575			
		7795293*PED	Nov 21, 2023				
		8052995	Aug 01, 2027	DP U-1306			
		8052995	Aug 01, 2027	DP U-1575			
		8052995*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA							
N 207027 001	>A>	6280959	Oct 30, 2018	DS DP U-1736		D-149	Jun 11, 2018
	>A>	7160870	Nov 20, 2022	DS DP U-1736		I-711	Jun 11, 2018
	>A>	7332481	May 24, 2021	U-1736		ODE	Nov 20, 2015
	>A>	7452874	May 24, 2021	DS DP		PED	Dec 11, 2018
	>A>	7473686	May 24, 2021	DS DP U-1736		PED	Dec 11, 2018
	>A>	7547719	Jul 13, 2025	DS DP U-1736			
	>A>	7790704	May 24, 2021	U-1736			
	>A>	7795293	May 24, 2023	U-1736			
ELUXADOLINE - VIBERZI							
N 206940 001		7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
		7786158	Mar 14, 2025	DS			
		8344011	Mar 14, 2025	U-1709			
		8609709	Mar 14, 2025	DS			
		8691860	Jul 07, 2028	DS U-1709			
	>A>	9115091	Jul 07, 2028	DS DP U-1738			
ELUXADOLINE - VIBERZI							
N 206940 002		7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
		7786158	Mar 14, 2025	DS			
		8344011	Mar 14, 2025	U-1709			
		8609709	Mar 14, 2025	DS			
		8691860	Jul 07, 2028	DS U-1709			
	>A>	9115091	Jul 07, 2028	DS DP U-1738			
ELVITEGRAVIR - VITEKTA							
N 203093 001		8981103	Oct 26, 2026	DS DP			
ELVITEGRAVIR - VITEKTA							
N 203093 002		8981103	Oct 26, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN - JARDIANCE							
N 204629 001						M-160	Jun 26, 2018
						M-161	Jun 26, 2018
EMPAGLIFLOZIN - JARDIANCE							
N 204629 002						M-160	Jun 26, 2018
						M-161	Jun 26, 2018
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI							
N 206073 001		6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
		6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
		7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
		7407955	Aug 12, 2023	DS DP			
		7459428	Feb 02, 2019	U-1651			
		7579449	Nov 05, 2025	DS			
		7713938	Apr 15, 2027	DS DP			
		8119648	Aug 12, 2023	U-1651			
		8178541	Aug 12, 2023	DP U-1653			
		8178541	Aug 12, 2023	DP U-1654			
		8551957	Oct 19, 2029	DP U-1651			
		8673927	May 04, 2027	DP U-1652			
		8846695	Jun 04, 2030	U-1652			
		8883805	Nov 26, 2025	DP			
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI							
N 206073 002		6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
		6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
		7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
		7407955	Aug 12, 2023	DS DP			
		7459428	Feb 02, 2019	U-1651			
		7579449	Nov 05, 2025	DS			
		7713938	Apr 15, 2027	DS DP			
		8119648	Aug 12, 2023	U-1651			
		8178541	Aug 12, 2023	DP U-1653			
		8178541	Aug 12, 2023	DP U-1654			
		8551957	Oct 19, 2029	DP U-1651			
		8673927	May 04, 2024	DP U-1652			
		8846695	Jun 04, 2030	U-1652			
		8883805	Nov 26, 2025	DP			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111 001	>A>	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	>A>	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111 002	>A>	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	>A>	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111 003	>A>	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	>A>	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111 004	>A>	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	>A>	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
ENZALUTAMIDE - XTANDI							
N 203415 001	>A>	9126941	May 15, 2026	U-1588			
EPINEPHRINE - AUVI-Q							
N 201739 001		8920377	Nov 23, 2024	DP			
		8926594	Mar 31, 2026	DP			
		9056170	Nov 23, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EPINEPHRINE - AUVI-Q							
N 201739	002	8920377	Nov 23, 2024	DP			
		8926594	Mar 31, 2026	DP			
		9056170	Nov 23, 2024	DP			
EPINEPHRINE - ADRENALIN							
N 204640	001	9119876	Mar 13, 2035	DP			
ERIBULIN MESYLATE - HALAVEN							
N 201532	001	6214865	Jul 20, 2023	DS			
ERLOTINIB HYDROCHLORIDE - TARCEVA							
N 021743	001	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
		5747498*PED	May 08, 2019			PED	Nov 14, 2016
		6900221	Nov 09, 2020	DS DP U-659			
		6900221	Nov 09, 2020	DS DP U-875			
		6900221	Nov 09, 2020	DS DP U-1046			
		6900221	Nov 09, 2020	DS DP U-1403			
		6900221*PED	May 09, 2021				
		7087613	Nov 09, 2020	U-659			
		7087613	Nov 09, 2020	U-1045			
		7087613	Nov 09, 2020	U-1403			
		7087613*PED	May 09, 2021				
		RE41065	Nov 08, 2018	DS DP			
		RE41065*PED	May 08, 2019				
ERLOTINIB HYDROCHLORIDE - TARCEVA							
N 021743	002	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
		5747498*PED	May 08, 2019			PED	Nov 14, 2016
		6900221	Nov 09, 2020	DS DP U-659			
		6900221	Nov 09, 2020	DS DP U-875			
		6900221	Nov 09, 2020	DS DP U-1046			
		6900221	Nov 09, 2020	DS DP U-1403			
		6900221*PED	May 09, 2021				
		7087613	Nov 09, 2020	U-659			
		7087613	Nov 09, 2020	U-1045			
		7087613	Nov 09, 2020	U-1403			
		7087613*PED	May 09, 2021				
		RE41065	Nov 08, 2018	DS DP			
		RE41065*PED	May 08, 2019				
ERLOTINIB HYDROCHLORIDE - TARCEVA							
N 021743	003	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
		5747498*PED	May 08, 2019			PED	Nov 14, 2016
		6900221	Nov 09, 2020	DS DP U-659			
		6900221	Nov 09, 2020	DS DP U-875			
		6900221	Nov 09, 2020	DS DP U-1046			
		6900221	Nov 09, 2020	DS DP U-1403			
		6900221*PED	May 09, 2021				
		7087613	Nov 09, 2020	U-659			
		7087613	Nov 09, 2020	U-1045			
		7087613	Nov 09, 2020	U-1403			
		7087613*PED	May 09, 2021				
		RE41065	Nov 08, 2018	DS DP			
		RE41065*PED	May 08, 2019				
ESLICARBAZEPINE ACETATE - APTIOM							
N 022416	001	>A> 5753646	Jun 27, 2016	DS DP U-1451		>A> D-150	Aug 27, 2018
		>A> 5753646	Jun 27, 2016	DS DP U-1746		>A> I-715	Aug 27, 2018
ESLICARBAZEPINE ACETATE - APTIOM							
N 022416	002	>A> 5753646	Jun 27, 2016	DS DP U-1451		>A> D-150	Aug 27, 2018
		>A> 5753646	Jun 27, 2016	DS DP U-1746		>A> I-715	Aug 27, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESLICARBAZEPINE ACETATE - APTIOM								
N 022416	003	>A>	5753646	Jun 27, 2016	DS DP U-1451		>A> D-150	Aug 27, 2018
		>A>	5753646	Jun 27, 2016	DS DP U-1746		>A> I-715	Aug 27, 2018
ESLICARBAZEPINE ACETATE - APTIOM								
N 022416	004	>A>	5753646	Jun 27, 2016	DS DP U-1451		>A> D-150	Aug 27, 2018
		>A>	5753646	Jun 27, 2016	DS DP U-1746		>A> I-715	Aug 27, 2018
ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR								
N 204655	001		5690960	Nov 25, 2014	DP U-1509			
			5690960*PED	May 25, 2015				
			5714504	Feb 03, 2015	DP U-1509			
			5714504*PED	Aug 03, 2015				
			5877192*PED	Nov 27, 2014				
			5900424	May 04, 2016	DS U-1509			
			5900424*PED	Nov 04, 2016				
			6369085	May 25, 2018	DS DP U-1509			
			6369085*PED	Nov 25, 2018				
			6428810	Nov 03, 2019	DP U-1509			
			6428810*PED	May 03, 2020				
			6875872*PED	Nov 27, 2014				
			7411070	May 25, 2018	DS			
			7411070*PED	Nov 25, 2018				
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO								
N 022511	001		8945621	Oct 17, 2031	U-1661			
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO								
N 022511	002		8945621	Oct 17, 2031	U-1661			
ESTRADIOL - MINIVELLE								
N 203752	005		6841716	Apr 27, 2020	DP			
			8231906	Jul 04, 2030	DS DP			
EVEROLIMUS - AFINITOR								
N 022334	001		8410131	Nov 01, 2025	DS DP U-1368			
			8410131*PED	May 01, 2026				
			9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR								
N 022334	002		8410131	Nov 01, 2025	DS DP U-1368			
			8410131*PED	May 01, 2026				
			9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR								
N 022334	003		8410131	Nov 01, 2025	DS DP U-1368			
			8410131*PED	May 01, 2026				
			9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR								
N 022334	004		8410131	Nov 01, 2025	DS DP U-1368			
			8410131*PED	May 01, 2026				
			9006224	Jul 01, 2028	U-1681			
EXENATIDE SYNTHETIC - BYDUREON								
N 022200	001						>A> M-162	Sep 24, 2018
FEBUXOSTAT - ULORIC								
N 021856	001		9107912	Sep 08, 2031	U-1346			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FEBUXOSTAT - ULORIC						
N 021856 002	9107912	Sep 08, 2031	U-1346			
FENTANYL CITRATE - LAZANDA						
N 022569 001	9078814	Jan 08, 2024	DP			
FENTANYL CITRATE - LAZANDA						
N 022569 002	9078814	Jan 08, 2024	DP			
FENTANYL HYDROCHLORIDE - IONSYS						
N 021338 001	6169920	Jan 02, 2018	DP U-736			
	6181963	Nov 02, 2019	DP			
	8301238	Sep 30, 2031	DP			
	8428708	May 21, 2032	U-736			
	8428709	Jun 11, 2032	DP U-736			
	8781571	Mar 31, 2032	DP U-736			
	9095706	Jan 17, 2033	DP			
FERRIC CITRATE - AURYXIA						
N 205874 001	8901349	Feb 18, 2024	U-1577			
	9050316	Feb 18, 2024	U-1577			
FERRIC PYROPHOSPHATE CITRATE - TRIFERIC						
N 206317 001	6689275	Dec 31, 2016	U-1656			
	6779468	Dec 31, 2016	U-1656			
	7816404	Apr 17, 2029	DP U-1656			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY						
N 201373 001	8933097	Aug 16, 2032	DP			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES						
N 201373 002	8933097	Aug 16, 2032	DP			
FINAFLOXACIN - XTORO						
N 206307 001	6133260	Apr 12, 2017	DS DP			
	6432948	Apr 12, 2017	DS DP			
	8536167	Aug 08, 2031	U-1679			
	9119859	Jul 02, 2030	U-1679			
FLIBANSERIN - ADDYI						
N 022526 001	7151103	May 09, 2023	U-1734		NCE	Aug 18, 2020
	7420057	Aug 01, 2022	DS DP			
	8227471	May 09, 2023	U-1734			
FLUOROURACIL - TOLAK						
N 022259 001					>A> NP	Sep 18, 2018
FLUTEMETAMOL F-18 - VIZAMYL						
N 203137 001	8916131	Sep 16, 2028	DP			
FLUTEMETAMOL F-18 - VIZAMYL						
N 203137 002	8916131	Sep 16, 2028	DP			
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA						
N 204275 001	6537983	Aug 03, 2021	DP U-1401		I-708	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1401			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1691			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA							
N 204275	001	8511304	Jun 14, 2027	DP U-1424			
		8511304	Jun 14, 2027	DP U-1691			
		RE44874	Mar 23, 2023	DS DP U-1548			
		RE44874	Mar 23, 2023	DS DP U-1691			
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA							
N 204275	002	5873360	Feb 23, 2016	DP		NP	Apr 30, 2018
		6537983	Aug 03, 2021	DP U-1691			
		6759398	Aug 03, 2021	DP U-1691			
		7101866	Aug 03, 2021	DS DP U-1691			
		7439393	Sep 11, 2022	DS DP U-1691			
		7629335	Aug 03, 2021	DP			
		7776895	Sep 11, 2022	DP			
		8113199	Oct 23, 2027	DP			
		8161968	Feb 05, 2028	DP			
		8511304	Jun 14, 2027	DP U-1691			
		8534281	Aug 10, 2029	DP			
		8746242	Oct 11, 2030	DP			
		RE44874	Mar 23, 2023	DS DP U-1691			
FLUTICASONE PROPIONATE - CUTIVATE							
N 021152	001					NPP	Jan 16, 2018
GADOXETATE DISODIUM - EOVIST							
N 022090	001					M-155	Mar 27, 2018
GADOXETATE DISODIUM - EOVIST							
N 022090	002					M-155	Mar 27, 2018
GEFITINIB - IRESSA							
N 206995	001	5770599	May 05, 2017	DS DP U-1403		NP	Jul 13, 2018
						ODE	Jul 13, 2022
GLATIRAMER ACETATE - COPAXONE							
N 020622	003	8969302	Aug 19, 2030	U-441			
	>A>	9155776	Aug 19, 2030	U-441			
GLYCEROL PHENYLBUTYRATE - RAVICTI							
N 203284	001	9095559	Mar 09, 2032	U-1383			
GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE							
A 200881	001					PC	May 30, 2015
GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE							
A 200881	002					PC	May 30, 2015
GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE							
A 200881	003					PC	May 30, 2015
GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE							
A 200881	004					PC	May 30, 2015
GUANFACINE HYDROCHLORIDE - INTUNIV							
N 022037	001					M-154	Mar 18, 2018
GUANFACINE HYDROCHLORIDE - INTUNIV							
N 022037	002					M-154	Mar 18, 2018
GUANFACINE HYDROCHLORIDE - INTUNIV							
N 022037	003					M-154	Mar 18, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GUANFACINE HYDROCHLORIDE - INTUNIV							
N 022037	004					M-154	Mar 18, 2018
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	001	>A> 9132096	Sep 12, 2034	DP			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	002	>A> 9132096	Sep 12, 2034	DP			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	003	>A> 9132096	Sep 12, 2034	DP			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	004	>A> 9132096	Sep 12, 2034	DP			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	005	>A> 9132096	Sep 12, 2034	DP			
HYDROCODONE BITARTRATE - ZOHYDRO ER							
N 202880	006	>A> 9132096	Sep 12, 2034	DP			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627	001	9023401	Oct 30, 2021	DP			
		9056052	Oct 30, 2021	DP			
		9060940	Oct 30, 2021			U-1556	
		9084816	Aug 24, 2027	DP			
		9095614	Aug 24, 2027			U-1556	
		9095615	Aug 24, 2027	DP			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627	002	9023401	Oct 30, 2021	DP			
		9056052	Oct 30, 2021	DP			
		9060940	Oct 30, 2021			U-1556	
		9084816	Aug 24, 2027	DP			
		9095614	Aug 24, 2027			U-1556	
		9095615	Aug 24, 2027	DP			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627	003	9023401	Oct 30, 2021	DP			
		9056052	Oct 30, 2021	DP			
		9060940	Oct 30, 2021			U-1556	
		9084816	Aug 24, 2027	DP			
		9095614	Aug 24, 2027			U-1556	
		9095615	Aug 24, 2027	DP			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627	004	9023401	Oct 30, 2021	DP			
		9056052	Oct 30, 2021	DP			
		9060940	Oct 30, 2021			U-1556	
		9084816	Aug 24, 2027	DP			
		9095614	Aug 24, 2027			U-1556	
		9095615	Aug 24, 2027	DP			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627	005	9056052	Oct 30, 2021	DP			
		9060940	Oct 30, 2021			U-1556	
		9084816	Aug 24, 2027	DP			
		9095614	Aug 24, 2027			U-1556	
		9095615	Aug 24, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627 006		9056052	Oct 30, 2021	DP			
		9060940	Oct 30, 2021	U-1556			
		9084816	Aug 24, 2027	DP			
		9095614	Aug 24, 2027	U-1556			
		9095615	Aug 24, 2027	DP			
HYDROCODONE BITARTRATE - HYSINGLA							
N 206627 007		9056052	Oct 30, 2021	DP			
		9060940	Oct 30, 2021	U-1556			
		9084816	Aug 24, 2027	DP			
		9095614	Aug 24, 2027	U-1556			
		9095615	Aug 24, 2027	DP			
IBRUTINIB - IMBRUVICA							
N 205552 001		8497277	Dec 28, 2026	U-1456		I-702	Jan 29, 2018
		8497277	Dec 28, 2026	U-1491		ODE	Jan 29, 2022
		8497277	Dec 28, 2026	U-1650			
		8957079	Dec 28, 2026	DS DP			
		8999999	Jun 03, 2031	U-1683			
		8999999	Jun 03, 2031	U-1684			
	>A>	9125889	Jun 03, 2031	U-1745			
IBUPROFEN - CALDOLOR							
N 022348 002		8871810	Sep 30, 2029	U-1599			
		9012508	Sep 14, 2030	U-981			
	>A>	9114068	Sep 30, 2029	U-1735			
ICATIBANT ACETATE - FIRAZYR							
N 022150 001		5648333	Jul 15, 2019	DS DP U-1187			
IDELALISIB - ZYDELIG							
N 205858 001		8138195	Apr 24, 2021	DS DP U-1549			
		8865730	Mar 05, 2033	DS DP U-1615			
		8980901	May 12, 2025	U-1678			
		RE44599	Jul 21, 2025	U-1558			
		RE44599	Jul 21, 2025	U-1615			
IDELALISIB - ZYDELIG							
N 205858 002		8138195	Apr 24, 2021	DS DP U-1549			
		8865730	Mar 05, 2033	DS DP U-1615			
		8980901	May 12, 2025	U-1678			
		RE44599	Jul 21, 2025	U-1558			
		RE44599	Jul 21, 2025	U-1615			
ILOPERIDONE - FANAPT							
N 022192 001		8652776	Aug 31, 2030	U-1685			
		8999638	Oct 28, 2030	U-1674			
		9072742	Jan 16, 2031	U-1674			
		9074254	Dec 28, 2031	U-1674			
		9074255	Dec 17, 2030	U-1674			
		9074256	Feb 10, 2031	U-1674			
	>A>	9138432	Sep 30, 2025	U-1737			
	>A>	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT							
N 022192 002		8652776	Aug 31, 2030	U-1685			
		8999638	Oct 28, 2030	U-1674			
		9072742	Jan 16, 2031	U-1674			
		9074254	Dec 28, 2031	U-1674			
		9074255	Dec 17, 2030	U-1674			
		9074256	Feb 10, 2031	U-1674			
	>A>	9138432	Sep 30, 2025	U-1737			
	>A>	9157121	Apr 05, 2030	U-1674			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ILOPERIDONE - FANAPT						
N 022192 002	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	>A> 9138432	Sep 30, 2025	U-1737			
	>A> 9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 003	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	>A> 9138432	Sep 30, 2025	U-1737			
	>A> 9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 004	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	>A> 9138432	Sep 30, 2025	U-1737			
	>A> 9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 005	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	>A> 9138432	Sep 30, 2025	U-1737			
	>A> 9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 006	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	>A> 9138432	Sep 30, 2025	U-1737			
	>A> 9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 007	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	>A> 9138432	Sep 30, 2025	U-1737			
	>A> 9157121	Apr 05, 2030	U-1674			
INDACATEROL MALEATE - ARCAPTA NEOHALER						
N 022383 001	8658673	Jun 02, 2020	DS DP U-1168			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INDOMETHACIN - TIVORBEX							
N 204768 001		8992982	Apr 23, 2030	DP			
		9089471	Apr 23, 2030	U-55			
INDOMETHACIN - TIVORBEX							
N 204768 002		8992982	Apr 23, 2030	DP			
		9089471	Apr 23, 2030	U-55			
INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH							
N 020986 005		8920383	Jul 17, 2026	DP			
		9108002	Jan 20, 2026	DP			
		9132239	Feb 01, 2032	DP			
INSULIN DEGLUDEC - RYZODEG 70/30							
N 203313 001	>A>	5866538	Jun 20, 2017	DP		>A> NCE	Sep 25, 2020
	>A>	6899699	Jan 02, 2022	DP			
	>A>	7615532	May 25, 2025	DS DP			
	>A>	7686786	Aug 03, 2026	DP			
	>A>	8672898	Jan 02, 2022	DP			
	>A>	8684969	Oct 20, 2025	DP			
	>A>	8920383	Jul 17, 2026	DP			
	>A>	9108002	Jan 20, 2026	DP			
	>A>	9132239	Feb 01, 2032	DP			
INSULIN DEGLUDEC - TRESIBA							
N 203314 001	>A>	6899699	Jan 02, 2022	DP		>A> NCE	Sep 25, 2020
	>A>	7615532	May 25, 2025	DS DP			
	>A>	7686786	Aug 03, 2026	DP			
	>A>	8672898	Jan 02, 2022	DP			
	>A>	8684969	Oct 20, 2025	DP			
	>A>	8920383	Jul 17, 2026	DP			
	>A>	9108002	Jan 20, 2026	DP			
	>A>	9132239	Feb 01, 2032	DP			
INSULIN DEGLUDEC - TRESIBA							
N 203314 002	>A>	6899699	Jan 02, 2022	DP		>A> NCE	Sep 25, 2020
	>A>	7615532	May 25, 2025	DS DP			
	>A>	7686786	Aug 03, 2026	DP			
	>A>	8672898	Jan 02, 2022	DP			
	>A>	8684969	Oct 20, 2025	DP			
	>A>	8920383	Jul 17, 2026	DP			
	>A>	9108002	Jan 20, 2026	DP			
	>A>	9132239	Feb 01, 2032	DP			
INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH							
N 021536 005		8920383	Jul 17, 2026	DP			
		9108002	Jan 20, 2026	DP			
		9132239	Feb 01, 2032	DP			
INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR							
N 021081 002		8992486	Jun 05, 2024	DP			
		9011391	Mar 26, 2024	DP			
INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR							
N 206538 001		7918833	Sep 23, 2027	DP		NP	Feb 25, 2018
		7918833*PED	Mar 23, 2028				
		8512297	Sep 15, 2024	DP			
		8556864	Mar 03, 2024	DP			
		8603044	Mar 02, 2024	DP			
		8679069	Apr 12, 2025	DP			
		8992486	Jun 05, 2024	DP			
		9011391	Mar 26, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR						
N 021629 003	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN						
N 205747 001	6034054	Jun 11, 2018	DP U-1707			
	6034054	Jun 11, 2018	DP U-1708			
	6551992	Jun 11, 2018	DP U-1707			
	6551992	Jun 11, 2018	DP U-1708			
	7291132	Aug 09, 2024	DP			
INSULIN RECOMBINANT HUMAN - AFREZZA						
N 022472 001	8912193	Jun 12, 2029	DP U-1538			
INSULIN RECOMBINANT HUMAN - AFREZZA						
N 022472 002	7943572	Aug 10, 2026	U-1539			
	8424518	Oct 17, 2031	DP			
	8623817	Sep 18, 2029	U-1537			
	8912193	Jun 12, 2029	DP U-1538			
INSULIN RECOMBINANT HUMAN - AFREZZA						
N 022472 003	6444226	Jun 29, 2020	DP U-1534		NP	Jun 27, 2017
	6652885	Jun 29, 2020	U-1535			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP U-1697			
	8394414	May 15, 2015	DP U-1533			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Jun 06, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			
IPRATROPIUM BROMIDE - ATROVENT HFA						
N 021527 001	8474447	Jan 17, 2030	DP			
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207500 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207501 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ISOTRETINOIN - ABSORICA							
N 021951 001		8952064	Sep 21, 2021	DP			
		9078925	Sep 21, 2021	DP			
	>A>	9089534	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA							
N 021951 002		8952064	Sep 21, 2021	DP			
		9078925	Sep 21, 2021	DP			
	>A>	9089534	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA							
N 021951 003		8952064	Sep 21, 2021	DP			
		9078925	Sep 21, 2021	DP			
	>A>	9089534	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA							
N 021951 004		8952064	Sep 21, 2021	DP			
		9078925	Sep 21, 2021	DP			
	>A>	9089534	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA							
N 021951 005		7435427	Sep 21, 2021	DP			
		8367102	Sep 21, 2021	U-1347			
		8952064	Sep 21, 2021	DP			
		9078925	Sep 21, 2021	DP			
	>A>	9089534	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA							
N 021951 006		7435427	Sep 21, 2021	DP			
		8367102	Sep 21, 2021	U-1347			
		8952064	Sep 21, 2021	DP			
		9078925	Sep 21, 2021	DP			
	>A>	9089534	Sep 21, 2021	DP			
IVABRADINE HYDROCHLORIDE - CORLANOR							
N 206143 001		7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
		7361650	Apr 14, 2026	DS DP U-1694			
		7867996	Feb 22, 2026	DS DP U-1694			
		7879842	Feb 22, 2026	DS DP U-1694			
IVABRADINE HYDROCHLORIDE - CORLANOR							
N 206143 002		7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
		7361650	Apr 14, 2026	DS DP U-1694			
		7867996	Feb 22, 2026	DS DP U-1694			
		7879842	Feb 22, 2026	DS DP U-1694			
IVACAFTOR - KALYDECO							
N 203188 001		8354427	Jul 06, 2026	U-1311		I-705	Dec 30, 2017
IVACAFTOR - KALYDECO							
N 207925 001		7495103	May 20, 2027	DS DP			
		8324242	Apr 18, 2027	U-1311			
		8354427	Jul 06, 2026	U-1311			
		8410274	Dec 28, 2026	DP			
		8754224	Dec 28, 2026	DS DP			
		8883206	Feb 27, 2033	DP			
IVACAFTOR - KALYDECO							
N 207925 002		7495103	May 20, 2027	DS DP			
		8324242	Apr 18, 2027	U-1311			
		8354427	Jul 06, 2026	U-1311			
		8410274	Dec 28, 2026	DP			
		8754224	Dec 28, 2026	DS DP			
		8883206	Feb 27, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR - KALYDECO						
N 207925 002	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 206038 001	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
	8324242	Apr 18, 2027	U-1311		ODE	Jul 02, 2022
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Nov 08, 2026	DP U-1718			
	8741933	Nov 08, 2026	U-1717			
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028	U-1717			
	8993600	Dec 11, 2030	DP			
IVERMECTIN - SOOLANTRA						
N 206255 001	5952372	Sep 18, 2018	U-1631			
	6133310	Apr 26, 2019	U-1631			
	7550440	Apr 22, 2024	DP U-1631			
	8080530	Apr 22, 2024	DP U-1631			
	8093219	Apr 22, 2024	DP U-1631			
	8415311	Apr 22, 2024	DP U-1631			
	8470788	Apr 22, 2024	DP U-1631			
	8815816	Apr 22, 2024	DP U-1631			
	9089587	Mar 13, 2034	U-1631			
KETOROLAC TROMETHAMINE - ACULAR LS						
N 021528 001	8946281	May 28, 2024	U-1662			
KETOROLAC TROMETHAMINE - ACUVAIL						
N 022427 001	8992952	Aug 05, 2024	DP			
KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA						
N 205388 001	9066856	Oct 23, 2033	DP			
LAMIVUDINE - LAMIVUDINE						
A 203564 001					PC	Sep 01, 2015
LAMIVUDINE - EPIVIR						
N 020564 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
LAMIVUDINE - EPIVIR						
N 020564 003	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
LAMIVUDINE - EPIVIR						
N 020596 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	6004968	Mar 20, 2018	DP U-248			
	6004968*PED	Sep 20, 2018				
LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022	U-1663			
	7435734	Oct 21, 2022	U-1663			
	7754731	Mar 11, 2029	DS DP U-1663			
	7820660	Apr 25, 2023	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAMOTRIGINE - LAMOTRIGINE						
A 200828 001					PC	Sep 28, 2015
LAMOTRIGINE - LAMOTRIGINE						
A 200828 002					PC	Sep 28, 2015
LAMOTRIGINE - LAMOTRIGINE						
A 200828 003					PC	Sep 28, 2015
LAMOTRIGINE - LAMOTRIGINE						
A 200828 004					PC	Sep 28, 2015
LAMOTRIGINE - LAMICTAL						
N 020241 001					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 002					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 003					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 004					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 005					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 006					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL CD						
N 020764 001					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL CD						
N 020764 002					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL CD						
N 020764 003					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL CD						
N 020764 004					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL ODT						
N 022251 001					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL ODT						
N 022251 002					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL ODT						
N 022251 003					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL ODT						
N 022251 004					M-159	May 18, 2018
LANTHANUM CARBONATE - FOSRENOL						
N 204734 001	8980327	Dec 01, 2030	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 204734 002	8980327	Dec 01, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAPATINIB DITOSYLATE - TYKERB						
N 022059 001	8821927	Sep 18, 2029	DS DP			
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 205834 001	9085573	Mar 21, 2028	DS DP U-1470			
LENALIDOMIDE - REVLIMID						
N 021880 001	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N 021880 002	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N 021880 003	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N 021880 004	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N 021880 005	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID						
N 021880 006	5635517	Oct 04, 2019	DS U-1211		I-706	Feb 17, 2018
	9056120	Apr 11, 2023	U-1215		ODE	Feb 17, 2022
	9101621	May 15, 2023	U-1216			
	9101622	May 15, 2023	U-1216			
LENVATINIB MESYLATE - LENVIMA						
N 206947 001	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027	U-1695			
LENVATINIB MESYLATE - LENVIMA						
N 206947 002	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027	U-1695			
LEUPROLIDE ACETATE - LUPRON DEPOT						
N 020517 003	7429559	Jan 13, 2019	DP			
	8815801	Jun 28, 2022	DP			
	8921326	Feb 05, 2031	DP U-1666			
LEVALBUTEROL HYDROCHLORIDE - XOPENEX						
N 020837 001					M-151	Jan 22, 2018
LEVALBUTEROL HYDROCHLORIDE - XOPENEX						
N 020837 002					M-151	Jan 22, 2018
LEVALBUTEROL HYDROCHLORIDE - XOPENEX						
N 020837 003					M-151	Jan 22, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVALBUTEROL HYDROCHLORIDE - XOPENEX						
N 020837 004					M-151	Jan 22, 2018
LEVALBUTEROL TARTRATE - XOPENEX HFA						
N 021730 001					M-156	Mar 12, 2018
LEVETIRACETAM - SPRITAM						
N 207958 001	6471992	Feb 20, 2018	DP			
LEVETIRACETAM - SPRITAM						
N 207958 002	6471992	Feb 20, 2018	DP			
LEVETIRACETAM - SPRITAM						
N 207958 003	6471992	Feb 20, 2018	DP			
LEVETIRACETAM - SPRITAM						
N 207958 004	6471992	Feb 20, 2018	DP			
LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM						
A 203563 001					PC	Oct 20, 2015
LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM						
A 203563 002					PC	Oct 20, 2015
LEVONORGESTREL - LILETTA						
N 206229 001					NP	Feb 26, 2018
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 202231 001	9006289	Oct 03, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 202231 002	9006289	Oct 03, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 202231 003	9006289	Oct 03, 2032	DP			
LINACLOTIDE - LINZESS						
N 202811 001	8933030	Feb 17, 2031	DP			
LINACLOTIDE - LINZESS						
N 202811 002	8933030	Feb 17, 2031	DP			
LINAGLIPTIN - TRADJENTA						
N 201280 001	8673927	May 04, 2027	U-1503			
	8853156	Mar 05, 2031	U-1642			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 001	8673927	May 04, 2027	U-1503			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 002	8673927	May 04, 2027	U-1503			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 003	8673927	May 04, 2027	U-1503			
LINEZOLID - LINEZOLID						
A 078061 001					PC	Dec 19, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINEZOLID - LINEZOLID							
A 200222	001					PC	Jul 04, 2015
LINEZOLID - ZYVOX							
N 021131	002	6559305	Jan 29, 2021	DS			
		6559305*PED	Jul 29, 2021				
LINEZOLID - ZYVOX							
N 021131	003	6559305	Jan 29, 2021	DS			
		6559305*PED	Jul 29, 2021				
LIRAGLUTIDE RECOMBINANT - VICTOZA							
N 022341	001	8846618	Jun 27, 2022	DP			
LIRAGLUTIDE RECOMBINANT - SAXENDA							
N 206321	001	6268343	Aug 22, 2022	DS DP U-1255			
		6458924	Aug 22, 2017	DS DP U-1255			
		6899699	Jan 01, 2022	DP			
		7235627	Aug 22, 2017	DS DP			
		7686786	Aug 03, 2026	DP			
		8114833	Aug 13, 2025	DP			
		8672898	Jan 02, 2022	DP			
		8684969	Oct 20, 2025	DP			
		8846618	Jun 27, 2022	DP			
		8920383	Jul 17, 2026	DP			
	>A>	9108002	Jan 26, 2026	DP			
	>A>	9132239	Feb 01, 2032	DP			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 021977	001	>A> 7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
		>A> 7223735	Feb 24, 2023	DP			
		>A> 7671031	Feb 24, 2023	U-727			
		>A> 7674774	Feb 24, 2023	DP U-842			
		>A> 7678770	Feb 24, 2023	U-842			
		>A> 7678771	Feb 24, 2023	DP U-842			
		>A> 7687467	Feb 24, 2023	DP U-842			
		>A> 7700561	Feb 24, 2023	DP			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 021977	002	>A> 7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
		>A> 7223735	Feb 24, 2023	DP			
		>A> 7671031	Feb 24, 2023	U-727			
		>A> 7674774	Feb 24, 2023	DP U-842			
		>A> 7678770	Feb 24, 2023	U-842			
		>A> 7678771	Feb 24, 2023	DP U-842			
		>A> 7687467	Feb 24, 2023	DP U-842			
		>A> 7700561	Feb 24, 2023	DP			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 021977	003	>A> 7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
		>A> 7223735	Feb 24, 2023	DP			
		>A> 7671031	Feb 24, 2023	U-727			
		>A> 7674774	Feb 24, 2023	DP U-842			
		>A> 7678770	Feb 24, 2023	U-842			
		>A> 7678771	Feb 24, 2023	DP U-842			
		>A> 7687467	Feb 24, 2023	DP U-842			
		>A> 7700561	Feb 24, 2023	DP			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 021977	004	>A> 7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
		>A> 7105486	Feb 24, 2023	U-842			
		>A> 7223735	Feb 24, 2023	DP			
		>A> 7671031	Feb 24, 2023	U-727			
		>A> 7674774	Feb 24, 2023	DP U-842			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 021977	004	>A> 7678770	Feb 24, 2023	U-842			
		>A> 7678771	Feb 24, 2023	DP U-842			
		>A> 7687467	Feb 24, 2023	DP U-842			
		>A> 7700561	Feb 24, 2023	DP			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 021977	005	>A> 7105486	Feb 24, 2023	U-842		I-703	Jan 30, 2018
		>A> 7671031	Feb 24, 2023	U-727			
		>A> 7674774	Feb 24, 2023	DP U-842			
		>A> 7678770	Feb 24, 2023	U-842			
		>A> 7678771	Feb 24, 2023	DP U-842			
		>A> 7687467	Feb 24, 2023	DP U-842			
		>A> 7700561	Feb 24, 2023	DP			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 021977	006	>A> 7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
		>A> 7105486	Feb 24, 2023	U-842			
		>A> 7223735	Feb 24, 2023	DP			
		>A> 7671031	Feb 24, 2023	U-727			
		>A> 7674774	Feb 24, 2023	DP U-842			
		>A> 7678770	Feb 24, 2023	U-842			
		>A> 7678771	Feb 24, 2023	DP U-842			
		>A> 7687467	Feb 24, 2023	DP U-842			
		>A> 7700561	Feb 24, 2023	DP			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 021977	007	>A> 7223735	Feb 24, 2023	DP		I-703	Jan 30, 2018
		>A> 7655630	Feb 24, 2023	DS			
		>A> 7659253	Feb 24, 2023	DS DP U-727			
		>A> 7659254	Feb 24, 2023	U-1034			
		>A> 7662787	Feb 24, 2023	DS			
		>A> 7662788	Feb 24, 2023	U-727			
		>A> 7671030	Feb 24, 2023	DP U-727			
		>A> 7671031	Feb 24, 2023	U-727			
		>A> 7674774	Feb 24, 2023	DP U-842			
		>A> 7678770	Feb 24, 2023	U-842			
		>A> 7678771	Feb 24, 2023	DP			
		>A> 7687466	Feb 24, 2023	DP			
		>A> 7687467	Feb 24, 2023	DP U-842			
		>A> 7700561	Feb 24, 2023	DP			
		>A> 7713936	Feb 24, 2023	U-727			
		>A> 7718619	Feb 24, 2023	DP U-842			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	001	5712279	Feb 21, 2016	DS U-1317			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	002	5712279	Feb 21, 2016	DS U-1317			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	003	5712279	Feb 21, 2016	DS U-1317			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	004	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
		6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
		7932268	Aug 19, 2027	U-1316			
		8618135	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	005	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
		6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
		7932268	Aug 19, 2027	U-1316			
		8618135	Mar 07, 2025	U-1316			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 005	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 006	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
LORATADINE - CLARITIN						
N 020641 002	6132758	Jun 01, 2018	DP			
LORCASERIN HYDROCHLORIDE - BELVIQ						
N 022529 001	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			
	8980881	Dec 20, 2025	U-1255			
	8999970	Feb 07, 2033	U-1688			
	8999970	Feb 07, 2033	U-1689			
	8999970	Feb 07, 2033	U-1692			
LOXAPINE - ADASUVE						
N 022549 001	8955512	Oct 26, 2021	DP			
	8991387	May 21, 2024	DP			
LULICONAZOLE - LUZU						
N 204153 001	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP U-540			
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 001	RE45573	Jun 23, 2025	DS			
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 002	RE45573	Jun 23, 2025	DS			
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 003	RE45573	Jun 23, 2025	DS			
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 004	RE45573	Jun 23, 2025	DS			
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 005	RE45573	Jun 23, 2025	DS			
MEGESTROL ACETATE - MEGACE ES						
N 021778 001	9040088	Apr 22, 2024	U-755			
	9101540	Apr 22, 2024	DP U-755			
	9101549	Apr 22, 2024	U-755			
	9107827	Apr 22, 2024	U-755			
MESALAMINE - ASACOL HD						
N 021830 001 >A>	9089492	Nov 15, 2021	DP			
MESALAMINE - APRISO						
N 022301 001	8940328	Apr 20, 2018	DP			
	8956647	Apr 20, 2018	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET							
N 021842 001		9101660	Jan 22, 2027	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET							
N 021842 002		9101660	Jan 22, 2027	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR							
N 022024 001		9060941	Sep 19, 2023	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR							
N 022024 002		9060941	Sep 19, 2023	DP			
METHOTREXATE - OTREXUP							
N 204824 001		8945063	Mar 19, 2030	DP		U-1442	
METHOTREXATE - OTREXUP							
N 204824 002		8945063	Mar 19, 2030	DP		U-1442	
METHOTREXATE - OTREXUP							
N 204824 003		8945063	Mar 19, 2030	DP		U-1442	
METHOTREXATE - OTREXUP							
N 204824 004		8945063	Mar 19, 2030	DP		U-1442	
METHOTREXATE - OTREXUP							
N 204824 005		8945063	Mar 19, 2030	DP		U-1442	
METHYLPHENIDATE - DAYTRANA							
N 021514 001		9034370	Oct 07, 2025	DP			
METHYLPHENIDATE - DAYTRANA							
N 021514 002		9034370	Oct 07, 2025	DP			
METHYLPHENIDATE - DAYTRANA							
N 021514 003		9034370	Oct 07, 2025	DP			
METHYLPHENIDATE - DAYTRANA							
N 021514 004		9034370	Oct 07, 2025	DP			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA							
N 021121 001		9000038	Jul 31, 2017			U-666	
		9000038	Jul 31, 2017			U-1693	
		9000038*PED	Jan 31, 2018				
		9029416	Jul 31, 2017	DP		U-666	
	>A>	9144549	Jul 31, 2017			U-1747	
	>A>	9144549	Jul 31, 2017			U-1748	
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA							
N 021121 002		9000038	Jul 31, 2017			U-666	
		9000038	Jul 31, 2017			U-1693	
		9000038*PED	Jan 31, 2018				
		9029416	Jul 31, 2017	DP		U-666	
	>A>	9144549	Jul 31, 2017			U-1747	
	>A>	9144549	Jul 31, 2017			U-1748	
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA							
N 021121 003		9000038	Jul 31, 2017			U-666	
		9000038	Jul 31, 2017			U-1693	
		9000038*PED	Jan 31, 2018				
		9029416	Jul 31, 2017	DP		U-666	
	>A>	9144549	Jul 31, 2017			U-1747	
	>A>	9144549	Jul 31, 2017			U-1748	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA							
N 021121 003		9000038	Jul 31, 2017	U-666			
		9000038	Jul 31, 2017	U-1693			
		9000038*PED	Jan 31, 2018				
		9029416	Jul 31, 2017	DP U-666			
	>A>	9144549	Jul 31, 2017	U-1747			
	>A>	9144549	Jul 31, 2017	U-1748			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA							
N 021121 004		9000038	Jul 31, 2017	U-666			
		9000038	Jul 31, 2017	U-1693			
		9000038*PED	Jan 31, 2018				
		9029416	Jul 31, 2017	DP U-666			
	>A>	9144549	Jul 31, 2017	U-1747			
	>A>	9144549	Jul 31, 2017	U-1748			
METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR							
N 202100 001		8956649	Feb 15, 2031	DP U-1665			
		9040083	Feb 15, 2031	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831 001		6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
		8580310	Dec 16, 2019	DP			
		9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831 002		6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
		8580310	Dec 16, 2019	DP			
		9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831 003		6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
		8580310	Dec 16, 2019	DP			
		9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831 004		6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
		8580310	Dec 16, 2019	DP			
		9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831 005		6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
		8580310	Dec 16, 2019	DP			
		9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831 006		6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR						
N 205831 006	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR						
N 205831 007	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
METRONIDAZOLE - NUVESSA						
N 205223 001	7893097	Feb 19, 2028	DP			
	8658678	Jun 27, 2028	U-1682			
	8877792	Feb 02, 2028	DP			
	8946276	Jun 28, 2032	U-1664			
MIFEPRISTONE - KORLYM						
N 202107 001	8921348	Aug 27, 2028	U-1643			
MINOCYCLINE HYDROCHLORIDE - MINOCIN						
N 050444 001	9084802	May 12, 2031	U-282			
MINOCYCLINE HYDROCHLORIDE - ARESTIN						
N 050781 001	7699609	Mar 29, 2022	DP			
MINOXIDIL - WOMEN'S ROGAINE						
N 021812 002	6946120	Apr 20, 2019	DP U-702			
MORPHINE SULFATE - MORPHINE SULFATE						
N 204223 001	9072781	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE						
N 204223 002	9072781	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE						
N 204223 003	9072781	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE						
N 204223 004	9072781	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE						
N 204223 005	9072781	Mar 12, 2034	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 001	8623418	Nov 07, 2029	U-1640			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 002	8623418	Nov 07, 2029	U-1640			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 003	8623418	Nov 07, 2029	U-1640			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 004	8623418	Nov 07, 2029	U-1640			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 005	8623418	Nov 07, 2029	U-1640			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 006	8623418	Nov 07, 2029	U-1640			
MOXIFLOXACIN HYDROCHLORIDE - MOXEZA						
N 022428 001	9114168	May 29, 2029	DP			
NALOXEGOL OXALATE - MOVANTIK						
N 204760 001	7056500	Jun 29, 2024	DP U-1185			
	9012469	Apr 02, 2032	DS DP			
NALOXEGOL OXALATE - MOVANTIK						
N 204760 002	7056500	Jun 29, 2024	DP U-1185			
	9012469	Apr 02, 2032	DS DP			
NALOXONE HYDROCHLORIDE - EVZIO						
N 205787 001	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ						
N 205777 001	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ						
N 205777 002	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ						
N 205777 003	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET						
N 021926 001	6060499	Aug 14, 2017	DP U-867			
	6060499*PED	Feb 14, 2018				
	6586458	Aug 14, 2017	DP U-867			
	6586458*PED	Feb 14, 2018				
	7332183	Oct 02, 2025	DP U-867			
	7332183*PED	Apr 02, 2026				
	8022095	Aug 14, 2017	DP U-867			
	8022095*PED	Feb 14, 2018				
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET						
N 021926 002	5872145	Aug 14, 2017	DP U-1719		NP	May 14, 2018
	5872145*PED	Feb 14, 2018			PED	Nov 14, 2018
	6060499	Aug 14, 2017	DP U-1719			
	6060499*PED	Feb 14, 2018				
	6586458	Aug 14, 2017	DP U-1719			
	6586458*PED	Feb 14, 2018				
	7332183	Oct 02, 2025	DP U-1719			
	7332183*PED	Apr 02, 2026				
NEPAFENAC - ILEVRO						
N 203491 001	8921337	Mar 31, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO						
N 205718 001	8951969	Nov 18, 2030	DP			
NICOTINE - NICODERM CQ						
N 020165 004	8999379	Feb 13, 2020	U-1686			
NICOTINE - NICODERM CQ						
N 020165 005	8999379	Feb 13, 2020	U-1686			
NICOTINE - NICODERM CQ						
N 020165 006	8999379	Feb 13, 2020	U-1686			
NICOTINE POLACRILEX - NICORETTE						
N 022360 001	8940772	Apr 30, 2029	DP			
NICOTINE POLACRILEX - NICORETTE						
N 022360 002	8940772	Apr 30, 2029	DP			
NINTEDANIB ESYLATE - OFEV						
N 205832 001	7989474	Apr 06, 2024	U-1677			
NINTEDANIB ESYLATE - OFEV						
N 205832 002	7989474	Apr 06, 2024	U-1677			
OLAPARIB - LYNPARZA						
N 206162 001	7151102	Apr 29, 2022	DS DP		ODE	Dec 19, 2021
	7449464	Oct 11, 2024	DS DP			
	7981889	Oct 11, 2024	DS DP			
	8143241	Aug 12, 2027	U-1634			
	8247416	Sep 24, 2028	DS			
	8859562	Aug 04, 2031	U-1634			
	8912187	Mar 12, 2024	U-1634			
OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT						
N 203108 001	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT						
N 206756 001	5964416	Oct 04, 2016	DP		NC	May 21, 2018
	6149054	Dec 19, 2016	DP		NCE	Jul 31, 2019
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7056916	Dec 07, 2023	DS DP			
	7104470	Oct 04, 2016	DP			
	7220742	May 12, 2025	DS DP U-1703			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025	U-1702			
	8044046	Nov 10, 2023	U-1702			
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP U-1702			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT						
N 206756 001	5964416	Oct 04, 2016	DP		NC	May 21, 2018
	6149054	Dec 19, 2016	DP		NCE	Jul 31, 2019
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7056916	Dec 07, 2023	DS DP			
	7104470	Oct 04, 2016	DP			
	7220742	May 12, 2025	DS DP U-1703			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025	U-1702			
	8044046	Nov 10, 2023	U-1702			
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP U-1702			
OLOPATADINE HYDROCHLORIDE - PAZEO						
N 206276 001	8791154	May 19, 2032	DP U-1680		NP	Jan 30, 2018
					PED	Jul 30, 2018
OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE						
N 207931 001	6037157	Jun 26, 2016	U-1635		NCE	Dec 19, 2019
	6037157*PED	Dec 26, 2016			NP	Jul 24, 2018
	6703403	Jun 26, 2016	U-1635			
	6703403*PED	Dec 26, 2016				
	7148359	Jul 19, 2019	DP			
	7148359*PED	Jan 19, 2020				
	7364752	Nov 10, 2020	DP			
	7364752*PED	May 10, 2021				
	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8420596	Apr 10, 2031	DS DP			
	8420596*PED	Oct 10, 2031				
	8642538	Sep 10, 2029	DS DP U-1638			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
OMEGA-3-CARBOXYLIC ACIDS - EPANOVA						
N 205060 001	9012501	Feb 07, 2025	DP U-1511			
	9050308	Jan 04, 2033	U-1511			
	9050309	Jan 04, 2033	DS			
>A>	9132112	Feb 07, 2025	DP U-1511			
OMEPRAZOLE - OMEPRAZOLE						
N 022032 001	9023391	Aug 16, 2025	DP			
ONDANSETRON - ZUPLENZ						
N 022524 001	9095577	Jul 13, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ONDANSETRON - ZUPLENZ						
N 022524 002	9095577	Jul 13, 2030	DP			
OSPEMIFENE - OSPHENA						
N 203505 001	8642079	Jul 09, 2028	DP			
OXCARBAZEPINE - OXTELLAR XR						
N 202810 001	9119791	Apr 13, 2027	U-1298			
OXCARBAZEPINE - OXTELLAR XR						
N 202810 002	9119791	Apr 13, 2027	U-1298			
OXCARBAZEPINE - OXTELLAR XR						
N 202810 003	9119791	Apr 13, 2027	U-1298			
OXYBUTYNIN CHLORIDE - GELNIQUE						
N 022204 001	8920392	Mar 26, 2031	U-1644			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 001	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 002	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 003	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 004	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 005	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 006	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 007	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
PACLITAXEL - ABRAXANE						
N 021660 001	9101543	Feb 21, 2026	U-1434			
PALBOCICLIB - IBRANCE						
N 207103 001	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
PALBOCICLIB - IBRANCE						
N 207103 002	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALBOCICLIB - IBRANCE						
N 207103 003	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 001	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 002	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 003	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
PALIPERIDONE PALMITATE - INVEGA TRINZA						
N 207946 004	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
PALONOSETRON HYDROCHLORIDE - ALOXI						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
	9125905	Jan 30, 2024	DP			
PALONOSETRON HYDROCHLORIDE - ALOXI						
N 021372 002	9125905	Jan 30, 2024	DP			
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 001	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 002	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 003	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
PAROXETINE MESYLATE - BRISDELLE						
N 204516 001	8946251	Aug 04, 2026	DS DP U-904			
PERAMPANEL - FYCOMPA						
N 202834 001					I-710	Jun 19, 2018
PERAMPANEL - FYCOMPA						
N 202834 002					I-710	Jun 19, 2018
PERAMPANEL - FYCOMPA						
N 202834 003					I-710	Jun 19, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PERAMPANEL - FYCOMPA						
N 202834 004					I-710	Jun 19, 2018
PERAMPANEL - FYCOMPA						
N 202834 005					I-710	Jun 19, 2018
PERAMPANEL - FYCOMPA						
N 202834 006					I-710	Jun 19, 2018
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 001	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 002	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 003	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 004	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PIRFENIDONE - ESBRIET						
N 022535 001	7696236	Dec 18, 2027	U-1601			
POLIDOCANOL - VARITHENA						
N 205098 001 >A>	RE40640	Oct 14, 2016	DS DP U-1462			
POMALIDOMIDE - POMALYST						
N 204026 001					I-707	Apr 23, 2018
POMALIDOMIDE - POMALYST						
N 204026 002					I-707	Apr 23, 2018
POMALIDOMIDE - POMALYST						
N 204026 003					I-707	Apr 23, 2018
POMALIDOMIDE - POMALYST						
N 204026 004					I-707	Apr 23, 2018
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 001	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 002	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 003	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PONATINIB HYDROCHLORIDE - ICLUSIG							
N 203469 003		9029533	Dec 22, 2026	U-1701			
POSACONAZOLE - NOXAFIL							
N 205596 001		9023790	Jul 04, 2031	DP U-1698			
PREDNISONE - RAYOS							
N 202020 001		9040085	Apr 23, 2024	U-1362			
PREDNISONE - RAYOS							
N 202020 002		9040085	Apr 23, 2024	U-1362			
PREDNISONE - RAYOS							
N 202020 003		9040085	Apr 23, 2024	U-1362			
REGADENOSON - LEXISCAN							
N 022161 001		9045519	Jun 22, 2019	DP			
		9085601	Feb 02, 2027	DP			
REGORAFENIB - STIVARGA							
N 203085 001		8637553	Feb 16, 2031	DS DP			
		8680124	Jun 02, 2030	U-1506			
RIFAXIMIN - XIFAXAN							
N 022554 001		6861053	Aug 11, 2019	U-1707		I-709	May 27, 2018
		6861053	Aug 11, 2019	U-1708			
		7452857	Aug 11, 2019	U-1707			
		7452857	Aug 11, 2019	U-1708			
		7605240	Aug 11, 2019	U-1707			
		7605240	Aug 11, 2019	U-1708			
		7718608	Aug 11, 2019	U-1707			
		7718608	Aug 11, 2019	U-1708			
		7915275	Feb 23, 2025	U-1707			
		7915275	Feb 23, 2025	U-1708			
		7935799	Aug 11, 2019	U-1707			
		7935799	Aug 11, 2019	U-1708			
		8193196	Sep 02, 2027	DS DP U-1707			
		8193196	Sep 02, 2027	DS DP U-1708			
		8309569	Jul 18, 2029	U-1707			
		8309569	Jul 18, 2029	U-1708			
		8741904	Feb 27, 2026	DS U-1526			
		8741904	Feb 27, 2026	DS U-1707			
		8741904	Feb 27, 2026	DS U-1708			
		8946252	Jul 24, 2029	U-1481			
		8969398	Oct 02, 2029	U-1481			
RILPIVIRINE HYDROCHLORIDE - EDURANT							
N 202022 001	>A>	7125879	Apr 14, 2023	DS DP U-1153		NPP	Aug 26, 2018
	>A>	7125879	Apr 14, 2023	DS DP U-1307			
	>A>	7125879	Apr 14, 2023	DS DP U-1740			
RISEDRONATE SODIUM - RISEDRONATE SODIUM							
A 077132 001						PC	Nov 28, 2015
RISEDRONATE SODIUM - RISEDRONATE SODIUM							
A 077132 002						PC	Nov 28, 2015
RISEDRONATE SODIUM - RISEDRONATE SODIUM							
A 077132 003						PC	Nov 28, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIVASTIGMINE - RIVASTIGMINE							
A 204403	003					PC	Feb 29, 2016
ROFLUMILAST - DALIRESP							
N 022522	001	5712298	Jan 27, 2020	DS DP U-1115			
ROLAPITANT HYDROCHLORIDE - VARUBI							
N 206500	001	>A> 7049230	Dec 08, 2023	DS DP U-1741		>A> NCE	Sep 01, 2020
		>A> 7563801	Apr 04, 2027	DP			
		>A> 7981905	Apr 04, 2027	U-1741			
		>A> 7981905	Apr 04, 2027	U-1742			
		>A> 8178550	Apr 04, 2027	DS DP			
		>A> 8361500	Oct 09, 2029	DP			
		>A> 8404702	Oct 09, 2029	U-1741			
		>A> 8470842	Jan 18, 2029	U-1741			
		>A> 8796299	Dec 17, 2022	U-1741			
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192	001	9079912	Dec 12, 2026	U-1573			
		9079912	Dec 12, 2026	U-1721			
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192	002	9079912	Dec 12, 2026	U-1573			
		9079912	Dec 12, 2026	U-1721			
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192	003	9079912	Dec 12, 2026	U-1573			
		9079912	Dec 12, 2026	U-1721			
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192	004	9079912	Dec 12, 2026	U-1573			
		9079912	Dec 12, 2026	U-1721			
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192	005	9079912	Dec 12, 2026	U-1573			
		9079912	Dec 12, 2026	U-1721			
SACUBITRIL; VALSARTAN - ENTRESTO							
N 207620	001	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
		8101659	Jan 14, 2023	DP			
		8404744	Jan 14, 2023	DP			
		8796331	Jan 14, 2023	U-1723			
		8877938	May 27, 2027	DS DP			
SACUBITRIL; VALSARTAN - ENTRESTO							
N 207620	002	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
		8101659	Jan 14, 2023	DP			
		8404744	Jan 14, 2023	DP			
		8796331	Jan 14, 2023	U-1723			
		8877938	May 27, 2027	DS DP			
SACUBITRIL; VALSARTAN - ENTRESTO							
N 207620	003	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
		8101659	Jan 14, 2023	DP			
		8404744	Jan 14, 2023	DP			
		8796331	Jan 14, 2023	U-1723			
		8877938	May 27, 2027	DS DP			
SIMEPREVIR SODIUM - OLYSIO							
N 205123	001	9040562	Jul 28, 2026	DS DP U-1467			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SIROLIMUS - RAPAMUNE						
N 021083 001					ODE	May 28, 2022
SIROLIMUS - RAPAMUNE						
N 021110 001					ODE	May 28, 2022
SIROLIMUS - RAPAMUNE						
N 021110 002					ODE	May 28, 2022
SIROLIMUS - RAPAMUNE						
N 021110 003					ODE	May 28, 2022
SIROLIMUS - RAPAMUNE						
N 021110 004					ODE	May 28, 2022
SODIUM OXYBATE - XYREM						
N 021196 001	8952062	Dec 22, 2019	U-1101			
	8952062	Dec 22, 2019	U-1102			
	9050302	Mar 15, 2033	U-1532			
SOFOSBUVIR - SOVALDI						
N 204671 001	9085573	Mar 21, 2028	DS DP U-1470			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO						
N 021148 008	8920383	Jul 17, 2026	DP			
>A>	9108002	Jan 20, 2026	DP			
>A>	9132239	Feb 01, 2032	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO						
N 021148 009	8920383	Jul 17, 2026	DP			
>A>	9108002	Jan 20, 2026	DP			
>A>	9132239	Feb 01, 2032	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO						
N 021148 010	8920383	Jul 17, 2026	DP			
>A>	9108002	Jan 20, 2026	DP			
>A>	9132239	Feb 01, 2032	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO						
N 021148 011	5849700	Dec 15, 2015	U-1041			
	5849704	Dec 15, 2015	DS DP U-1041			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
	8920383	Jul 17, 2026	DP			
>A>	9108002	Jan 20, 2026	DP			
>A>	9132239	Feb 01, 2032	DP			
SONIDEGIB PHOSPHATE - ODOMZO						
N 205266 001	8063043	Sep 15, 2029	DS DP		NCE	Jul 24, 2020
	8178563	Feb 06, 2029	DS U-1722			
SORAFENIB TOSYLATE - NEXAVAR						
N 021923 001	8124630	Jan 12, 2020	U-1459			
	8841330	Jan 12, 2020	U-1696			
SPINOSAD - NATROBA						
N 022408 001	6063771	Jul 25, 2023	DP U-1670		M-152	Nov 30, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SUMATRIPTAN SUCCINATE - ZECUITY							
N 202278 001		8983594	Nov 19, 2030	DP U-1328			
TACROLIMUS - ENVARSUS XR							
N 206406 001		7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
TACROLIMUS - ENVARSUS XR							
N 206406 002		7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
TACROLIMUS - ENVARSUS XR							
N 206406 003		7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533 001	>A>	8536130	Sep 22, 2028	U-1739			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533 002	>A>	8536130	Sep 22, 2028	U-1739			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533 003	>A>	8536130	Sep 22, 2028	U-1739			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533 004	>A>	8536130	Sep 22, 2028	U-1739			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533 005	>A>	8536130	Sep 22, 2028	U-1739			
TASIMELTEON - HETLIOZ							
N 205677 001		9060995	Jan 25, 2033	U-1710			
TEDUGLUTIDE RECOMBINANT - GATTEX KIT							
N 203441 001		5789379	Apr 14, 2016	DS DP U-1320			
		9060992	Nov 01, 2025	U-1320			
TESTOSTERONE - ANDROGEL							
N 021015 001		9125816	Aug 30, 2020	U-490			
	>A>	9132089	Aug 30, 2020	U-490			
TESTOSTERONE - ANDROGEL							
N 021015 002		9125816	Aug 30, 2020	U-490			
	>A>	9132089	Aug 30, 2020	U-490			
TESTOSTERONE - ANDROGEL							
N 021015 003		9125816	Aug 30, 2020	U-490			
	>A>	9132089	Aug 30, 2020	U-490			
TESTOSTERONE - ANDROGEL							
N 022309 001		9125816	Aug 30, 2020	U-1103			
	>A>	9132089	Aug 30, 2020	U-1103			
TESTOSTERONE - ANDROGEL							
N 022309 002		9125816	Aug 30, 2020	U-1103			
	>A>	9132089	Aug 30, 2020	U-1103			
TESTOSTERONE - ANDROGEL							
N 022309 003		9125816	Aug 30, 2020	U-1103			
	>A>	9132089	Aug 30, 2020	U-1103			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE - AXIRON							
N 022504 001		8435944	Sep 27, 2027	U-1390			
		8993520	Jun 02, 2026	U-1390			
TICAGRELOR - BRILINTA							
N 022433 001						>A> I-714	Sep 03, 2018
TICAGRELOR - BRILINTA							
N 022433 002	>A>	6251910	Jul 15, 2018	DS		>A> NS	Sep 03, 2018
	>A>	6525060	Dec 02, 2019	DS DP U-1171			
	>A>	7250419	Dec 02, 2019	DS DP U-1171			
	>A>	7265124	Jul 09, 2021	DS DP U-1171			
	>A>	8425934	Apr 17, 2017	DP			
TIGECYCLINE - TYGACIL							
N 021821 001		8975242	Oct 24, 2028	DP			
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT							
N 021936 001		8733341	Dec 16, 2029	DP			
		9027967	Mar 31, 2027	DP			
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT							
N 021936 002	>A>	5964416	Oct 04, 2016	DP		>A> NP	Sep 15, 2018
	>A>	6149054	Dec 16, 2016	DP			
	>A>	6176442	May 31, 2016	DP			
	>A>	6453795	Dec 05, 2016	DP			
	>A>	6726124	Oct 04, 2016	DP			
	>A>	6846413	Aug 28, 2018	DP			
	>A>	6977042	Aug 28, 2018	DP			
	>A>	6988496	Feb 23, 2020	DP			
	>A>	7104470	Oct 04, 2016	DP			
	>A>	7246615	May 31, 2016	DP			
	>A>	7284474	Aug 26, 2024	DP			
	>A>	7396341	Oct 10, 2026	DP			
	>A>	7802568	Feb 26, 2019	DP			
	>A>	7837235	Mar 13, 2028	DP			
	>A>	7896264	May 26, 2025	DP			
	>A>	7988001	Aug 04, 2021	DP			
	>A>	8733341	Dec 16, 2029	DP			
	>A>	9027967	Mar 31, 2027	DP			
	>A>	RE39820	Jan 30, 2018	DS DP			
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF							
N 207981 001						>A> NCE	Sep 22, 2020
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF							
N 207981 002						>A> NCE	Sep 22, 2020
TOPIRAMATE - TROKENDI XR							
N 201635 001	>A>	8298576	Apr 04, 2028	DP U-106			
		8992989	Nov 16, 2027	DP U-1675			
TOPIRAMATE - TROKENDI XR							
N 201635 002	>A>	8298576	Apr 04, 2028	DP U-106			
		8992989	Nov 16, 2027	DP U-1675			
TOPIRAMATE - TROKENDI XR							
N 201635 003	>A>	8298576	Apr 04, 2028	DP U-106			
		8992989	Nov 16, 2027	DP U-1675			
TOPIRAMATE - TROKENDI XR							
N 201635 004	>A>	8298576	Apr 04, 2028	DP U-106			
		8992989	Nov 16, 2027	DP U-1675			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOPIRAMATE - TROKENDI XR							
N 201635 004	>A>	8298576	Apr 04, 2028	DP		U-106	
		8992989	Nov 16, 2027	DP		U-1675	
TOPIRAMATE - QUDEXY XR							
N 205122 001		9101545	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR							
N 205122 002		9101545	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR							
N 205122 003		9101545	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR							
N 205122 004		9101545	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR							
N 205122 005		9101545	Mar 19, 2033	DP			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST							
N 204114 001		8703781	Oct 15, 2030	DS DP		U-1712	
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST							
N 204114 002		8703781	Oct 15, 2030	DS DP		U-1712	
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST							
N 204114 003		8703781	Oct 15, 2030	DS DP		U-1712	
TRANEXAMIC ACID - LYSTEDA							
N 022430 001		8957113	Mar 04, 2025	DP		U-1182	
		9060939	Mar 04, 2025	DP			
TRAVOPROST - IZBA							
N 204822 001		8178582	Oct 10, 2029	DP			
	>A>	9144561	Mar 13, 2029	DP			
TRAZODONE HYDROCHLORIDE - DESYREL							
N 018207 001		8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL							
N 018207 002		8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL							
N 018207 003		8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL							
N 018207 004		8133893	Mar 13, 2029	DS DP			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496 001		7417070	Jul 30, 2026	DS			
		9050311	May 24, 2024	DS DP			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496 002		7417070	Jul 30, 2026	DS			
		9050311	May 24, 2024	DS DP			
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496 003		7417070	Jul 30, 2026	DS			
		9050311	May 24, 2024	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 004	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
TRETINOIN - RETIN-A-MICRO						
N 020475 003	5955109	Sep 21, 2016	DP U-134			
ULIPRISTAL ACETATE - ELLA						
N 022474 001	8962603	Jun 12, 2030	U-1657			
UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA						
N 203975 001	8511304	Jun 14, 2027	DP U-1476			
URIDINE TRIACETATE - XURIDEN						
N 208169 001					>A> NCE	Sep 04, 2020
					>A> ODE	Sep 04, 2022
VALGANCICLOVIR HYDROCHLORIDE - VALCYTE						
N 021304 001					D-148	Apr 23, 2018
					NPP	Apr 23, 2018
VALGANCICLOVIR HYDROCHLORIDE - VALCYTE						
N 022257 001					D-148	Apr 23, 2018
					NPP	Apr 23, 2018
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 001					D-146	Mar 16, 2018
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 002					D-146	Mar 16, 2018
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 003					D-146	Mar 16, 2018
VORTIOXETINE HYDROBROMIDE - BRINTELLIX						
N 204447 001	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - BRINTELLIX						
N 204447 002	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - BRINTELLIX						
N 204447 003	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - BRINTELLIX						
N 204447 004	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
ZOLMITRIPTAN - ZOMIG						
N 021450 003					NPP	Jun 12, 2018
ZOLMITRIPTAN - ZOMIG						
N 021450 004					NPP	Jun 12, 2018

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 35th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm